FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Brown, DW
   Warrener, L
   Scobie, HM
   Donadel, M
   Waku-Kouomou, D
   Mulders, MN
   Rota, PA
AF Brown, David W.
   Warrener, Lenesha
   Scobie, Heather M.
   Donadel, Morgane
   Waku-Kouomou, Diane
   Mulders, Mick N.
   Rota, Paul A.
TI Rapid diagnostic tests to address challenges for global measles
   surveillance
SO CURRENT OPINION IN VIROLOGY
LA English
DT Review
ID ORAL FLUID; RUBELLA ELIMINATION; LABORATORY NETWORK; CARE TEST; POINT;
   TRANSMISSION; OUTBREAK; DISEASES; ENGLAND; STATES
AB Recently, a lateral flow rapid diagnostic test (RDT) with good accuracy has been described. This test enables measles specific IgM antibody detection in serum, capillary blood and oral fluid. RDTs have the potential to transform measles surveillance by allowing real-time case confirmation outside of central/regional laboratories and by facilitating a timely public health response. Measles virus genes can also be amplified and sequenced consistently from dried IgM-positive RDTs stored outside of cold chain, which will enable more complete virologic surveillance. Critical questions remain regarding operational use of RDTs as part of global measles surveillance. Projects to evaluate RDT use as part of national surveillance programs and to commercialize the RDT are underway.
C1 [Brown, David W.; Warrener, Lenesha] Publ Hlth England, Natl Infect Serv, Virus Reference Dept, London, England.
   [Brown, David W.] Fiocruz MS, Inst Oswaldo Cruz, Lab Virus Resp & Sarampo, Rio De Janeiro, RJ, Brazil.
   [Scobie, Heather M.; Donadel, Morgane] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA.
   [Waku-Kouomou, Diane] Cherokee Nat Assurance, Catoosa, OK USA.
   [Mulders, Mick N.] WHO, Dept Immunizat Vaccines & Biol, Geneva, Switzerland.
   [Rota, Paul A.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA.
RP Brown, DW (corresponding author), Publ Hlth England, Natl Infect Serv, Virus Reference Dept, London, England.; Brown, DW (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Virus Resp & Sarampo, Rio De Janeiro, RJ, Brazil.
EM David.Brown@PHE.gov.uk
FU Public Health England; U.S. Centers for Disease Control and
   PreventionUnited States Department of Health & Human ServicesCenters for
   Disease Control & Prevention - USA; Bill and Melinda Gates Foundation,
   Seattle, WABill & Melinda Gates Foundation [OPP1066619]
FX This work was supported by Public Health England; the U.S. Centers for
   Disease Control and Prevention; and the Bill and Melinda Gates
   Foundation, Seattle, WA [grant number OPP1066619].
CR [Anonymous], 2018, Wkly Epidemiol Rec, V93, P55
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P205
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P373
   [Anonymous], 1998, Wkly Epidemiol Rec, V73, P265
   [Anonymous], 2011, PLOS MED, V8
   Asiimwe C, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-5
   Bolotin S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181172
   Breakwell L, 2015, MMWR-MORBID MORTAL W, V64, P1088, DOI 10.15585/mmwr.mm6438a7
   BROWN D, 1994, PRACTITIONER, V238, P778
   BROWN DWG, 1994, BRIT MED J, V308, P1015, DOI 10.1136/bmj.308.6935.1015
   Brown KE, 2019, MMWR-MORBID MORTAL W, V68, P587, DOI 10.15585/mmwr.mm6826a3
   Castillo-Solorzano C, 2011, J INFECT DIS, V204, pS683, DOI 10.1093/infdis/jir471
   Centers for Disease Control and Prevention (CDC), 2008, MMWR Morb Mortal Wkly Rep, V57, P657
   Durrheim DN, 2019, INT J INFECT DIS, V83, P95, DOI 10.1016/j.ijid.2019.04.016
   Gardy JL, 2015, J INFECT DIS, V212, P1574, DOI 10.1093/infdis/jiv271
   Gay NJ, 2004, J INFECT DIS, V189, pS36, DOI 10.1086/377695
   Grant GB, 2019, VACCINE, V37, P5754, DOI 10.1016/j.vaccine.2019.01.081
   Hubschen JM, 2017, CLIN MICROBIOL INFEC, V23, P511, DOI 10.1016/j.cmi.2017.04.009
   Jin L, 2002, B WORLD HEALTH ORGAN, V80, P76
   Kosack CS, 2017, B WORLD HEALTH ORGAN, V95, P639, DOI 10.2471/BLT.16.187468
   Kuupiel D, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4351-3
   Manikkavasagan G, 2010, EMERG INFECT DIS, V16, P1532, DOI 10.3201/eid1610.100560
   Mulders MN, 2017, J INFECT DIS, V216, pS324, DOI 10.1093/infdis/jix077
   Mulders MN, 2016, MMWR-MORBID MORTAL W, V65, P438, DOI 10.15585/mmwr.mm6517a3
   Oliveira SA, 2001, EPIDEMIOL INFECT, V127, P509, DOI 10.1017/S0950268801005908
   Osorio L, 2018, INFECT DIS POVERTY, V7, DOI 10.1186/s40249-018-0474-8
   Pai NP, 2015, POINT CARE, V14, P81
   Pai NP, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001306
   Pascoe SJS, 2009, AIDS PATIENT CARE ST, V23, P571, DOI 10.1089/apc.2008.0225
   Patel MK, 2019, MMWR-MORBID MORTAL W, V68, P1105, DOI 10.15585/mmwr.mm6848a1
   Patel MK, 2018, VACCINE, V36, P7385, DOI 10.1016/j.vaccine.2018.10.007
   Peeling RW, 2006, SEX TRANSM INFECT, V82, pV1, DOI 10.1136/sti.2006.024265
   Penedos AR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143081
   Public Health England, MEASL NOT CONF CAS O
   Ramsay ME, 2003, J INFECT DIS, V187, pS198, DOI 10.1086/368024
   Rota JS, 1996, J INFECT DIS, V173, P32, DOI 10.1093/infdis/173.1.32
   Scobie HM, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.30.6335
   Shonhai A, 2015, EPIDEMIOL INFECT, V143, P3442, DOI 10.1017/S0950268815000540
   Thomas S, 2017, EMERG INFECT DIS, V23, P1063, DOI 10.3201/eid2307.161145
   THORNTON J, 2019, BMJ-BRIT MED J, V364, DOI DOI 10.1136/BMJ.L634
   Warrener L, EVALUATION RAPID DIA
   Warrener L, 2011, B WORLD HEALTH ORGAN, V89, P675, DOI 10.2471/BLT.11.088427
   WHO, 2018, MAN LAB BAS SURV MEA
   World Health Organization, MEASL NUCL SURV DAT
   World Health Organization, 2018, VACC PREV DIS SURV S
NR 45
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1879-6257
J9 CURR OPIN VIROL
JI Curr. Opin. Virol.
PD APR
PY 2020
VL 41
BP 77
EP 84
DI 10.1016/j.coviro.2020.05.007
PG 8
WC Virology
SC Virology
GA NU5GU
UT WOS:000573670500010
PM 32615510
DA 2020-12-08
ER

PT J
AU Bharucha, T
   Nashef, L
   Moran, N
   Watkins, S
   Brown, D
   Zuckerman, M
AF Bharucha, Tehmina
   Nashef, Lina
   Moran, Nick
   Watkins, Sue
   Brown, David
   Zuckerman, Mark
TI A 9-month retrospective evaluation of the aetiology and management of
   patients presenting with encephalitis/meningoencephalitis at a South
   London hospital
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Encephalitis; infectious disease; infectious disease epidemiology
ID INFECTIOUS ENCEPHALITIS; ADULTS
AB Encephalitis causes high morbidity and mortality. An incidence of 4.3 cases of encephalitis/100 000 population has been reported in the UK. We performed a retrospective evaluation of the diagnosis and management of adults admitted to hospital with a clinical diagnosis of encephalitis/meningoencephalitis. Clinical, laboratory and radiological data were collated from electronic records. Thirty-six patients, median age 55 years and 24 (67%) male were included. The aetiology was confirmed over nine months in 25 (69%) of whom 16 were infections (six viral, seven bacterial, two parasitic and one viral and parasitic co-infection); 7 autoimmune; 1 metabolic and 1 neoplastic. Of 24 patients with fever, 15 (63%) had an infection. The median time to computed topography, magnetic resonance imaging and electroencephalography (EEG) was 1, 8 and 3 days respectively. Neuroimaging was abnormal in 25 (69%) and 17 (89%) had abnormal EEGs. Only 19 (53%) received aciclovir treatment. Six (17%) made good recoveries, 16 (44%) had moderate disability, 8 (22%) severe disability and 6 (17%) died. Outcomes were worse for those with an infectious cause. In summary, a diagnosis was made in 69.4% of patients admitted with encephalitis/meningoencephalitis. Autoimmune causes are important to consider at an early stage due to a successful response to treatment. Only 53% of patients received aciclovir on admission. Neuroimaging and EEG studies were delayed. The results of this work resulted in further developing the clinical algorithm for managing these patients.
C1 [Bharucha, Tehmina; Nashef, Lina; Moran, Nick; Watkins, Sue; Zuckerman, Mark] Kings Coll Hosp London, London, England.
   [Moran, Nick] East Kent Hosp Univ NHS Fdn Trust, Kent & Canterbury Hosp, Neurosci, Canterbury CT1 3NG, Kent, England.
   [Brown, David] Publ Hlth England, London, England.
RP Bharucha, T (corresponding author), Kings Coll Hosp London, London, England.
EM t.bharucha@doctors.org.uk
CR Antoine JC, 2016, LANCET NEUROL, V15, P349, DOI 10.1016/S1474-4422(16)00025-9
   Backman R, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0224-2
   Bell DJ, 2009, CLIN MED, V9, P231, DOI 10.7861/clinmedicine.9-3-231
   Brouwer MC, 2018, LANCET INFECT DIS, V18, P930, DOI 10.1016/S1473-3099(18)30287-1
   Calistri A, 2015, CLIN INFECT DIS, V60, P889, DOI 10.1093/cid/ciu913
   Glaser CA, 2006, CLIN INFECT DIS, V43, P1565, DOI 10.1086/509330
   Granerod J, 2010, EPIDEMIOL INFECT, V138, P783, DOI 10.1017/S0950268810000725
   Granerod J, 2007, NEUROPSYCHOL REHABIL, V17, P406, DOI 10.1080/09602010600989620
   Granerod J, 2010, LANCET INFECT DIS, V10, P835, DOI 10.1016/S1473-3099(10)70222-X
   Kelly C, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-145
   Mailles A, 2012, CLIN INFECT DIS, V54, P1455, DOI 10.1093/cid/cis226
   Marra CWR, 2014, INFECT CENTRAL NERVO, P1
   Maschke M, 2004, CURR OPIN NEUROL, V17, P475, DOI 10.1097/01.wco.0000137540.29857.bf
   McGill F, 2018, LANCET INFECT DIS, V18, P992, DOI 10.1016/S1473-3099(18)30245-7
   Michael BD, 2010, QJM-INT J MED, V103, P749, DOI 10.1093/qjmed/hcq121
   Solomon T, 2012, J INFECTION, V64, P347, DOI 10.1016/j.jinf.2011.11.014
   Stahl JP, 2017, MED MALADIES INFECT, V47, P179, DOI 10.1016/j.medmal.2017.01.005
   Venkatesan A, 2013, CLIN INFECT DIS, V57, P1114, DOI 10.1093/cid/cit458
   2014, REG ANESTH PAIN MED, V9
NR 19
TC 0
Z9 0
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PY 2020
VL 148
AR e23
DI 10.1017/S0950268820000047
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA KH7QY
UT WOS:000510845900001
PM 32019624
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Kadambari, S
   Braccio, S
   Ribeiro, S
   Allen, DJ
   Pebody, R
   Brown, D
   Cunney, R
   Sharland, M
   Ladhani, S
AF Kadambari, Seilesh
   Braccio, Serena
   Ribeiro, Sonia
   Allen, David J.
   Pebody, Richard
   Brown, David
   Cunney, Robert
   Sharland, Mike
   Ladhani, Shamez
TI Enterovirus and parechovirus meningitis in infants younger than 90 days
   old in the UK and Republic of Ireland: a British Paediatric Surveillance
   Unit study
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
ID VIRAL MENINGITIS; INFECTION; ENGLAND; MENINGOENCEPHALITIS; CHILDHOOD;
   CHILDREN; OUTCOMES; IMPACT; WALES
AB Objectives This study aimed to prospectively collect detailed clinical information for all enterovirus (EV) and human parechovirus (HPeV) meningitis cases in infants aged <90 days in the UK and Ireland.
   Participants, design and setting Prospective, active national surveillance during July 2014 to July 2015 through the British Paediatric Surveillance Unit. Reporting paediatricians completed questionnaires requesting information on clinical presentation, investigations, management and outcomes at hospital discharge and after 12 months.
   Main outcome measures To describe the clinical burden of EV and HPeV meningitis in infants aged <90 days.
   Results During the 13-month surveillance period, 703 cases (668 EV, incidence0.79/1,000 live-births; 35 HPeV, 0.04/1,000 live-births) were identified. The most common clinical presentations were fever (EV: 570/668(85%); HPeV: 28/35(80%)), irritability (EV: 441/668(66%); HPeV: 23/35(66%)) and reduced feeding (EV: 363/668(54%); HPeV 23/35(66%)). Features of circulatory shock were present in 27% (182/668) of EV and 43% (15/35) of HPeV cases. Overall, 11% (76/668) of EV and 23% (8/35) of HPeV cases required intensive care support. Nearly all cases (678/703, 96%) were confirmed by cerebrospinal fluid (CSF) PCR, with 52% (309/600) having normal CSF white cell count for age. Two infants with EV meningitis died (2/668, 0.3%) and four survivors (4/666, 0.6%) had long-term complications at 12 months' follow-up. Infants with HPeV meningitis survived without sequelae. Overall 189 infants had a formal hearing test and none had sensorineural hearing loss.
   Conclusion The incidence of laboratory-confirmed EV/HPeV meningitis in young infants is more than twice that for bacterial meningitis. Less than 1% will develop severe neurological complications or die of their infection. Further studies are required to formally assess long-term neurodevelopmental sequelae.
C1 [Kadambari, Seilesh; Sharland, Mike; Ladhani, Shamez] St Georges Univ London, Paediat Infect Dis Res Grp, London, England.
   [Kadambari, Seilesh] Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford, England.
   [Kadambari, Seilesh] NIHR Oxford Biomed Res Ctr, Oxford, England.
   [Ribeiro, Sonia; Ladhani, Shamez] Publ Hlth England, Immunisat Hepatitis & Blood Safety Dept, London, England.
   [Allen, David J.; Brown, David] Publ Hlth England, Virol Reference Dept, London, England.
   [Pebody, Richard] Publ Hlth England, Influenza & Other Resp Viruses Sect, London, England.
   [Cunney, Robert] Temple St Childrens Univ Hosp, Dept Microbiol, Dublin, Ireland.
RP Kadambari, S (corresponding author), Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford, England.; Kadambari, S (corresponding author), NIHR Oxford Biomed Res Ctr, Oxford, England.
EM seilesh.kadambari@paediatrics.ox.ac.uk
CR ABZUG MJ, 1995, J PEDIATR-US, V126, P447, DOI 10.1016/S0022-3476(95)70466-3
   Antolin LF, 2018, ARCH DIS CHILD, V103, P1061, DOI 10.1136/archdischild-2017-314281
   Baker RC, 1996, CLIN PEDIATR, V35, P295, DOI 10.1177/000992289603500602
   Balasubramanian H, 2016, J PAEDIATR CHILD H, V52, P327, DOI 10.1111/jpc.13083
   BERGMAN I, 1987, J PEDIATR-US, V110, P705, DOI 10.1016/S0022-3476(87)80006-9
   Britton PN, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2848
   FARMER K, 1975, J PEDIATR-US, V87, P568, DOI 10.1016/S0022-3476(75)80823-7
   Hall SM, 1998, CHILD CARE HLTH DEV, V24, P129
   Hamilton MS, 1999, PEDIATR INFECT DIS J, V18, P533, DOI 10.1097/00006454-199906000-00011
   Harvala H., 2014, Eurosurveillance, V19, P20772, DOI 10.2807/1560-7917.ES2014.19.15.20772
   Harvala H, 2009, J CLIN VIROL, V45, P1, DOI 10.1016/j.jcv.2009.03.009
   Kadambari S, 2014, CLIN MICROBIOL INFEC, V20, P1289, DOI 10.1111/1469-0691.12753
   Kadambari S, 2014, J INFECTION, V69, P326, DOI 10.1016/j.jinf.2014.05.012
   Kestenbaum LA, 2010, PEDIATRICS, V125, P257, DOI 10.1542/peds.2009-1181
   Khatami A, 2015, CLIN INFECT DIS, V60, P228, DOI 10.1093/cid/ciu784
   Maguire H C, 1999, Commun Dis Public Health, V2, P122
   Martin NG, 2016, LANCET INFECT DIS, V16, P1279, DOI 10.1016/S1473-3099(16)30201-8
   MODLIN JF, 1981, NEW ENGL J MED, V305, P368, DOI 10.1056/NEJM198108133050703
   Okike IO, 2014, CLIN INFECT DIS, V59, pE150, DOI 10.1093/cid/ciu514
   Piralla A, 2012, J MED VIROL, V84, P686, DOI 10.1002/jmv.23197
   Poelman R, 2015, J CLIN VIROL, V62, P1, DOI 10.1016/j.jcv.2014.11.011
   Ramers C, 2000, JAMA-J AM MED ASSOC, V283, P2680, DOI 10.1001/jama.283.20.2680
   RORABAUGH ML, 1993, PEDIATRICS, V92, P206
   Sadarangani M, 2015, ARCH DIS CHILD, V100, P292, DOI 10.1136/archdischild-2014-306813
   SELLS CJ, 1975, NEW ENGL J MED, V293, P1, DOI 10.1056/NEJM197507032930101
   Sharp J, 2013, PEDIATR INFECT DIS J, V32, P213, DOI 10.1097/INF.0b013e318276b328
   Tebruegge M, 2009, SEMIN FETAL NEONAT M, V14, P222, DOI 10.1016/j.siny.2009.02.002
   Verboon-Maciolek MA, 2008, ANN NEUROL, V64, P266, DOI 10.1002/ana.21445
   Vergnano S, 2015, EUR J PEDIATR, V174, P919, DOI 10.1007/s00431-014-2483-3
   Wang LY, 2016, MOLECULES, V21, DOI 10.3390/molecules21040473
   Wildenbeest JG, 2014, CLIN MICROBIOL INFEC, V20, pO640, DOI 10.1111/1469-0691.12542
   Yun KW, 2012, ARCH DIS CHILD, V97, P874, DOI 10.1136/archdischild-2012-301884
NR 32
TC 11
Z9 11
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
EI 1468-2044
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD JUN
PY 2019
VL 104
IS 6
BP 552
EP 557
DI 10.1136/archdischild-2018-315643
PG 6
WC Pediatrics
SC Pediatrics
GA IC6KI
UT WOS:000471080500012
PM 30530486
OA Green Accepted
DA 2020-12-08
ER

PT J
AU Benjamin, LA
   Bryer, A
   Lucas, S
   Stanley, A
   Allain, TJ
   Joekes, E
   Emsley, H
   Turnbull, I
   Downey, C
   Toh, CH
   Brown, K
   Brown, D
   Ison, C
   Smith, C
   Corbett, EL
   Nath, A
   Heyderman, RS
   Connor, MD
   Solomon, T
AF Benjamin, Laura A.
   Bryer, Alan
   Lucas, Sebastian
   Stanley, Alan
   Allain, Theresa J.
   Joekes, Elizabeth
   Emsley, Hedley
   Turnbull, Ian
   Downey, Colin
   Toh, Cheng-Hock
   Brown, Kevin
   Brown, David
   Ison, Catherine
   Smith, Colin
   Corbett, Elizabeth L.
   Nath, Avindra
   Heyderman, Robert S.
   Connor, Myles D.
   Solomon, Tom
TI Arterial ischemic stroke in HIV Defining and classifying etiology for
   research studies
SO NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SMALL VESSEL DISEASE;
   CENTRAL-NERVOUS-SYSTEM; ANTIPHOSPHOLIPID SYNDROME; NEUROSYPHILIS
   DIAGNOSIS; CONSENSUS CONFERENCE; CEREBROSPINAL-FLUID; PRIMARY ANGIITIS;
   RISK-FACTORS; INFECTION
AB HIV infection, and potentially its treatment, increases the risk of an arterial ischemic stroke. Multiple etiologies and lack of clear case definitions inhibit progress in this field. Several etiologies, many treatable, are relevant to HIV-related stroke. To fully understand the mechanisms and the terminology used, a robust classification algorithm to help ascribe the various etiologies is needed. This consensus paper considers the strengths and limitations of current case definitions in the context of HIV infection. The case definitions for the major etiologies in HIV-related strokes were refined (e.g., varicella zoster vasculopathy and antiphospholipid syndrome) and in some instances new case definitions were described (e.g., HIV-associated vasculopathy). These case definitions provided a framework for an algorithm to help assign a final diagnosis, and help classify the subtypes of HIV etiology in ischemic stroke.
C1 [Benjamin, Laura A.; Corbett, Elizabeth L.; Heyderman, Robert S.] Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi.
   [Benjamin, Laura A.; Allain, Theresa J.] Univ Malawi, Coll Med, Dept Med, Blantyre, Malawi.
   [Benjamin, Laura A.; Emsley, Hedley; Solomon, Tom] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.
   [Benjamin, Laura A.; Solomon, Tom] Walton Ctr NHS Fdn Trust, Liverpool, Merseyside, England.
   [Bryer, Alan; Stanley, Alan] Univ Cape Town, Div Neurol, Groote Schuur Hosp, Dept Med, ZA-7700 Rondebosch, South Africa.
   [Lucas, Sebastian] St Thomas Hosp, Dept Histopathol, London, England.
   [Joekes, Elizabeth] Royal Liverpool Hospital, Dept Radiol, London, England.
   [Downey, Colin; Toh, Cheng-Hock] Royal Liverpool Hospital, Dept Haematol, London, England.
   [Emsley, Hedley] Preston Hosp, London, England.
   [Turnbull, Ian] North Manchester Gen Hosp, London, England.
   [Brown, Kevin; Brown, David] Publ Hlth England, Reference Dept, London, England.
   [Ison, Catherine] Publ Hlth England, Syphilis Reference Dept, London, England.
   [Smith, Colin] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH8 9YL, Midlothian, Scotland.
   [Connor, Myles D.] Univ Edinburgh, Div Clin Neurosci, Edinburgh EH8 9YL, Midlothian, Scotland.
   [Corbett, Elizabeth L.] London Sch Hyg & Trop Med, Dept Clin Res, London, England.
   [Nath, Avindra] NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Heyderman, Robert S.] UCL, Div Infect & Immun, London WC1E 6BT, England.
   [Connor, Myles D.] NHS Borders, Melrose, Scotland.
   [Connor, Myles D.] Univ Witwatersrand, Sch Publ Hlth, ZA-2050 Johannesburg, South Africa.
   [Solomon, Tom] Natl Inst Hlth Res Hlth Protect, Res Unit Emerging & Zoonot Infect, Liverpool, Merseyside, England.
RP Benjamin, LA (corresponding author), Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi.; Benjamin, LA (corresponding author), Univ Malawi, Coll Med, Dept Med, Blantyre, Malawi.; Benjamin, LA (corresponding author), Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.; Benjamin, LA (corresponding author), Walton Ctr NHS Fdn Trust, Liverpool, Merseyside, England.
EM l.benjamin@liverpool.ac.uk
OI Benjamin, Laura/0000-0002-9685-1664; Heyderman,
   Robert/0000-0003-4573-449X; Emsley, Hedley/0000-0003-0129-4488
FU Wellcome TrustWellcome Trust; NIHR Health Protection Research Unit in
   Emerging and Zoonotic Infections at Liverpool; National Institute for
   Health ResearchNational Institute for Health Research (NIHR)
   [NF-SI-0514-10177, RP-PG-0108-10048] Funding Source: researchfish
FX L.B. was supported by the Wellcome Trust. T.S. was supported by the NIHR
   Health Protection Research Unit in Emerging and Zoonotic Infections at
   Liverpool.
CR Adams HP, 1999, NEUROLOGY, V53, P126, DOI 10.1212/WNL.53.1.126
   ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Amarenco P, 2009, CEREBROVASC DIS, V27, P502, DOI 10.1159/000210433
   Ay H, 2005, ANN NEUROL, V58, P688, DOI 10.1002/ana.20617
   Belizna CC, 2009, RHEUMATOLOGY, V48, P475, DOI 10.1093/rheumatology/kep026
   Benjamin LA, 2016, NEUROLOGY, V86, P324, DOI 10.1212/WNL.0000000000002278
   Benjamin LA, 2012, LANCET NEUROL, V11, P878, DOI 10.1016/S1474-4422(12)70205-3
   BERGER JR, 1990, AIDS, V4, P239, DOI 10.1097/00002030-199003000-00010
   Bermel C, 2009, J NEUROL, V256, P1563, DOI 10.1007/s00415-009-5146-y
   Brecher ME, 2008, J CLIN APHERESIS, V23, P186, DOI 10.1002/jca.20176
   Brey RL, 2003, LUPUS, V12, P508, DOI 10.1191/0961203303lu390oa
   Butt AA, 2009, CLIN INFECT DIS, V49, P225, DOI 10.1086/599371
   Centers for Disease Control and Prevention, 2010, SEX TRANSM DIS TREAT
   Chahine LM, 2011, INT J STROKE, V6, P136, DOI 10.1111/j.1747-4949.2010.00568.x
   Connor MD, 2000, STROKE, V31, P2117, DOI 10.1161/01.STR.31.9.2117
   de Jong G, 2003, J CLIN EPIDEMIOL, V56, P262, DOI 10.1016/S0895-4356(02)00572-3
   Fugate JE, 2014, LANCET INFECT DIS, V14, P869, DOI 10.1016/S1473-3099(14)70755-8
   Granerod J, 2010, EPIDEMIOL INFECT, V138, P783, DOI 10.1017/S0950268810000725
   Granerod J, 2010, LANCET INFECT DIS, V10, P835, DOI 10.1016/S1473-3099(10)70222-X
   Gutierrez J, 2011, CLIN NEURORADIOL, V21, P145, DOI 10.1007/s00062-011-0087-0
   Gutierrez J, 2015, NEUROLOGY, V85, P1139, DOI 10.1212/WNL.0000000000001976
   Hajj-Ali RA, 2011, LANCET NEUROL, V10, P561, DOI 10.1016/S1474-4422(11)70081-3
   Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626
   Ho EL, 2015, SEX TRANSM DIS, V42, P48, DOI 10.1097/OLQ.0000000000000222
   Inusa B, 2014, BMJ CASE REP, V2014
   Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715
   Kabanda T, 2014, CLIN INFECT DIS, V58, P113, DOI 10.1093/cid/cit641
   Larrue V, 2011, NEUROLOGY, V76, P1983, DOI 10.1212/WNL.0b013e31821e5517
   Laurence J, 1997, SEMIN HEMATOL, V34, P98
   Li LX, 2015, LANCET NEUROL, V14, P903, DOI 10.1016/S1474-4422(15)00132-5
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lui G, 2006, QJM-INT J MED, V99, P143, DOI 10.1093/qjmed/hcl014
   Marais S, 2010, LANCET INFECT DIS, V10, P803, DOI 10.1016/S1473-3099(10)70138-9
   Marra CM, 2012, SEX TRANSM DIS, V39, P453, DOI 10.1097/OLQ.0b013e31824b1cde
   Marra CM, 2010, SEX TRANSM DIS, V37, P283, DOI 10.1097/OLQ.0b013e3181d877a1
   Melica G, 2009, J MED VIROL, V81, P578, DOI 10.1002/jmv.21462
   Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x
   Mochan A, 2003, STROKE, V34, P10, DOI 10.1161/01.STR.0000043821.35051.FA
   Nagel MA, 2008, NEUROLOGY, V70, P853, DOI 10.1212/01.wnl.0000304747.38502.e8
   Nogueras C, 2002, ARCH NEUROL-CHICAGO, V59, P468, DOI 10.1001/archneur.59.3.468
   O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3
   Ortiz G, 2007, NEUROLOGY, V68, P1257, DOI 10.1212/01.wnl.0000259515.45579.1e
   Pantoni L, 2010, LANCET NEUROL, V9, P689, DOI 10.1016/S1474-4422(10)70104-6
   Petrovas C, 1999, J AUTOIMMUN, V13, P347, DOI 10.1006/jaut.1999.0324
   REIBER H, 1991, CLIN CHEM, V37, P1153
   Ruiz-Irastorza G, 2010, LANCET, V376, P1498, DOI 10.1016/S0140-6736(10)60709-X
   Sacco RL, 2013, STROKE, V44, P2064, DOI 10.1161/STR.0b013e318296aeca
   Sarode R, 2014, J CLIN APHERESIS, V29, P148, DOI 10.1002/jca.21302
   Sico JJ, 2015, NEUROLOGY, V84, P1933, DOI 10.1212/WNL.0000000000001560
   Soontornniyomkij V, 2014, AIDS, V28, P1297, DOI 10.1097/QAD.0000000000000262
   Taylor CL, 2008, INT J STD AIDS, V19, P141, DOI 10.1258/ijsa.2007.007187
   Thakur KT, 2016, J NEUROVIROL, V22, P50, DOI 10.1007/s13365-015-0363-x
   Thwaites GE, 2005, LANCET NEUROL, V4, P160, DOI 10.1016/S1474-4422(05)01013-6
   Tipping B, 2007, J NEUROL NEUROSUR PS, V78, P1320, DOI 10.1136/jnnp.2007.116103
   Tipping B, 2006, ARCH NEUROL-CHICAGO, V63, P1640, DOI 10.1001/archneur.63.11.1640
   Urbanus RT, 2009, LANCET NEUROL, V8, P998, DOI 10.1016/S1474-4422(09)70239-X
   Vishnu P, 2015, BRIT J HAEMATOL, V171, P695, DOI 10.1111/bjh.13783
   Wardlaw JM, 2013, LANCET NEUROL, V12, P822, DOI 10.1016/S1474-4422(13)70124-8
   Warlow C, 2003, LANCET, V362, P1211, DOI 10.1016/S0140-6736(03)14544-8
   Winchester SA, 2011, J CLIN VIROL, V50, P93, DOI 10.1016/j.jcv.2010.09.005
NR 60
TC 24
Z9 25
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2332-7812
J9 NEUROL-NEUROIMMUNOL
JI Neurol.-Neuroimmunol. Neuroinflammation
PD AUG
PY 2016
VL 3
IS 4
AR e254
DI 10.1212/NXI.0000000000000254
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA EG6PR
UT WOS:000391168900016
PM 27386505
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-08
ER

PT J
AU Michael, BD
   Griffiths, MJ
   Granerod, J
   Brown, D
   Keir, G
   Wnek, G
   Cox, DJ
   Vidyasagar, R
   Borrow, R
   Parkes, LM
   Solomon, T
AF Michael, Benedict Daniel
   Griffiths, Michael J.
   Granerod, Julia
   Brown, David
   Keir, Geoff
   Wnek, Gosia
   Cox, Daniel J.
   Vidyasagar, Rishma
   Borrow, Ray
   Parkes, Laura M.
   Solomon, Tom
TI The Interleukin-1 Balance During Encephalitis Is Associated With
   Clinical Severity, Blood-Brain Barrier Permeability, Neuroimaging
   Changes, and Disease Outcome
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE encephalitis; cytokine; chemokine; herpes simplex; blood-brain barrier
ID IL-1 RECEPTOR ANTAGONIST; CEREBROSPINAL-FLUID; ANTIINFLAMMATORY
   CYTOKINES; COMBINATION THERAPY; ADULT PATIENTS; VIRUS; EXPRESSION;
   ACYCLOVIR; SERUM; CHEMOKINES
AB Background. Encephalitis is parenchymal brain inflammation, commonly due to herpes simplex virus ( HSV). Key host inflammatory mediators and their relationship to blood- brain barrier ( BBB) permeability, neuroimaging changes, and disease outcome are poorly understood.
   Methods.aEuro integral We measured levels of 38 mediators in serum (n = 78) and cerebrospinal fluid (n = 37) specimens from patients with encephalitis, including 17 with disease due to HSV infection. Outcome measures were Glasgow coma and outcome scores; CSF to serum albumin ratio, reflecting BBB permeability; and, in patients with HSV infection, magnetic resonance imaging-based temporal lobe volume.
   Results.aEuro integral Serum interleukin 1 receptor antagonist (IL-1RA) levels were elevated in patients with a good outcome (P = .004). Among patients infected with HSV, the ratio of CSF IL-1 beta to IL-1RA was associated with a worse outcome (P = .009); a ratio of a parts per thousand yen0.55 pg/mL had high specificity and sensitivity for a poor outcome (100% and 83%; P = .015). Temporal lobe volume had a negative correlation with serum IL-1RA level (P = .012) and a positive correlation with serum IL-1 alpha level (P = .0003) and CSF IL-1 beta level (P = .007). A normal coma score was associated with an elevated interleukin 10 (IL-10) level in serum specimens from HSV-infected patients (P = .007) and CSF specimens from all patients (P = .016); the IL-10 level correlated inversely with BBB permeability (P = .005).
   Conclusions.aEuro integral A proinflammatory cytokine response is associated with greater clinical severity, BBB permeability, and neuroimaging damage during encephalitis. IL-1 antagonists should be investigated as adjunctive treatment in encephalitis.
C1 [Michael, Benedict Daniel; Griffiths, Michael J.; Wnek, Gosia; Solomon, Tom] Univ Liverpool, Inst Infect & Global Hlth, 1st Fl Ronald Ross,W Derby St, Liverpool L69 3BX, Merseyside, England.
   [Michael, Benedict Daniel; Griffiths, Michael J.; Solomon, Tom] Univ Liverpool, Hlth Protect Res Unit Emerging & Zoonot Infect, Natl Inst Hlth Res, Liverpool, Merseyside, England.
   [Michael, Benedict Daniel; Keir, Geoff; Solomon, Tom] Walton Ctr Natl Hlth Serv NHS Fdn Trust, Liverpool, Merseyside, England.
   [Griffiths, Michael J.] Alderhey Childrens NHS Fdn Trust, Liverpool, Merseyside, England.
   [Granerod, Julia; Brown, David] Publ Hlth England, London, England.
   [Cox, Daniel J.; Vidyasagar, Rishma; Parkes, Laura M.] Univ Manchester, Inst Populat Hlth, Ctr Imaging Sci, Fac Med & Human Sci, Manchester, Lancs, England.
   [Borrow, Ray] Publ Hlth England, Vaccine Evaluat Unit, Manchester, Lancs, England.
   [Brown, David] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Influenza & Measles Lab, Rio De Janeiro, Brazil.
RP Michael, BD (corresponding author), Univ Liverpool, Inst Infect & Global Hlth, 1st Fl Ronald Ross,W Derby St, Liverpool L69 3BX, Merseyside, England.
EM benmic@liv.ac.uk
OI Solomon, Tom/0000-0001-7266-6547; Parkes, Laura/0000-0001-6488-507X;
   Michael, Benedict/0000-0002-8693-8926
FU laboratory team at the Vaccine Evaluation Unit, Public Health England,
   Manchester, United Kingdom; NIHR, United Kingdom; NIHR Health Protection
   Research Unit in Emerging and Zoonotic Infections, Liverpool, United
   Kingdom; MRCMedical Research Council UK (MRC); Academy of Medical
   Sciences (AMS)Academy of Medical Sciences (AMS) [SGL015\\1016] Funding
   Source: researchfish; National Institute for Health ResearchNational
   Institute for Health Research (NIHR) [NF-SI-0514-10177, 3546,
   ACF-2008-07-001, CL-2014-07-002, DRF-2010-03-97] Funding Source:
   researchfish
FX This work was supported by the laboratory team at the Vaccine Evaluation
   Unit, Public Health England, Manchester, United Kingdom; the NIHR,
   United Kingdom (doctoral research fellowship to B. D. M.); and the NIHR
   Health Protection Research Unit in Emerging and Zoonotic Infections,
   Liverpool, United Kingdom (to T. S.); and the MRC (to T. S.).
CR Alheim K, 1998, ANN NY ACAD SCI, V840, P51, DOI 10.1111/j.1749-6632.1998.tb09548.x
   AURELIUS E, 1994, J INFECT DIS, V170, P678, DOI 10.1093/infdis/170.3.678
   Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1177/096228029900800204
   Boutin H, 2003, MOL NEUROBIOL, V27, P239, DOI 10.1385/MN:27:3:239
   Burger D, 2009, P NATL ACAD SCI USA, V106, P4355, DOI 10.1073/pnas.0812183106
   Burton JM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006921.pub3
   Conrady CD, 2010, J NEUROIMMUNOL, V220, P1, DOI 10.1016/j.jneuroim.2009.09.013
   Day NPJ, 1999, J INFECT DIS, V180, P1288, DOI 10.1086/315016
   DEMAEREL P, 1992, NEURORADIOLOGY, V34, P490, DOI 10.1007/BF00598957
   Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115
   Ellermann-Eriksen S, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-59
   Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882
   Furlan R, 2007, GENE THER, V14, P93, DOI 10.1038/sj.gt.3302805
   Gibson RM, 2004, VET J, V168, P230, DOI 10.1016/j.tvjl.2003.10.016
   Granerod J, 2010, LANCET INFECT DIS, V10, P835, DOI 10.1016/S1473-3099(10)70222-X
   Griffiths MJ, 2012, J INFECT DIS, V206, P881, DOI 10.1093/infdis/jis446
   Hallahan BP, 2011, NEUROIMAGE, V54, P16, DOI 10.1016/j.neuroimage.2010.08.015
   Ichiyama T, 2008, CYTOKINE, V44, P149, DOI 10.1016/j.cyto.2008.07.002
   Kamei S, 2005, J NEUROL NEUROSUR PS, V76, P1544, DOI 10.1136/jnnp.2004.049676
   Kamei S, 2009, CYTOKINE, V46, P187, DOI 10.1016/j.cyto.2009.01.004
   Kennedy PGE, 2005, J NEUROL, V252, P268, DOI 10.1007/s00415-005-0770-7
   Labus J, 2014, J NEUROSCI METH, V228, P35, DOI 10.1016/j.jneumeth.2014.03.002
   Lokensgard JR, 2001, J NEUROVIROL, V7, P208
   Mackay CE, 2000, MAGN RESON IMAGING, V18, P1187, DOI 10.1016/S0730-725X(00)00220-4
   Marcotte TD, 2013, J NEUROIMMUNE PHARM, V8, P1123, DOI 10.1007/s11481-013-9504-2
   Marques CP, 2004, GLIA, V47, P358, DOI 10.1002/glia.20045
   Meyding-Lamade UK, 2003, J NEUROVIROL, V9, P118, DOI 10.1080/13550280390173373
   Michael BD, 2013, CYTOKINE, V64, P90, DOI 10.1016/j.cyto.2013.07.019
   Molina-Holgado E, 2002, NEUROSCI LETT, V324, P237, DOI 10.1016/S0304-3940(02)00209-4
   Ramakrishna C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002071
   Raschilas F, 2002, CLIN INFECT DIS, V35, P254, DOI 10.1086/341405
   REIBER H, 1995, CLIN CHEM, V41, P256
   Rosler A, 1998, J NEUROL SCI, V157, P82, DOI 10.1016/S0022-510X(98)00061-6
   Salliot C, 2009, ANN RHEUM DIS, V68, P25, DOI 10.1136/ard.2007.083188
   Saxena V, 2008, ARCH VIROL, V153, P283, DOI 10.1007/s00705-007-1098-7
   Saxena V, 2008, MICROBES INFECT, V10, P1210, DOI 10.1016/j.micinf.2008.06.015
   Sergerie Y, 2007, J INFECT DIS, V196, P853, DOI 10.1086/520094
   Solomon T, 2012, J INFECTION, V64, P347, DOI 10.1016/j.jinf.2011.11.014
   Szelenyi J, 2001, BRAIN RES BULL, V54, P329, DOI 10.1016/S0361-9230(01)00428-2
   Szodoray P, 2007, RHEUMATOLOGY, V46, P417, DOI 10.1093/rheumatology/kel306
   Tse MCL, 2009, J NEUROIMMUNOL, V213, P12, DOI 10.1016/j.jneuroim.2009.06.007
   TUMPEY TM, 1994, J IMMUNOL, V153, P2258
   Tunkel AR, 2008, CLIN INFECT DIS, V47, P303, DOI 10.1086/589747
   UPTON ARM, 1971, LANCET, V1, P861
   Vitkovic L, 2001, NEUROIMMUNOMODULAT, V9, P295, DOI 10.1159/000059387
   WHITLEY RJ, 1986, NEW ENGL J MED, V314, P144, DOI 10.1056/NEJM198601163140303
   Wilson EH, 2005, J NEUROIMMUNOL, V165, P63, DOI 10.1016/j.jneuroim.2005.04.018
   Winter PM, 2004, J INFECT DIS, V190, P1618, DOI 10.1086/423328
   WRIGHT JL, 1994, J NEURO-ONCOL, V20, P17, DOI 10.1007/BF01057957
NR 49
TC 25
Z9 26
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 15
PY 2016
VL 213
IS 10
BP 1651
EP 1660
DI 10.1093/infdis/jiv771
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DM8XX
UT WOS:000376648900018
PM 26712949
OA Bronze, Green Published
DA 2020-12-08
ER

PT J
AU Solomon, T
   Baylis, M
   Brown, D
AF Solomon, Tom
   Baylis, Matthew
   Brown, David
TI Zika virus and neurological disease-approaches to the unknown
SO LANCET INFECTIOUS DISEASES
LA English
DT Editorial Material
ID BRAZIL; INFECTION; ENCEPHALITIS
C1 [Solomon, Tom; Baylis, Matthew] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 7BE, Merseyside, England.
   [Solomon, Tom] Walton Ctr NHS Fdn Trust, Liverpool, Merseyside, England.
   [Solomon, Tom; Baylis, Matthew; Brown, David] Natl Inst Hlth Res, Hlth Protect Res Unit Emerging & Zoonot Infect, Liverpool, Merseyside, England.
   [Brown, David] Oswaldo Cruz Inst Fiocruz, Influenza Lab, Rio De Janeiro, Brazil.
   [Brown, David] Publ Hlth England, Virus Reference Dept, Natl Infect Serv, London, England.
RP Solomon, T (corresponding author), Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 7BE, Merseyside, England.; Solomon, T (corresponding author), Walton Ctr NHS Fdn Trust, Liverpool, Merseyside, England.; Solomon, T (corresponding author), Natl Inst Hlth Res, Hlth Protect Res Unit Emerging & Zoonot Infect, Liverpool, Merseyside, England.
EM tsolomon@liv.ac.uk
RI Baylis, Matthew/S-7694-2019
OI Solomon, Tom/0000-0001-7266-6547; Baylis, Matthew/0000-0003-0335-187X
FU Biotechnology and Biological Sciences Research CouncilBiotechnology and
   Biological Sciences Research Council (BBSRC) [BB/K018507/1] Funding
   Source: researchfish; Medical Research CouncilMedical Research Council
   UK (MRC) [MC_PC_15090] Funding Source: researchfish; National Institute
   for Health ResearchNational Institute for Health Research (NIHR)
   [NF-SI-0514-10177, RP-PG-0108-10048] Funding Source: researchfish;
   Medical Research CouncilMedical Research Council UK (MRC) [MC_PC_15096]
   Funding Source: Medline; Department of Health [RP-PG-0108-10048] Funding
   Source: Medline
CR Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Carod-Artal FJ, 2013, LANCET NEUROL, V12, P906, DOI 10.1016/S1474-4422(13)70150-9
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Musso D, 2015, EMERG INFECT DIS, V21, P1887, DOI 10.3201/eid2110.151125
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Solomon T, 2000, LANCET, V355, P1053, DOI 10.1016/S0140-6736(00)02036-5
   Solomon T, 1998, LANCET, V351, P1094, DOI 10.1016/S0140-6736(97)07509-0
   Solomon T, 2006, NEW ENGL J MED, V355, P869, DOI 10.1056/NEJMp058263
   Tsetsarkin KA, 2007, PLOS PATHOG, V3, P1895, DOI 10.1371/journal.ppat.0030201
   Victora CG, 2016, LANCET, V387, P621, DOI 10.1016/S0140-6736(16)00273-7
NR 11
TC 21
Z9 21
U1 0
U2 41
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD APR
PY 2016
VL 16
IS 4
BP 402
EP 404
DI 10.1016/S1473-3099(16)00125-0
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA DH0CH
UT WOS:000372449600015
PM 26923117
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Atchison, CJ
   Stowe, J
   Andrews, N
   Collins, S
   Allen, DJ
   Nawaz, S
   Brown, D
   Ramsay, ME
   Ladhani, SN
AF Atchison, Christina J.
   Stowe, Julia
   Andrews, Nick
   Collins, Sarah
   Allen, David J.
   Nawaz, Sameena
   Brown, David
   Ramsay, Mary E.
   Ladhani, Shamez N.
TI Rapid Declines in Age Group-Specific Rotavirus Infection and Acute
   Gastroenteritis Among Vaccinated and Unvaccinated Individuals Within 1
   Year of Rotavirus Vaccine Introduction in England and Wales
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE rotavirus; diarrhea; gastroenteritis; vaccination; immunization
ID IMMUNIZATION PROGRAM; INDIRECT PROTECTION; INTESTINAL DISEASE;
   COST-EFFECTIVENESS; HOSPITALIZATIONS; IMPACT; REDUCTION; COMMUNITY;
   AUSTRALIA; DIARRHEA
AB Background. The oral infant rotavirus vaccine, Rotarix, was introduced in England and Wales in July 2013. We estimated the impact on laboratory-confirmed rotavirus infections and hospitalizations for all-cause acute gastroenteritis (AGE) during the first year after introduction.
   Methods. We extracted data on laboratory-confirmed rotavirus infections (July 2000 through June 2015) and all-cause AGE-associated hospitalizations (July 2007 through June 2014) for all age groups using national databases (LabBase2 and HES). We determined the ratio of the rate during the 2013-2014 rotavirus season to the rate during the prevaccination era.
   Results. In infants, there was a 77% decline (rate ratio [RR], 0.23; 95% confidence interval [CI], .16-.32) in laboratory-confirmed rotavirus infections and a 26% decline (RR, 0.74; 95% CI, .65-.84) in all-cause AGE-associated hospitalizations in 2013-2014, compared with the prevaccination era. Large reductions were also observed in older children, adults, and older adults. We estimated that 10 884 laboratory-confirmed infections and 50 427 all-cause AGE-associated hospital admissions were averted in 2013-2014. Similar reductions have been observed for laboratory-confirmed rotavirus infections during the 2014-2015 season.
   Conclusions. The rapid declines in rotavirus infection and AGE in vaccinated and unvaccinated age groups within 1 year of introducing an infant rotavirus vaccination program are far greater than expected and than previously reported by other countries.
C1 [Atchison, Christina J.; Stowe, Julia; Andrews, Nick; Collins, Sarah; Ramsay, Mary E.; Ladhani, Shamez N.] Univ London Imperial Coll Sci Technol & Med, Immunisat Hepatitis & Blood Safety Dept, London, England.
   [Allen, David J.; Nawaz, Sameena; Brown, David] Univ London Imperial Coll Sci Technol & Med, Publ Hlth England, Ctr Infect Dis Surveillance & Control, Virus Reference Dept, London, England.
   [Atchison, Christina J.] Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Publ Hlth, London, England.
RP Ladhani, SN (corresponding author), Publ Hlth England, Ctr Infect Dis Surveillance & Control, Immunisat Hepatitis & Blood Safety Dept, 61 Colindale Ave, London NW9 5EQ, England.
EM Shamez.Ladhani@phe.gov.uk
RI ; ramsay, mary elizabeth/S-8281-2016
OI Atchison, Christina/0000-0001-8304-7389; Collins,
   Sarah/0000-0001-9989-8794; ramsay, mary elizabeth/0000-0002-7156-7640;
   Stowe, Julia/0000-0002-3999-6461; Allen, David/0000-0002-1194-0415
FU National Institute for Health Research Health Protection Research Unit
   in Immunisation at the London School of Hygiene and Tropical Medicine;
   Public Health England; National Institute for Health ResearchNational
   Institute for Health Research (NIHR) [CL-2011-21-008] Funding Source:
   researchfish
FX This work was supported by the National Institute for Health Research
   Health Protection Research Unit in Immunisation at the London School of
   Hygiene and Tropical Medicine, in partnership with Public Health
   England.
CR Anderson EJ, 2013, CLIN INFECT DIS, V56, P755, DOI 10.1093/cid/cis1010
   [Anonymous], 2014, PHE HEALTH PROTECTIO, V8, P36
   Atchison C, 2015, J INFECTION, V20, P00028
   Atchison CJ, 2009, EUROSURVEILLANCE, V14
   Burns EM, 2012, J PUBLIC HEALTH-UK, V34, P138, DOI 10.1093/pubmed/fdr054
   Buttery JP, 2011, PEDIATR INFECT DIS J, V30, pS25, DOI 10.1097/INF.0b013e3181fefdee
   Dey A, 2012, MED J AUSTRALIA, V197, P453, DOI 10.5694/mja12.10062
   Field EJ, 2010, PEDIATRICS, V126, pE506, DOI 10.1542/peds.2010-0443
   Giaquinto C, 2010, SCAND J INFECT DIS, V42, P142, DOI 10.3109/00365540903380495
   Hahne S, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.43.20945
   Hanquet G, 2011, VACCINE, V29, P4698, DOI 10.1016/j.vaccine.2011.04.098
   Harris JP, 2007, VACCINE, V25, P3962, DOI 10.1016/j.vaccine.2007.02.072
   Jit M, 2007, VACCINE, V25, P3971, DOI 10.1016/j.vaccine.2007.02.070
   Jit M, 2010, VACCINE, V28, P7457, DOI 10.1016/j.vaccine.2010.08.060
   Leino T, 2012, VACCINE, V31, P176, DOI 10.1016/j.vaccine.2012.10.068
   Leshem E, 2014, PEDIATRICS, V134, P15, DOI 10.1542/peds.2013-3849
   Lopman BA, 2011, J INFECT DIS, V204, P980, DOI 10.1093/infdis/jir492
   O'Brien SJ, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-39
   O'Ryan M, 2011, EXPERT REV VACCINES, V10, P1645, DOI [10.1586/erv.11.152, 10.1586/ERV.11.152]
   Office_of_National_Statistics, 2013, ENGL WAL POP EST 201
   Paulke-Korinek M, 2013, VACCINE, V31, P2686, DOI 10.1016/j.vaccine.2013.04.001
   Paulke-Korinek M, 2010, PEDIATR INFECT DIS J, V29, P319, DOI 10.1097/INF.0b013e3181c18434
   Quintanar-Solares M, 2011, PEDIATR INFECT DIS J, V30, pS11, DOI 10.1097/INF.0b013e3181fefb32
   Raes M, 2011, PEDIATR INFECT DIS J, V30, pE120, DOI 10.1097/INF.0b013e318214b811
   Soares-Weiser K, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008521.pub3
   Tam CC, 2012, GUT, V61, P69, DOI 10.1136/gut.2011.238386
   Vesikari T, 2013, PEDIATR INFECT DIS J, V32, P1365, DOI 10.1097/INF.0000000000000086
   World_Health_Organisation_(WHO), 2013, INT CLASS DIS ICD VE
   Zeller M, 2010, VACCINE, V28, P7507, DOI 10.1016/j.vaccine.2010.09.004
NR 29
TC 50
Z9 52
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN 15
PY 2016
VL 213
IS 2
BP 243
EP 249
DI 10.1093/infdis/jiv398
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DF3IQ
UT WOS:000371237900011
PM 26232438
OA Bronze
DA 2020-12-08
ER

PT J
AU Atchison, C
   Collins, S
   Brown, D
   Ramsay, ME
   Ladhani, S
AF Atchison, Christina
   Collins, Sarah
   Brown, David
   Ramsay, Mary E.
   Ladhani, Shamez
TI Reduction in rotavirus disease due to the infant immunisation programme
   in England; evidence from national surveillance
SO JOURNAL OF INFECTION
LA English
DT Letter
DE Rotavirus; Gastroenteritis; Diarrhoea; Vaccination; Immunisation
ID VACCINATION
C1 [Atchison, Christina; Collins, Sarah] Publ Hlth England, CIDSC, Immunisat Hepatitis & Blood Safety Dept, London NW9 5EQ, England.
   [Brown, David] Publ Hlth England, CIDSC, Virus Reference Dept, London NW9 5EQ, England.
   [Ramsay, Mary E.; Ladhani, Shamez] Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Publ Hlth, London W6 8RF, England.
RP Atchison, C (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Publ Hlth, Room 332,Reynolds Bldg,Charing Cross Campus, London W6 8RF, England.
EM christina.atchison11@imperial.ac.uk
RI ramsay, mary elizabeth/S-8281-2016
OI ramsay, mary elizabeth/0000-0002-7156-7640; Collins,
   Sarah/0000-0001-9989-8794; Atchison, Christina/0000-0001-8304-7389
FU National Institute for Health ResearchNational Institute for Health
   Research (NIHR) [CL-2011-21-008] Funding Source: researchfish
CR Atchison CJ, 2009, EUROSURVEILLANCE, V14
   Glass RI, 2014, J INFECTION, V68, pS9, DOI 10.1016/j.jinf.2013.09.010
   Hahne S, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.43.20945
   Hanquet G, 2011, VACCINE, V29, P4698, DOI 10.1016/j.vaccine.2011.04.098
   Harris JP, 2007, VACCINE, V25, P3962, DOI 10.1016/j.vaccine.2007.02.072
   Iturriza-Gomara M, 2009, J INFECT DIS, V200, pS215, DOI 10.1086/605052
   Office for National Statistics, 2014, BIRTHS ENGL WAL 2013
   Public Health England, 2014, HLTH PROT REP WEEKL, V8
   Russell K, 2013, PROPOSED SURVEILLANC
   UK Met Office, UK MEAN TEMP WINT
NR 10
TC 12
Z9 12
U1 0
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD JUL
PY 2015
VL 71
IS 1
BP 128
EP 131
DI 10.1016/j.jinf.2015.01.007
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA CJ9NV
UT WOS:000355830200015
PM 25614960
DA 2020-12-08
ER

PT J
AU Pathak, S
   Horton, DL
   Lucas, S
   Brown, D
   Quaderi, S
   Polhill, S
   Walker, D
   Nastouli, E
   Nunez, A
   Wise, EL
   Fooks, AR
   Brown, M
AF Pathak, Smriti
   Horton, Daniel L.
   Lucas, Sebastian
   Brown, David
   Quaderi, Shumonta
   Polhill, Sara
   Walker, David
   Nastouli, Eleni
   Nunez, Alejandro
   Wise, Emma L.
   Fooks, Anthony R.
   Brown, Michael
TI Diagnosis, management and post-mortem findings of a human case of rabies
   imported into the United Kingdom from India: a case report
SO VIROLOGY JOURNAL
LA English
DT Article
DE Rabies; Milwaukee protocol; Diagnosis
ID MILWAUKEE PROTOCOL; PCR ASSAY; VIRUS; ENCEPHALITIS; PATHOGENESIS;
   RECOVERY; THERAPY; FAILURE; INFLAMMATION; CLEARANCE
AB Background: Human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the Milwaukee Protocol for intensive care management has recently been employed, with limited success in improving survival. Access to molecular diagnostics, pre- and post-mortem, and documentation of pathophysiological responses while using the Milwaukee protocol, can add useful insights for the future of rabies management.
   Case presentation: A 58-year-old British Asian woman was referred to a regional general hospital in the UK with hydrophobia, anxiety and confusion nine weeks after receiving a dog bite in North West India. Nuchal skin biopsy, saliva, and a skin biopsy from the site of the dog bite wound, taken on the day of admission, all demonstrated the presence of rabies virus RNA. Within 48 hours sequence analysis of viral RNA confirmed the diagnosis and demonstrated that the virus was a strain closely related to canine rabies viruses circulating in South Asia. Her condition deteriorated rapidly with increased agitation and autonomic dysfunction. She was heavily sedated and intubated on the day after admission, treated according to a modified Milwaukee protocol, and remained stable until she developed heart block and profound acidosis and died on the eighth day. Analysis of autopsy samples showed a complete absence of rabies neutralizing antibody in cerebrospinal fluid and serum, and corresponding high levels of virus antigen and nucleic acid in brain and cerebrospinal fluid. Quantitative PCR showed virus was also distributed widely in peripheral tissues despite mild or undetectable histopathological changes. Vagus nerve branches in the heart showed neuritis, a probable Negri body but no demonstrable rabies antigen.
   Conclusion: Rapid molecular diagnosis and strain typing is helpful in the management of human rabies infection. Post-mortem findings such as vagal neuritis highlight clinically important effects on the cardiovascular system which are typical for the clinical course of rabies in humans. Management guided by the Milwaukee protocol is feasible within well-resourced intensive care units, but its role in improving outcome for canine-derived rabies remains theoretical.
C1 [Pathak, Smriti; Lucas, Sebastian; Quaderi, Shumonta; Polhill, Sara; Walker, David; Nastouli, Eleni; Brown, Michael] Univ Coll Hosp NHS Fdn Trust, Hosp Trop Dis, Virol Unit, London, England.
   [Pathak, Smriti; Lucas, Sebastian; Quaderi, Shumonta; Polhill, Sara; Walker, David; Nastouli, Eleni; Brown, Michael] Univ Coll Hosp NHS Fdn Trust, Intens Care Unit, London, England.
   [Horton, Daniel L.; Nunez, Alejandro; Wise, Emma L.; Fooks, Anthony R.] Anim Hlth & Vet Labs Agcy, Wildlife Zoonoses & Vector Borne Dis Res Grp, Dept Virol, Weybridge KT15 3NB, Surrey, England.
   [Brown, David] Publ Hlth England, Hlth Protect Agcy, London, England.
   [Fooks, Anthony R.] Univ Liverpool, Dept Clin Infect Microbiol & Immunol, Liverpool L3 5TQ, Merseyside, England.
   [Brown, Michael] London Sch Hyg & Trop Med, London WC1, England.
   [Lucas, Sebastian] St Thomas Hosp, Dept Histopathol, London SE1 7EH, England.
RP Brown, M (corresponding author), Univ Coll Hosp NHS Fdn Trust, Hosp Trop Dis, Virol Unit, London, England.
EM Michael.brown@lshtm.ac.uk
RI Fooks, Anthony R/F-5418-2010; Castel, Alejandro Nunez/C-2560-2011; Wise,
   Emma/AAX-8268-2020; Horton, Daniel/D-9909-2011
OI Wise, Emma/0000-0002-0279-3900; Horton, Daniel/0000-0002-9126-2756;
   Nunez, Alejandro/0000-0001-5926-7541; Walker, David/0000-0002-7140-6855
FU Department for Environment, Food and Rural Affairs (Defra)Department for
   Environment, Food & Rural Affairs (DEFRA) [SV3500]
FX The UK National Reference Laboratory for rabies at AHVLA is funded by
   the Department for Environment, Food and Rural Affairs (Defra) under
   grant SV3500. The authors wish to acknowledge Denise Marston and Dr
   Richard Ellis (AHVLA) for sequence analysis; Dr Daniel Hicks (AHVLA
   Pathology Department) for technical support; Dr Emma Crawley-Boevey,
   Dilys Morgan, Kevin Brown, Hilary Kirkbride and colleagues at Public
   Health England for their contribution to the public health response; and
   Dr R Willoughby (Wisconsin, USA) for his helpful advice during
   management of the case.
CR ALVAREZ L, 1994, PEDIATR INFECT DIS J, V13, P1154, DOI 10.1097/00006454-199412000-00020
   Aramburo A, 2011, CLIN INFECT DIS, V53, P572, DOI 10.1093/cid/cir483
   Banyard AC, 2011, ADV VIRUS RES, V79, P239, DOI 10.1016/B978-0-12-387040-7.00012-3
   Centers for Disease Control and Prevention, 1977, MMWR-MORBID MORTAL W, V26, P183
   Centers for Disease Control and Prevention (CDC), 2008, MMWR Morb Mortal Wkly Rep, V57, P197
   Centers for Disease Control and Prevention (CDC), 2012, MMWR Morb Mortal Wkly Rep, V60, P1734
   Centers for Disease Control Prevention (CDC), 2007, MMWR-MORBID MORTAL W, V56, P361
   Children's Hospital of Wisconsin, RAB REG HOM PAG
   Dietzschold B, 2008, FUTURE VIROL, V3, P481, DOI 10.2217/17460794.3.5.481
   EMMONS R W, 1973, Intervirology, V1, P60, DOI 10.1159/000148833
   Feiden W, 2013, PATHOLOGE, V34, P165, DOI 10.1007/s00292-012-1720-7
   Fooks AR, 2007, VET REC, V161, P289, DOI 10.1136/vr.161.9.289
   Fooks AR, 2003, J APPL MICROBIOL, V94, p31S
   Galelli A, 2000, J NEUROVIROL, V6, P359, DOI 10.3109/13550280009018300
   Gautret P, 2007, VACCINE, V25, P2656, DOI 10.1016/j.vaccine.2006.12.034
   Gilbert AT, 2012, AM J TROP MED HYG, V87, P206, DOI 10.4269/ajtmh.2012.11-0689
   HATTWICK MA, 1972, ANN INTERN MED, V76, P931, DOI 10.7326/0003-4819-76-6-931
   Heaton PR, 1997, J CLIN MICROBIOL, V35, P2762, DOI 10.1128/JCM.35.11.2762-2766.1997
   Hemachudha T, 2006, J NEUROVIROL, V12, P407, DOI 10.1080/13550280600902295
   Hemachudha T, 2013, LANCET NEUROL, V12, P498, DOI 10.1016/S1474-4422(13)70038-3
   Hicks DJ, 2009, J COMP PATHOL, V140, P113, DOI 10.1016/j.jcpa.2008.09.001
   Holzmann-Pazgal G., 2010, Morbidity and Mortality Weekly Report, V59, P185
   Hooper DC, 1998, J VIROL, V72, P3711, DOI 10.1128/JVI.72.5.3711-3719.1998
   Horowitz A, 2010, J IMMUNOL, V185, P2808, DOI 10.4049/jimmunol.1000844
   Hunter M, 2010, J MED VIROL, V82, P1255, DOI 10.1002/jmv.21785
   Jackson AC, 2006, CURR OPIN NEUROL, V19, P267, DOI 10.1097/01.wco.0000227036.93199.3b
   Jackson AC, 2013, ANTIVIR RES, V99, P61, DOI 10.1016/j.antiviral.2013.01.003
   Jackson AC, 2011, ADV VIRUS RES, V79, P365, DOI 10.1016/B978-0-12-387040-7.00017-2
   Johnson N, 2002, J CLIN VIROL, V25, P351, DOI 10.1016/S1386-6532(02)00131-2
   Johnson N, 2011, EMERG INFECT DIS, V17, P753, DOI [10.3201/eid1704.101154, 10.3201/eid1706.101154]
   Knobel DL, 2005, B WORLD HEALTH ORGAN, V83, P360
   Kuzmin IV, 2008, EPIDEMIOL INFECT, V136, P509, DOI 10.1017/S095026880700903X
   Laothamatas J, 2003, AM J NEURORADIOL, V24, P1102
   Maier T, 2010, CLIN INFECT DIS, V50, P1112, DOI 10.1086/651267
   Mallewa M, 2007, EMERG INFECT DIS, V13, P136, DOI 10.3201/eid1301.060810
   McDermid RC, 2008, CAN MED ASSOC J, V178, P557, DOI 10.1503/cmaj.071326
   METZE K, 1991, NEW ENGL J MED, V324, P1814, DOI 10.1056/NEJM199106203242515
   MRAK RE, 1994, J NEUROPATH EXP NEUR, V53, P1, DOI 10.1097/00005072-199401000-00001
   Nadin-Davis SA, 2007, EMERG INFECT DIS, V13, P111, DOI 10.3201/eid1301.060702
   O'Sullivan A, 2013, J PROTEOME RES, V12, P481, DOI 10.1021/pr3009176
   OIE-World organisation for animal health, 2012, MAN DIAGN TESTS VACC
   Phares TW, 2006, J IMMUNOL, V176, P7666, DOI 10.4049/jimmunol.176.12.7666
   Pleasure SJ, 2000, ARCH NEUROL-CHICAGO, V57, P1765, DOI 10.1001/archneur.57.12.1765
   PORRAS C, 1976, ANN INTERN MED, V85, P44, DOI 10.7326/0003-4819-85-1-44
   Rubin J, 2009, SCAND J INFECT DIS, V41, P372, DOI 10.1080/00365540902798333
   RUBIN RH, 1970, J INFECT DIS, V122, P318, DOI 10.1093/infdis/122.4.318
   Schmiedel S, 2007, EUROSURVEILLANCE, V12
   Smith J, 2003, J MED VIROL, V69, P150, DOI 10.1002/jmv.10253
   Solomon T, 2005, BRIT MED J, V331, P501, DOI 10.1136/bmj.331.7515.501
   The Medical College of Wisconsin, 2009, CAR RAB VERS 3 1
   Wakeley PR, 2005, J CLIN MICROBIOL, V43, P2786, DOI 10.1128/JCM.43.6.2786-2792.2005
   Warrell MJ, 2004, LANCET, V363, P959, DOI 10.1016/S0140-6736(04)15792-9
   Willoughby RE, 2009, J INHERIT METAB DIS, V32, P65, DOI 10.1007/s10545-008-0949-z
   Willoughby RE, 2005, NEW ENGL J MED, V352, P2508, DOI 10.1056/NEJMoa050382
   Willoughby RE, 2007, SCI AM, V296, P88, DOI 10.1038/scientificamerican0407-88
NR 55
TC 8
Z9 8
U1 0
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PD APR 7
PY 2014
VL 11
AR 63
DI 10.1186/1743-422X-11-63
PG 7
WC Virology
SC Virology
GA AF7DT
UT WOS:000334874500001
PM 24708671
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-12-08
ER

PT J
AU Nisii, C
   Castilletti, C
   Raoul, H
   Hewson, R
   Brown, D
   Gopal, R
   Eickmann, M
   Gunther, S
   Mirazimi, A
   Koivula, T
   Feldmann, H
   Di Caro, A
   Capobianchi, MR
   Ippolito, G
AF Nisii, Carla
   Castilletti, Concetta
   Raoul, Herve
   Hewson, Roger
   Brown, David
   Gopal, Robin
   Eickmann, Markus
   Gunther, Stephan
   Mirazimi, Ali
   Koivula, Tuija
   Feldmann, Heinz
   Di Caro, Antonino
   Capobianchi, Maria R.
   Ippolito, Giuseppe
TI Biosafety Level-4 Laboratories in Europe: Opportunities for Public
   Health, Diagnostics, and Research
SO PLOS PATHOGENS
LA English
DT Editorial Material
ID HIGHLY INFECTIOUS-DISEASES; HEMORRHAGIC-FEVER; OUTBREAK; ANGOLA
C1 [Nisii, Carla; Castilletti, Concetta; Di Caro, Antonino; Capobianchi, Maria R.; Ippolito, Giuseppe] L Spallanzani Natl Inst Infect Dis, Rome, Italy.
   [Raoul, Herve] French Natl Inst Hlth & Med Res, Lyon, France.
   [Hewson, Roger] Hlth Protect Agcy, Salisbury, Wilts, England.
   [Brown, David; Gopal, Robin] Hlth Protect Agcy, London, England.
   [Eickmann, Markus] Univ Marburg, Marburg, Germany.
   [Gunther, Stephan] Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany.
   [Mirazimi, Ali; Koivula, Tuija] Swedish Inst Communicable Dis Control, Solna, Sweden.
   [Feldmann, Heinz] NIAID, Div Intramural Res DIR, NIH, Rocky Mt Labs, Hamilton, MT USA.
RP Nisii, C (corresponding author), L Spallanzani Natl Inst Infect Dis, Rome, Italy.
EM Giuseppe.ippolito@inmi.it
RI nisii, carla/B-8871-2017; raoul, herve/G-3403-2013; Castilletti,
   Concetta/AAA-8408-2019; Castilletti, Concetta/B-6545-2016; Ippolito,
   Giuseppe/J-7207-2017; Di Caro, Antonino/K-6854-2016
OI nisii, carla/0000-0001-5369-0437; Castilletti,
   Concetta/0000-0001-9819-236X; Castilletti, Concetta/0000-0001-9819-236X;
   Di Caro, Antonino/0000-0001-6027-3009; Gunther,
   Stephan/0000-0002-6562-0230; Ippolito, Giuseppe/0000-0002-1076-2979;
   Capobianchi, Maria Rosaria/0000-0003-3465-0071
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [ZIAAI001089, ZIAAI001168, ZIAAI001168, ZIAAI001163, ZIAAI001089,
   ZIAAI001163, ZIAAI001163, ZIAAI001163, ZIAAI001163, ZIAAI001089,
   ZIAAI001089, ZIAAI001089, ZIAAI001089, ZIAAI001089, ZIAAI001163,
   ZIAAI001089, ZIAAI001089, ZIAAI001089, ZIAAI001168, ZIAAI001163] Funding
   Source: NIH RePORTER
CR Baka A, 2007, EUROSURVEILLANCE, V12, P5
   Bannister B, 2009, CLIN MICROBIOL INFEC, V15, P740, DOI 10.1111/j.1469-0691.2009.02872.x
   European Commission, 2010, EUR RES INFR HIGHL P
   European Commission, 2007, DEC AD JOINTL EUR PA
   European Commission, 2011, QUAL ASS EX NETW DET
   European Commission, 2012, HARM EUR IN HIGH LEV
   Grolla A, 2005, Bull Soc Pathol Exot, V98, P205
   Grolla A, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001183
   Ippolito G, 2009, CLIN MICROBIOL INFEC, V15, P706, DOI 10.1111/j.1469-0691.2009.02876.x
   Ippolito G, 2008, NAT REV MICROBIOL, V6, DOI 10.1038/nrmicro1896-c1
   Ippolito G, 2009, EMERG INFECT DIS, V15, P1858, DOI 10.3201/eid1511.091134
   LeDuc JW, 2009, EMERG INFECT DIS, V15, P1
   Nisii C, 2009, CLIN MICROBIOL INFEC, V15, P720, DOI 10.1111/j.1469-0691.2009.02946.x
   Onyango CO, 2007, J INFECT DIS, V196, pS193, DOI 10.1086/520609
   Towner JS, 2007, J INFECT DIS, V196, pS205, DOI 10.1086/520601
   Towner JS, 2006, J VIROL, V80, P6497, DOI 10.1128/JVI.00069-06
   Towner JS, 2004, J VIROL, V78, P4330, DOI 10.1128/JVI.78.8.4330-4341.2004
   United States Government Accountability Office, 2007, HIGH CONT BIOS LAB P
   Wildlife Conservation Society, 2007, ON WORLD ON HLTH EV
   World Health Organization International Health Regulations, 2005, INT HLTH REG
NR 20
TC 14
Z9 15
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD JAN
PY 2013
VL 9
IS 1
AR e1003105
DI 10.1371/journal.ppat.1003105
PG 4
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 083LG
UT WOS:000314464600017
PM 23349630
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Zakikhany, K
   Allen, DJ
   Brown, D
   Iturriza-Gomara, M
AF Zakikhany, Katherina
   Allen, David J.
   Brown, David
   Iturriza-Gomara, Miren
TI Molecular Evolution of GII-4 Norovirus Strains
SO PLOS ONE
LA English
DT Article
ID GASTROENTERITIS OUTBREAKS; HOST SUSCEPTIBILITY; NORWALK VIRUS; VARIANT;
   INFECTION; DISEASE
AB Background: Human Noroviruses (NoV) are the major cause of acute nonbacterial gastroenteritis and the leading cause of outbreaks of gastroenteritis worldwide. Genotype II-4 (GII-4) NoV has been shown to spread rapidly and is the most commonly detected strain worldwide, particularly in association with outbreaks. Previously, we have shown that circulating GII-4 NoV strains exist as populations of selectively neutral variants, and that the emergence of epidemic GII-4 NoV strains correlated with mutations in at least two key sites (Sites A and B) within the P2 domain of the surface exposed major capsid protein (VP1).
   Methodology: We developed a rapid pyrosequencing method for screening of the two Sites A and B and a homology based modelling system was used to predict the effects of amino acid substitutions at these sites on the antigenic properties of the virus (defined as surface motif types).
   Principle Finding/Conclusion: Here, we describe the characterisation of amino acid diversity at Sites A and B for 1062 GII-4 NoV strains from clinical specimen associated with outbreak of gastroenteritis (2000-2011) and 250 GII-4 NoV sequences from Genbank. Our data identified a high diversity of different Site A and B site combinations at amino acid level and amino acid diversity was higher at Site B than Site A. Site A motifs could be grouped into 3 clusters based on similar surface motif types. We predict that Site A is a major epitope on the virus surface, responsible for defining the antigenic profile, and a more subtle role for Site B, maintaining minor antigenic variation within the virus population.
C1 [Zakikhany, Katherina; Allen, David J.; Brown, David; Iturriza-Gomara, Miren] Hlth Protect Agcy Microbiol Serv, Virus Reference Dept, London, England.
   [Zakikhany, Katherina] European Ctr Dis Prevent & Control ECDC, European Programme Publ Hlth Microbiol Training E, Stockholm, Sweden.
RP Allen, DJ (corresponding author), Hlth Protect Agcy Microbiol Serv, Virus Reference Dept, London, England.
EM david.james.allen@hpa.org.uk
RI Gomara, Miren Iturriza/B-4351-2013
OI Gomara, Miren Iturriza/0000-0001-5816-6423; Allen,
   David/0000-0002-1194-0415
CR Allen DJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001485
   Allen DJ, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-150
   Bok K, 2009, J VIROL, V83, P11890, DOI 10.1128/JVI.00864-09
   Bull RA, 2006, J CLIN MICROBIOL, V44, P327, DOI 10.1128/JCM.44.2.327-333.2006
   Cao S, 2007, J VIROL, V81, P5949, DOI 10.1128/JVI.00219-07
   Debbink K, 2012, J VIROL, V86, P1214, DOI 10.1128/JVI.06189-11
   Donaldson EF, 2010, NAT REV MICROBIOL, V8, P231, DOI 10.1038/nrmicro2296
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Hall T. A, 1999, NUCL ACIDS S SER, DOI DOI 10.1021/BK-1999-0734.CH008
   Harris JP, 2008, EMERG INFECT DIS, V14, P1546, DOI 10.3201/eid1410.080188
   Hutson AM, 2004, TRENDS MICROBIOL, V12, P279, DOI 10.1016/j.tim.2004.04.005
   JOHNSON PC, 1990, J INFECT DIS, V161, P18, DOI 10.1093/infdis/161.1.18
   KOOPMAN JS, 1982, AM J EPIDEMIOL, V115, P173, DOI 10.1093/oxfordjournals.aje.a113288
   Kroneman A, 2004, EUROSURVEILLANCE, V8
   Lindesmith LC, 2008, PLOS MED, V5, P269, DOI 10.1371/journal.pmed.0050031
   Lindesmith LC, 2011, J VIROL, V85, P231, DOI 10.1128/JVI.01364-10
   Lopman B, 2004, LANCET, V363, P682, DOI 10.1016/S0140-6736(04)15641-9
   Matsui SM, 2000, J INFECT DIS, V181, pS331, DOI 10.1086/315587
   Mattner F, 2006, CLIN MICROBIOL INFEC, V12, P69, DOI 10.1111/j.1469-0691.2005.01299.x
   Shanker S, 2011, J VIROL, V85, P8635, DOI 10.1128/JVI.00848-11
   Siebenga JJ, 2007, J VIROL, V81, P9932, DOI 10.1128/JVI.00674-07
   Siebenga JJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000884
   Tam CC, 2012, GUT, V61, P69, DOI 10.1136/gut.2011.238386
   Tan M, 2005, TRENDS MICROBIOL, V13, P285, DOI 10.1016/j.tim.2005.04.004
   Tan M, 2008, J INFECT DIS, V198, P940, DOI 10.1086/589810
   Teunis PFM, 2008, J MED VIROL, V80, P1468, DOI 10.1002/jmv.21237
   Vega E, 2011, EMERG INFECT DIS, V17, P1389, DOI 10.3201/eid1708.101837
   Wingfield T, 2010, J CLIN VIROL, V49, P219, DOI 10.1016/j.jcv.2010.07.025
   Xerry J, 2008, J CLIN MICROBIOL, V46, P947, DOI 10.1128/JCM.02240-07
   Yen C, 2011, CLIN INFECT DIS, V53, P568, DOI 10.1093/cid/cir478
   Zheng DP, 2006, VIROLOGY, V346, P312, DOI 10.1016/j.virol.2005.11.015
NR 31
TC 33
Z9 37
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 26
PY 2012
VL 7
IS 7
AR e41625
DI 10.1371/journal.pone.0041625
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 012MO
UT WOS:000309240600035
PM 22844506
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-08
ER

PT J
AU Warrener, L
   Slibinskas, R
   Chua, KB
   Nigatu, W
   Brown, KE
   Sasnauskas, K
   Samuel, D
   Brown, D
AF Warrener, Lenesha
   Slibinskas, Rimantas
   Chua, Kaw Bing
   Nigatu, Wondatir
   Brown, Kevin E.
   Sasnauskas, Kestutis
   Samuel, Dhanraj
   Brown, David
TI A point-of-care test for measles diagnosis: detection of
   measles-specific IgM antibodies and viral nucleic acid
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID ORAL FLUID SAMPLES; PCR ASSAY; VIRUS; MUMPS; IDENTIFICATION;
   NUCLEOPROTEIN
AB Objective To evaluate the performance of a newly developed point-of-care test (POCT) for the detection of measles-specific IgM antibodies in serum and oral fluid specimens and to assess if measles virus nucleic acid could be recovered from used POCT strips.
   Methods The POCT was used to test 170 serum specimens collected through measles surveillance or vaccination programmes in Ethiopia, Malaysia and the Russian Federation: 69 were positive for measles immunoglobulin M (IgM) antibodies, 74 were positive for rubella IgM antibodies and 7 were positive for both. Also tested were 282 oral fluid specimens from the measles, mumps and rubella (MMR) surveillance programme of the United Kingdom of Great Britain and Northern Ireland. The Microimmune measles IgM capture enzyme immunoassay was the gold standard for comparison. A panel of 24 oral fluids was used to investigate if measles virus haemagglutinin (H) and nucleocapsid (N) genes could be amplified by polymerase chain reaction directly from used POCT strips.
   Findings With serum POCT showed a sensitivity and specificity of 90.8% (69/76) and 93.6% (88/94), respectively; with oral fluids, sensitivity and specificity were 90.0% (63/70) and 96.2% (200/208), respectively. Both H and N genes were reliably detected in POCT strips and the N genes could be sequenced for genotyping. Measles virus genes could be recovered from POCT strips after storage for 5 weeks at 20-25 degrees C.
   Conclusion The POCT has the sensitivity and specificity required of a field-based test for measles diagnosis. However, its role in global measles control programmes requires further evaluation.
C1 [Warrener, Lenesha; Brown, Kevin E.; Samuel, Dhanraj; Brown, David] Hlth Protect Agcy, Ctr Infect, Virus Reference Dept, 61 Colindale Ave, London NW9 5EQ, England.
   [Slibinskas, Rimantas; Sasnauskas, Kestutis] Vilnius Univ, Inst Biotechnol, Vilnius, Lithuania.
   [Chua, Kaw Bing] Natl Publ Hlth Lab, Selangor, Malaysia.
   [Nigatu, Wondatir] Ethiopian Hlth & Nutr Res Inst, Addis Ababa, Ethiopia.
RP Warrener, L (corresponding author), Hlth Protect Agcy, Ctr Infect, Virus Reference Dept, 61 Colindale Ave, London NW9 5EQ, England.
EM lenesha.warrener@hpa.org.uk
FU Health Protection Agency, United Kingdom
FX This project was funded by the Health Protection Agency, United Kingdom.
CR [Anonymous], 2008, Wkly Epidemiol Rec, V83, P229
   Anonymous, 2009, Morbidity and Mortality Weekly Report, V58, P1321
   Centers for Disease Control and Prevention (CDC), 2008, MMWR Morb Mortal Wkly Rep, V57, P657
   Choi YH, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-338
   Featherstone D, 2003, J INFECT DIS, V187, pS264, DOI 10.1086/368054
   Jin L, 2002, B WORLD HEALTH ORGAN, V80, P76
   Kuhne M, 2006, INFECT GENET EVOL, V6, P269, DOI 10.1016/j.meegid.2005.08.003
   Nigatu W, 2001, J MED VIROL, V65, P373, DOI 10.1002/jmv.2044
   Samuel D, 2003, J CLIN VIROL, V28, P121, DOI 10.1016/S1386-6532(02)00273-1
   SANDERS R, 2010, RISK ANAL MEASLES RE
   Slibinskas R, 2004, J BIOTECHNOL, V107, P115, DOI 10.1016/j.jbiotec.2003.10.018
   Thomas B, 2007, J MED VIROL, V79, P1587, DOI 10.1002/jmv.20997
   Vyse AJ, 2006, EPIDEMIOL INFECT, V134, P1303, DOI 10.1017/S0950268806006340
   Vyse AJ, 1997, J VIROL METHODS, V63, P93, DOI 10.1016/S0166-0934(96)02118-0
   Warrener L, 2010, J MED VIROL, V82, P485, DOI 10.1002/jmv.21693
   *WHO, 1998, WKLY EPIDEMIOL REC, V73, P265
   *WHO, 2001, MEASL MORT RED REG E
   *WHO, 2005, WKLY EPIDEMIOL REC, V80, P347
   WHO, 2001, WKLY EPIDEMIOL REC, V76, P242
   World Health Organization, 2007, MAN LAB DIAGN MEASL
NR 20
TC 16
Z9 17
U1 0
U2 11
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
EI 1564-0604
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD SEP
PY 2011
VL 89
IS 9
BP 675
EP 682
DI 10.2471/BLT.11.088427
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 824YZ
UT WOS:000295239400025
PM 21897488
OA Green Published
DA 2020-12-08
ER

PT J
AU Abernathy, ES
   Hubschen, JM
   Muller, CP
   Jin, L
   Brown, D
   Komase, K
   Mori, Y
   Xu, WB
   Zhu, Z
   Siqueira, MM
   Shulga, S
   Tikhonova, N
   Pattamadilok, S
   Incomserb, P
   Smit, SB
   Akoua-Koffi, C
   Bwogi, J
   Lim, WWL
   Woo, GKS
   Triki, H
   Jee, Y
   Mulders, MN
   de Filippis, AMB
   Ahmed, H
   Ramamurty, N
   Featherstone, D
   Icenogle, JP
AF Abernathy, Emily S.
   Huebschen, Judith M.
   Muller, Claude P.
   Jin, Li
   Brown, David
   Komase, Katsuhiro
   Mori, Yoshio
   Xu, Wenbo
   Zhu, Zhen
   Siqueira, Marilda M.
   Shulga, Sergey
   Tikhonova, Nina
   Pattamadilok, Sirima
   Incomserb, Patcha
   Smit, Sheilagh B.
   Akoua-Koffi, Chantal
   Bwogi, Josephine
   Lim, Wilina W. L.
   Woo, Gibson K. S.
   Triki, Hinda
   Jee, Youngmee
   Mulders, Mick N.
   de Filippis, Ana Maria Bispo
   Ahmed, Hinda
   Ramamurty, Nalini
   Featherstone, David
   Icenogle, Joseph P.
TI Status of Global Virologic Surveillance for Rubella Viruses
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT Global Technical Consultation to Assess the Feasibility of Measles
   Eradication
CY JUL 28-30, 2010
CL Washington, DC
ID PHYLOGENETIC ANALYSIS; MEASLES; EPIDEMIOLOGY; TRANSMISSION; CIRCULATION;
   ELIMINATION; POLIOVIRUS; OUTBREAK
AB The suspected measles case definition captures rubella cases. Therefore, measles surveillance will be improved in the course of the control and eventual elimination of rubella transmission. One aspect of rubella control, virologic surveillance, is reviewed here. A systematic nomenclature for rubella viruses (RVs) based on 13 genotypes has been established and is updated when warranted by increases in information about RVs. From 2005 through 2010, the genotypes of RVs most frequently reported were 1E, 1G, and 2B, and genotypes 1a, 1B, 1C, 1h, 1j, and 2C were less frequently reported. Virologic surveillance can support rubella control and elimination. Synopses of rubella virologic surveillance in various countries, regions, and globally are given, including characterization of viruses from imported cases in a country that has eliminated rubella and studies of endemic viruses circulating in countries without rubella control objectives. Current challenges are discussed.
C1 [Abernathy, Emily S.; Icenogle, Joseph P.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Huebschen, Judith M.; Muller, Claude P.] Ctr Rech Publ Sante, Lab Natl Sante, Inst Immunol, Luxembourg, Luxembourg.
   [Jin, Li; Brown, David] Hlth Protect Agcy, Ctr Infect, Virus Reference Dept, London, England.
   [Komase, Katsuhiro; Mori, Yoshio] Natl Inst Infect Dis, Dept Virol 3, Tokyo, Japan.
   [Xu, Wenbo; Zhu, Zhen] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China.
   [Siqueira, Marilda M.] Minist Hlth, Oswaldo Cruz Fdn, Inst Oswaldo Cruz, Measles Natl Reference Lab, Rio De Janeiro, Brazil.
   [Shulga, Sergey; Tikhonova, Nina] Gabricheysky GN Res Inst Epidemiol & Microbiol, Moscow, Russia.
   [Pattamadilok, Sirima; Incomserb, Patcha] Natl Inst Hlth, Dept Med Sci, Nonthaburi, Thailand.
   [Smit, Sheilagh B.] Natl Inst Communicable Dis, Johannesburg, South Africa.
   [Akoua-Koffi, Chantal] Inst Pasteur Cote dIvoire, Reg Reference Lab Measles Rubella, Abidjan, Cote Ivoire.
   [Bwogi, Josephine] Minist Hlth, Expanded Program Immunizat Lab, Uganda Virus Res Inst, Entebbe, Uganda.
   [Lim, Wilina W. L.; Woo, Gibson K. S.] Ctr Hlth Protect, Publ Hlth Lab Serv, Dept Hlth, Kowloon, Hong Kong, Peoples R China.
   [Triki, Hinda] Inst Pateur Tunis, Lab Clin Virol, Tunis, Tunisia.
   [Jee, Youngmee] World Hlth Org WHO Reg Off Western Pacific, Manila, Philippines.
   [Mulders, Mick N.] WHO Reg Off Europe, Copenhagen, Denmark.
   [de Filippis, Ana Maria Bispo] WHO, Pan Amer Hlth Org, Washington, DC USA.
   [Ahmed, Hinda] WHO Reg Off Eastern Mediterranean, Cairo, Egypt.
   [Ramamurty, Nalini] WHO Reg Off SE Asia, New Delhi, India.
   [Featherstone, David] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland.
RP Icenogle, JP (corresponding author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,Mail Stop C-22, Atlanta, GA 30333 USA.
EM jci1@cdc.gov
RI Shulga, Sergei/S-5156-2018; Hubschen, Judith/AAF-5113-2020
OI Shulga, Sergei/0000-0003-0931-9803; Tikhonova, Nina
   Timofeevna/0000-0002-8762-4355; AKOUA KOFFI,
   Chantal/0000-0003-0975-6632; Hubschen, Judith/0000-0002-5001-2128
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
FX This article is part of a supplement entitled "Global Progress Toward
   Measles Eradication and Prevention of Rubella and Congenital Rubella
   Syndrome," which was sponsored by the Centers for Disease Control and
   Prevention.
CR Abernathy E, 2009, J CLIN MICROBIOL, V47, P182, DOI 10.1128/JCM.01231-08
   [Anonymous], 2007, Wkly Epidemiol Rec, V82, P216
   [Anonymous], 2005, Wkly Epidemiol Rec, V80, P126
   [Anonymous], 2008, Wkly Epidemiol Rec, V83, P395
   Best J. M., 2009, Principles and practice of clinical virology, P561, DOI 10.1002/9780470741405.ch23
   Caidi H, 2008, J CLIN VIROL, V42, P86, DOI 10.1016/j.jcv.2007.11.013
   Centers for Disease Control and Prevention (CDC), 2008, MMWR Morb Mortal Wkly Rep, V57, P657
   Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P1160
   Centers for Disease Control and Prevention (CDC), 2005, MMWR-MORBID MORTAL W, V54, P1100
   Doshi S, 2009, INT J EPIDEMIOL, V38, P182, DOI 10.1093/ije/dyn261
   EUVAC, RUB SURV REP 2009
   EUVAC, RUB SURV REP 2008
   EUVAC.NET, RUB SURV REP 2000 20
   EUVAC.NET, VACC SCHED MMR OV
   Frey TK, 1998, J INFECT DIS, V178, P642, DOI 10.1086/515370
   Hahne S, 2009, PEDIATR INFECT DIS J, V28, P795, DOI 10.1097/INF.0b013e3181a3e2d5
   Hubschen JM, 2007, J GEN VIROL, V88, P1960, DOI 10.1099/vir.0.82580-0
   Icenogle JP, 2006, CLIN INFECT DIS, V43, P5133, DOI 10.1086/505945
   Icenogle JP, J INFECT DI IN PRESS
   Irons B, 2003, J INFECT DIS, V187, pS153, DOI 10.1086/368031
   Jin L, 2007, J MED VIROL, V79, P1017, DOI 10.1002/jmv.20847
   Jorba J, 2008, J VIROL, V82, P4429, DOI 10.1128/JVI.02354-07
   Kouadio IK, 2009, EPIDEMIOL INFECT, V137, P1593, DOI 10.1017/S0950268809002520
   Novo A, 2009, EUROSURVEILLANCE, V14, P707
   Pan American Health Organization, 2009, MEASL RUB WEEKL B WE
   Pan American Health Organization, IMM NEWSL
   Pan American Health Organization, 2008, MEASL RUB WEEKL B WE
   Pan American Health Organization, EL RUB CONG RUB SYND
   Pan American Health Organization, PUBL G PAN AM HLTH O
   Pan American Health Organization, MEASL EL FIELD GUID
   Pan American Health Organization, 2010, MEASL RUB WEEKL B WE
   Reef SE, J INFECT DI IN PRESS
   Reef SE, 2006, CLIN INFECT DIS, V43, pS123, DOI 10.1086/505943
   Rota PA, 2009, CURR TOP MICROBIOL, V330, P129
   Saitoh M, 2006, MICROBIOL IMMUNOL, V50, P179, DOI 10.1111/j.1348-0421.2006.tb03784.x
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   TAMURA K, 1992, MOL BIOL EVOL, V9, P678
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Tiunnikov GI, 2007, ZH MIKROBIOL EPIDEMI, V6, P26
   Vauloup-Fellous C, 2010, J CLIN MICROBIOL, V48, P2530, DOI 10.1128/JCM.00181-10
   Watson J C, 1998, MMWR Recomm Rep, V47, P1
   WHO, EXP PROGR IMM
   World Health Organization, 2010, PUBL WHO
   World Health Organization, RUB REP CAS
   Yan DM, 2010, J CLIN MICROBIOL, V48, P3274, DOI 10.1128/JCM.00712-10
   Zheng DP, 2003, J INFECT DIS, V187, P1587, DOI 10.1086/374972
   Zheng Du-Ping, 2005, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P19
   Zhu Z, 2010, J CLIN MICROBIOL, V48, P1775, DOI 10.1128/JCM.02055-09
NR 48
TC 38
Z9 43
U1 0
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 15
PY 2011
VL 204
SU 1
BP S524
EP S532
DI 10.1093/infdis/jir099
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 802YT
UT WOS:000293547600067
PM 21666209
OA Bronze
DA 2020-12-08
ER

PT J
AU Rota, PA
   Brown, K
   Mankertz, A
   Santibanez, S
   Shulga, S
   Muller, CP
   Hubschen, JM
   Siqueira, M
   Beirnes, J
   Ahmed, H
   Triki, H
   Al-Busaidy, S
   Dosseh, A
   Byabamazima, C
   Smit, S
   Akoua-Koffi, C
   Bwogi, J
   Bukenya, H
   Wairagkar, N
   Ramamurty, N
   Incomserb, P
   Pattamadilok, S
   Jee, Y
   Lim, W
   Xu, WB
   Komase, K
   Takeda, M
   Tran, T
   Castillo-Solorzano, C
   Chenoweth, P
   Brown, D
   Mulders, MN
   Bellini, WJ
   Featherstone, D
AF Rota, Paul A.
   Brown, Kevin
   Mankertz, Annette
   Santibanez, Sabine
   Shulga, Sergey
   Muller, Claude P.
   Huebschen, Judith M.
   Siqueira, Marilda
   Beirnes, Jennifer
   Ahmed, Hinda
   Triki, Henda
   Al-Busaidy, Suleiman
   Dosseh, Annick
   Byabamazima, Charles
   Smit, Sheilagh
   Akoua-Koffi, Chantal
   Bwogi, Josephine
   Bukenya, Henry
   Wairagkar, Niteen
   Ramamurty, Nalini
   Incomserb, Patcha
   Pattamadilok, Sirima
   Jee, Youngmee
   Lim, Wilina
   Xu, Wenbo
   Komase, Katsuhiro
   Takeda, Makoto
   Tran, Thomas
   Castillo-Solorzano, Carlos
   Chenoweth, Paul
   Brown, David
   Mulders, Mick N.
   Bellini, William J.
   Featherstone, David
TI Global Distribution of Measles Genotypes and Measles Molecular
   Epidemiology
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT Global Technical Consultation to Assess the Feasibility of Measles
   Eradication
CY JUL 28-30, 2010
CL Washington, DC
ID VIRUS GENOTYPES; GEOGRAPHICAL-DISTRIBUTION; GENETIC-CHARACTERIZATION;
   UNITED-STATES; TAMIL-NADU; TRANSMISSION; STRAINS; AFRICA; INDIA;
   IDENTIFICATION
AB A critical component of laboratory surveillance for measles is the genetic characterization of circulating wildtype viruses. The World Health Organization (WHO) Measles and Rubella Laboratory Network (LabNet), provides for standardized testing in 183 countries and supports genetic characterization of currently circulating strains of measles viruses. The goal of this report is to describe the lessons learned from nearly 20 years of virologic surveillance for measles, to describe the global databases for measles sequences, and to provide regional updates about measles genotypes detected by recent surveillance activities. Virologic surveillance for measles is now well established in all of the WHO regions, and most countries have conducted at least some baseline surveillance. The WHO Global Genotype Database contains >7000 genotype reports, and the Measles Nucleotide Surveillance (MeaNS) contains >4000 entries. This sequence information has proven to be extremely useful for tracking global transmission patterns and for documenting the interruption of transmission in some countries. The future challenges will be to develop quality control programs for molecular methods and to continue to expand virologic surveillance activities in all regions.
C1 [Rota, Paul A.; Chenoweth, Paul; Bellini, William J.] World Hlth Org WHO Global Specialized Lab, Atlanta, GA USA.
   [Brown, Kevin; Brown, David] WHO Reg Reference Lab, WHO Global Specialized Lab, London, England.
   [Mankertz, Annette] WHO Reg Reference Lab, Berlin, Germany.
   [Shulga, Sergey] WHO Reg Reference Lab, Moscow, Russia.
   [Muller, Claude P.] WHO Reg Reference Lab, Luxembourg, Luxembourg.
   [Siqueira, Marilda] WHO Reg Reference Lab, Rio De Janeiro, Brazil.
   [Beirnes, Jennifer] WHO Reg Reference Lab, Winnipeg, MB, Canada.
   [Ahmed, Hinda] WHO Reg Off, Cairo, Egypt.
   [Triki, Henda] WHO Reg Reference Lab, Tunis, Tunisia.
   [Al-Busaidy, Suleiman] WHO Reg Reference Lab, Muscat, Oman.
   [Dosseh, Annick] WHO Reg Off, Ouagadougou, Burkina Faso.
   [Byabamazima, Charles] WHO Reg Off, Harare, Zimbabwe.
   [Smit, Sheilagh] WHO Reg Reference Lab, Johannesburg, South Africa.
   [Akoua-Koffi, Chantal] WHO Reg Reference Lab, Abidjan, Cote Ivoire.
   [Bwogi, Josephine; Bukenya, Henry] WHO Reg Reference Lab, Entebbe, Uganda.
   [Wairagkar, Niteen; Ramamurty, Nalini] WHO Reg Off SE Asian Reg, Delhi, India.
   [Incomserb, Patcha; Pattamadilok, Sirima] WHO Reg Reference Lab, Bangkok, Thailand.
   [Jee, Youngmee] WHO Reg Off, Manila, Philippines.
   [Lim, Wilina] WHO Reg Reference Lab, Hong Kong, Hong Kong, Peoples R China.
   [Xu, Wenbo] WHO Reg Reference Lab, Beijing, Peoples R China.
   [Komase, Katsuhiro; Takeda, Makoto] WHO Global Specialized Lab, Tokyo, Japan.
   [Tran, Thomas] WHO Reg Reference Lab, Western Pacific Region, Vic, Australia.
   [Castillo-Solorzano, Carlos] WHO Reg Off, Washington, DC USA.
   [Mulders, Mick N.] WHO Reg Off, Copenhagen, Denmark.
   [Featherstone, David] WHO Headquarters, Geneva, Switzerland.
RP Rota, PA (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS C-22, Atlanta, GA 30333 USA.
EM prota@cdc.gov
RI Hubschen, Judith/AAF-5113-2020; Shulga, Sergei/S-5156-2018; Takeda,
   Makoto/J-2550-2018
OI Shulga, Sergei/0000-0003-0931-9803; Takeda, Makoto/0000-0002-8194-7727;
   Hubschen, Judith/0000-0002-5001-2128; Mankertz,
   Annette/0000-0002-0131-5739; AKOUA KOFFI, Chantal/0000-0003-0975-6632
FU World Health OrganizationWorld Health Organization
FX This study was supported in part by the World Health Organization
CR Alla A, 2002, J MED VIROL, V68, P441, DOI 10.1002/jmv.10223
   Alla A, 2006, J MED VIROL, V78, P1465, DOI 10.1002/jmv.20720
   [Anonymous], 2007, Wkly Epidemiol Rec, V82, P216
   [Anonymous], 2003, Wkly Epidemiol Rec, V78, P229
   [Anonymous], 2005, Wkly Epidemiol Rec, V80, P126
   [Anonymous], 2001, Wkly Epidemiol Rec, V76, P249
   [Anonymous], 2006, Wkly Epidemiol Rec, V81, P474
   [Anonymous], 2008, MMWR MORB MORTAL WKL, V57, P657
   Baliraine FN, 2011, EMERG INFECT DIS, V17, P110, DOI 10.3201/eid1701.100753
   Bankamp B, 2008, VIRUS RES, V135, P298, DOI 10.1016/j.virusres.2008.04.008
   Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P1100
   Chen TH, 2007, PEDIATR INFECT DIS J, V29, P794
   Chibo D, 2002, EMERG INFECT DIS, V8, P735, DOI 10.3201/eid0807.010409
   Cohuet S, 2009, EPIDEMIOL INFECT, V137, P1759, DOI 10.1017/S0950268809002714
   Djebbi A, 2005, J CLIN VIROL, V34, P1, DOI 10.1016/j.jcv.2004.11.026
   El Mubarak HS, 2002, J GEN VIROL, V83, P1437, DOI 10.1099/0022-1317-83-6-1437
   *EPI, 1998, WKLY EPIDEMIOL REC, V73, P265
   Gouandjika-Vasilache I, 2006, J MED VIROL, V78, P964, DOI 10.1002/jmv.20648
   Grigg M. A., 2008, Morbidity and Mortality Weekly Report, V57, P893
   Haddad-Boubaker S, 2010, VIRUS RES, V153, P258, DOI 10.1016/j.virusres.2010.08.011
   Hanses F, 1999, J GEN VIROL, V80, P871, DOI 10.1099/0022-1317-80-4-871
   Hassidim A., 2008, Morbidity and Mortality Weekly Report, V57, P203
   Hunt E., 2008, Morbidity and Mortality Weekly Report, V57, P169
   Kouomou DW, 2002, J MED VIROL, V68, P433, DOI 10.1002/jmv.10222
   Kreis S, 1997, J GEN VIROL, V78, P1581, DOI 10.1099/0022-1317-78-7-1581
   Kremer JR, 2008, EMERG INFECT DIS, V14, P107, DOI 10.3201/eid1401.070778
   Kremer JR, 2010, EMERG INFECT DIS, V16, P1724, DOI 10.3201/eid1611.100777
   Kremer JR, 2009, LANCET, V373, P356, DOI 10.1016/S0140-6736(08)61850-4
   Marinova L, 2009, EUROSURVEILLANCE, V14, P1
   Mbugua FM, 2003, J MED VIROL, V71, P599, DOI 10.1002/jmv.10515
   Mohan A, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-143
   Mulders MN, 2003, J INFECT DIS, V187, pS277, DOI 10.1086/368036
   Mulders MN, 2001, VACCINE, V19, P2245, DOI 10.1016/S0264-410X(00)00453-9
   Muwonge A, 2005, EMERG INFECT DIS, V11, P1522, DOI 10.3201/eid1110.050431
   Nigatu W, 2001, J MED VIROL, V65, P373, DOI 10.1002/jmv.2044
   Ono N, 2001, J VIROL, V75, P4399, DOI 10.1128/JVI.75.9.4399-4401.2001
   Ramamurty N, 2006, J MED VIROL, V78, P508, DOI 10.1002/jmv.20569
   Redd S. B., 2008, Morbidity and Mortality Weekly Report, V57, P494
   Richard JL, 2009, EURO SURVEILL, V14
   Riddell MA, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-87
   RIMA BK, 1995, J GEN VIROL, V76, P1173, DOI 10.1099/0022-1317-76-5-1173
   Rota J, 2006, EMERG INFECT DIS, V12, P1779, DOI 10.3201/eid1211.060635
   ROTA JS, 1992, VIROLOGY, V188, P135, DOI 10.1016/0042-6822(92)90742-8
   ROTA JS, 1994, VIRUS RES, V31, P317, DOI 10.1016/0168-1702(94)90025-6
   Rota JS, 1998, J INFECT DIS, V177, P204, DOI 10.1086/513825
   Rota JS, 1996, J INFECT DIS, V173, P32, DOI 10.1093/infdis/173.1.32
   Rota PA, 2009, CURR TOP MICROBIOL, V330, P129
   Rota PA, 2003, J INFECT DIS, V187, pS270, DOI 10.1086/368042
   Rota PA, 2002, EMERG INFECT DIS, V8, P902, DOI 10.3201/eid0809.020206
   Santibanez S, 2002, J GEN VIROL, V83, P2699, DOI 10.1099/0022-1317-83-11-2699
   Schmid D, 2010, EPIDEMIOL INFECT, V138, P415, DOI 10.1017/S0950268809990604
   Shulga SV, 2009, CLIN MICROBIOL INFEC, V15, P528, DOI 10.1111/j.1469-0691.2009.02748.x
   Smit SB, 2005, J MED VIROL, V77, P550, DOI 10.1002/jmv.20491
   Truong AT, 2001, VIRUS RES, V76, P71, DOI 10.1016/S0168-1702(01)00255-6
   Vaidya SR, 2008, VIRUS GENES, V36, P31, DOI 10.1007/s11262-007-0172-2
   Wairagkar N, 2002, J MED VIROL, V68, P611, DOI 10.1002/jmv.10228
   Waku-Kouomou D, 2010, J MED VIROL, V82, P1033, DOI 10.1002/jmv.21766
   WHO, 2005, Wkly Epidemiol Rec, V80, P347
   WHO, 2007, MAN DIAGN MEASL RUB
   Woodfill C., 2007, Morbidity and Mortality Weekly Report, V56, P144
   World Health Organization, 2005, Wkly Epidemiol Rec, V80, P384
   World Health Organization, 2001, WKLY EPIDEMIOL REC, V76, P242
   Zhang Y, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-14
   Zhang Y, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-120
   Zhang Yan, 2009, Zhongguo Yi Miao He Mian Yi, V15, P304
   Zhang Yan, 2009, Zhongguo Yi Miao He Mian Yi, V15, P97
   Zhang Y, 2010, EMERG INFECT DIS, V16, P943, DOI 10.3201/eid1606.100089
NR 67
TC 155
Z9 165
U1 0
U2 14
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 15
PY 2011
VL 204
SU 1
BP S514
EP S523
DI 10.1093/infdis/jir118
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 802YT
UT WOS:000293547600066
PM 21666208
OA Bronze
DA 2020-12-08
ER

PT J
AU Baroody, FM
   Brown, D
   Gavanescu, L
   DeTineo, M
   Naclerio, RM
AF Baroody, Fuad M.
   Brown, David
   Gavanescu, Laura
   DeTineo, Marcy
   Naclerio, Robert M.
TI Oxymetazoline adds to the effectiveness of fluticasone furoate in the
   treatment of perennial allergic rhinitis
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Allergic rhinitis; perennial; fluticasone furoate; oxymetazoline;
   clinical trial; rhinitis medicamentosa
ID NASAL SPRAY; MOMETASONE FUROATE; BENZALKONIUM CHLORIDE; MEDICAMENTOSA;
   PLACEBO; PROPIONATE; HYDROCHLORIDE; DRUG
AB Background: In clinical trials, only about 60% of subjects report an excellent response to intranasal steroids, suggesting a need to add therapies to intranasal steroids to provide additional efficacy.
   Objective: To determine whether the combination of fluticasone furoate and oxymetazoline is more efficacious than either agent alone, and to determine whether rhinitis medicamentosa develops after treatment.
   Methods: We performed a double-blind, double-dummy, randomized, placebo-controlled parallel study. Sixty patients with perennial allergy were randomized to 4 weeks of once-a-night treatment with fluticasone furoate, oxymetazoline hydrochloride, the combination, or placebo. They were monitored during treatment and for 2 weeks posttreatment.
   Results: The total nasal symptom score over the 4 weeks of treatment was lower with the combination (median, 143; range, 30-316) compared with treatment with placebo (262; 116-358) and oxymetazoline alone (219; 78-385; ANOVA, P = .04). When acoustic rhinometry was compared between the groups at the end of 4 weeks of treatment, the combination resulted in significantly higher nasal volume (mean + SEM, 15.8 + 1.1 mL; P < .03) compared with both placebo (12.1 + 0.9 mL) and oxymetazoline (12.4 + 0.8 mL) alone. The quality of life data showed no significant differences among the groups. Peak flow showed a nonsignificant improvement with the groups on fluticasone furoate. There was no evidence of rhinitis medicamentosa.
   Conclusion: The addition of oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. The lack of development of rhinitis medicamentosa suggests the need for a large multicenter study to develop a once-a-day combination of an intranasal steroid and a long-acting topical decongestant. (J Allergy Clin Immunol 2011;127:927-34.)
C1 [Naclerio, Robert M.] Univ Chicago, Med Ctr, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA.
   Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
RP Naclerio, RM (corresponding author), Univ Chicago, Med Ctr, Sect Otolaryngol Head & Neck Surg, 5841 S Maryland Ave,MC 1035, Chicago, IL 60637 USA.
EM rnacleri@surgery.bsd.uchicago.edu
FU McHugh Otolaryngology Research Fund; GlaxoSmithKlineGlaxoSmithKline;
   MerckMerck & Company; McNeil
FX Supported in part by the McHugh Otolaryngology Research Fund and an
   Investigator Initiated Grant from GlaxoSmithKline.; Disclosure of
   potential conflict of interest: F. M. Baroody is a speaker for Merck and
   has received research support from GlaxoSmithKline. R. M. Naclerio is a
   speaker for GlaxoSmithKline, Merck, and Sepracor; is a consultant for
   Boehringer Ingelheim; has received research support from
   GlaxoSmithKline, Merck, and McNeil; and is a member of the American
   Academy of Otolaryngology-Head and Neck Surgery and the American Academy
   of Allergy, Asthma & Immunology.
CR Beck-Speier I, 2006, J PHARMACOL EXP THER, V316, P843, DOI 10.1124/jpet.105.093278
   Beck-Speier I, 2009, J PHARMACOL SCI, V110, P276, DOI 10.1254/jphs.09012FP
   Bickford L, 1999, BRIT J CLIN PHARMACO, V48, P53, DOI 10.1046/j.1365-2125.1999.00972.x
   Bousquet J, 2010, ALLERGY, V65, P1212, DOI 10.1111/j.1398-9995.2010.02480.x
   Corboz MR, 2008, PULM PHARMACOL THER, V21, P449, DOI 10.1016/j.pupt.2007.06.007
   Elwany S, 2001, EUR ARCH OTO-RHINO-L, V258, P116, DOI 10.1007/s004050000309
   Ferguson BJ, 2001, OTOLARYNG HEAD NECK, V125, P253, DOI 10.1067/mhn.2001.117717
   Graf P, 2000, CLIN THER, V22, P894
   GRAF P, 1995, CLIN EXP ALLERGY, V25, P395, DOI 10.1111/j.1365-2222.1995.tb01069.x
   Graf P, 1997, ORL J OTO-RHINO-LARY, V59, P39, DOI 10.1159/000276903
   Graf P, 1999, ARCH OTOLARYNGOL, V125, P1128, DOI 10.1001/archotol.125.10.1128
   Graf Peter, 1996, Rhinology (Utrecht), V34, P9
   Graf PM, 1997, AM J RHINOL, V11, P67, DOI 10.2500/105065897781446865
   Graf PM, 1998, ORL J OTO-RHINO-LARY, V60, P334, DOI 10.1159/000027620
   Gross G, 2010, J ALLERGY CLIN IMMUN, V125, pAB174, DOI 10.1016/j.jaci.2009.12.681
   JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x
   Koelsch S, 2007, ARZNEIMITTELFORSCH, V57, P475
   Lanier BQ, 2010, J ALLERGY CLIN IMMUN, V125, pAB173, DOI 10.1016/j.jaci.2009.12.678
   Lin CY, 2004, ANN OTO RHINOL LARYN, V113, P147, DOI 10.1177/000348940411300213
   Lockey RF, 2006, J ALLERGY CLIN IMMUN, V118, P1017, DOI 10.1016/j.jaci.2006.06.018
   Molderings GJ, 2000, HYPERTENSION, V36, P405, DOI 10.1161/01.HYP.36.3.405
   PETRUSON B, 1981, Rhinology (Utrecht), V19, P167
   Ratner PH, 2008, ANN ALLERG ASTHMA IM, V100, P74, DOI 10.1016/S1081-1206(10)60408-5
   Sudsakorn S, 2006, J PHARMACEUT BIOMED, V40, P1273, DOI 10.1016/j.jpba.2005.09.018
   TALAAT M, 1981, J LARYNGOL OTOL, V95, P125, DOI 10.1017/S0022215100090526
   Tas A, 2005, OTOLARYNG HEAD NECK, V132, P608, DOI 10.1016/j.otohns.2005.01.010
   Vaidyanathan S, 2010, AM J RESP CRIT CARE, V182, P19, DOI 10.1164/rccm.200911-1701OC
   Watanabe H, 2003, RHINOLOGY, V41, P167
   Westerveld GJ, 2000, EUR RESPIR J, V16, P437, DOI 10.1034/j.1399-3003.2000.016003437.x
   YOO JK, 1998, LARYNGOSCOPE, V108, P1255
   Zhang L, 2008, ANN OTO RHINOL LARYN, V117, P127, DOI 10.1177/000348940811700211
NR 31
TC 42
Z9 47
U1 0
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD APR
PY 2011
VL 127
IS 4
BP 927
EP 934
DI 10.1016/j.jaci.2011.01.037
PG 8
WC Allergy; Immunology
SC Allergy; Immunology
GA 743YL
UT WOS:000289055800014
PM 21377716
DA 2020-12-08
ER

PT J
AU Phillips, G
   Tam, CC
   Conti, S
   Rodrigues, LC
   Brown, D
   Iturriza-Gomara, M
   Gray, J
   Lopman, B
AF Phillips, Gemma
   Tam, Clarence C.
   Conti, Stefano
   Rodrigues, Laura C.
   Brown, David
   Iturriza-Gomara, Miren
   Gray, Jim
   Lopman, Ben
TI Community Incidence of Norovirus-associated Infectious Intestinal
   Disease in England: Improved Estimates Using Viral Load for Norovirus
   Diagnosis
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE England; gastroenteritis; incidence; Monte Carlo method; Norovirus;
   primary health care; reverse transcriptase polymerase chain reaction
ID VIRUS-LIKE PARTICLES; MOLECULAR EPIDEMIOLOGY; GASTROENTERITIS;
   OUTBREAKS; SURVEILLANCE; VOLUNTEERS; DIVERSITY; EMERGENCE; PATTERN;
   VARIANT
AB Existing estimates of the incidence of infectious intestinal disease (IID) caused by norovirus are based on electron microscopy or reverse transcription-polymerase chain reaction (RT-PCR). Neither method accurately represents norovirus disease burden: Electron microscopy has poor diagnostic sensitivity, and RT-PCR has poor diagnostic specificity. In this study, viral load measurements were used to identify cases of norovirus-associated IID and to produce new incidence estimates for England. IID cases were ascertained in the Study of Infectious Intestinal Disease in England (1993-1996), and stool specimens were tested by semiquantitative real-time RT-PCR for norovirus. The age-adjusted community incidence of norovirus-associated IID was 4.5/100 person-years (95% credibility interval: 3.8, 5.2), equating to 2 million episodes/year. Among children aged less than 5 years, the community incidence was 21.4/100 person-years (95% credibility interval: 15.9, 27.7), and the incidence of consultations to general practitioners for norovirus-associated IID was 3.2/100 person-years (95% credibility interval: 2.6, 3.8), with 100,000 children visiting their general practitioner for norovirus-associated IID each year. Norovirus is the most common cause of IID in the community in England and is responsible for a similar number of pediatric primary care consultations as rotavirus.
C1 [Phillips, Gemma] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Infect Dis Epidemiol Unit, London WC1E 7HT, England.
   [Phillips, Gemma; Lopman, Ben] Hlth Protect Agcy Ctr Infect, Dept Gastrointestinal Emerging & Zoonot Infect, London, England.
   [Conti, Stefano] Hlth Protect Agcy Ctr Infect, Stat Unit, London, England.
   [Brown, David; Iturriza-Gomara, Miren; Gray, Jim] Hlth Protect Agcy Ctr Infect, Virus Reference Dept, London, England.
RP Phillips, G (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Infect Dis Epidemiol Unit, Keppel St, London WC1E 7HT, England.
EM gemma.phillips@lshtm.ac.uk
RI Gomara, Miren Iturriza/B-4351-2013
OI Gomara, Miren Iturriza/0000-0001-5816-6423; Rodrigues, Laura
   Cunha/0000-0001-9008-660X; Tam, Clarence/0000-0003-1697-286X
CR Adamson WE, 2007, J CLIN MICROBIOL, V45, P4058, DOI 10.1128/JCM.01853-07
   Amar CFL, 2007, EUR J CLIN MICROBIOL, V26, P311, DOI 10.1007/s10096-007-0290-8
   Atmar RL, 2008, EMERG INFECT DIS, V14, P1553, DOI 10.3201/eid1410.080117
   Ball JM, 1999, GASTROENTEROLOGY, V117, P40, DOI 10.1016/S0016-5085(99)70548-2
   Bull RA, 2006, J CLIN MICROBIOL, V44, P327, DOI 10.1128/JCM.44.2.327-333.2006
   de Wit MAS, 2001, AM J EPIDEMIOL, V154, P666, DOI 10.1093/aje/154.7.666
   Food Standards Agency, 2000, REP STUD INF INT DIS
   Froggatt PC, 2004, J MED VIROL, V72, P307, DOI 10.1002/jmv.10569
   Gallimore CI, 2007, ARCH VIROL, V152, P1295, DOI 10.1007/s00705-007-0954-9
   Gallimore CI, 2004, J CLIN MICROBIOL, V42, P1396, DOI 10.1128/JCM.42.4.1396-1401.2004
   Garcia C, 2006, J CLIN MICROBIOL, V44, P2997, DOI 10.1128/JCM.00065-06
   HARUKI K, 1991, MICROBIOL IMMUNOL, V35, P83, DOI 10.1111/j.1348-0421.1991.tb01536.x
   Hellard ME, 2001, ENVIRON HEALTH PERSP, V109, P773, DOI 10.2307/3454818
   Karsten C, 2009, EUR J CLIN MICROBIOL, V28, P935, DOI 10.1007/s10096-009-0729-1
   Koopmans M, 2000, J INFECT DIS, V181, pS262, DOI 10.1086/315573
   Lau CS, 2004, J MED VIROL, V73, P113, DOI 10.1002/jmv.20066
   Lopman B, 2004, LANCET, V363, P682, DOI 10.1016/S0140-6736(04)15641-9
   Lopman BA, 2004, EMERG INFECT DIS, V10, P1827, DOI 10.3201/eid1010.030941
   Lopman BA, 2003, EMERG INFECT DIS, V9, P71
   Lopman BA, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-13
   Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011
   Lyon MJ, 2005, COMMUN DIS INTELL, V29, P370
   Marshall JA, 2003, J MED VIROL, V69, P568, DOI 10.1002/jmv.10346
   Noel JS, 1999, J INFECT DIS, V179, P1334, DOI 10.1086/314783
   O'Ryan ML, 2009, PEDIATR INFECT DIS J, V28, P879, DOI 10.1097/INF.0b013e3181a4bb60
   Oh DY, 2003, J MED VIROL, V71, P82, DOI 10.1002/jmv.10449
   Patel MM, 2008, EMERG INFECT DIS, V14, P1224, DOI 10.3201/eid1408.071114
   Phillips G, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-63
   Phillips G, 2009, J CLIN VIROL, V44, P242, DOI 10.1016/j.jcv.2008.12.001
   Sethi D, 1999, Commun Dis Public Health, V2, P101
   Tacket CO, 2003, CLIN IMMUNOL, V108, P241, DOI 10.1016/S1521-6616(03)00120-7
   THORNHILL TS, 1975, J INFECT DIS, V132, P28, DOI 10.1093/infdis/132.1.28
   Tompkins D S, 1999, Commun Dis Public Health, V2, P108
   Tu ETV, 2008, CLIN INFECT DIS, V46, P413, DOI 10.1086/525259
   Wheeler JG, 1999, BMJ-BRIT MED J, V318, P1046, DOI 10.1136/bmj.318.7190.1046
NR 35
TC 91
Z9 96
U1 0
U2 17
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD MAY 1
PY 2010
VL 171
IS 9
BP 1014
EP 1022
DI 10.1093/aje/kwq021
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 587NJ
UT WOS:000276999100008
PM 20360244
OA Green Accepted, Bronze, Green Published
DA 2020-12-08
ER

PT J
AU Jones, R
   Brown, D
   Nelson, M
   Low, E
   Bhagani, S
   Atkins, M
   Danta, M
   Dusheiko, G
   Pybus, O
   Asboe, D
AF Jones, Rachael
   Brown, David
   Nelson, Mark
   Low, Emma
   Bhagani, Sanjay
   Atkins, Mark
   Danta, Mark
   Dusheiko, Geoff
   Pybus, Oliver
   Asboe, David
TI Re-emergent Hepatitis C Viremia After Apparent Clearance in HIV-Positive
   Men Who Have Sex With Men: Reinfection or Late Recurrence? (vol 53, pg
   547, 2010)
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Correction
C1 [Jones, Rachael; Nelson, Mark; Low, Emma; Atkins, Mark; Asboe, David] Chelsea & Westminster NHS Fdn Trust, London, England.
   [Brown, David; Bhagani, Sanjay; Dusheiko, Geoff] Royal Free & Univ Coll Med Sch, London WC1E 6BT, England.
   [Danta, Mark] Univ New S Wales, Sydney, NSW, Australia.
   [Pybus, Oliver] Univ Oxford, Oxford, England.
RP Jones, R (corresponding author), Chelsea & Westminster NHS Fdn Trust, London, England.
RI Dusheiko, Geoffrey M/C-7677-2010; Pybus, Oliver G/B-2640-2012
OI Pybus, Oliver G/0000-0002-8797-2667
CR Jones R, 2010, JAIDS-J ACQ IMM DEF, V53, P547, DOI 10.1097/QAI.0b013e3181ba41e2
NR 1
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD MAY 1
PY 2010
VL 54
IS 1
BP 112
EP 112
DI 10.1097/QAI.0b013e3181e0f647
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 587OG
UT WOS:000277001500018
DA 2020-12-08
ER

PT J
AU Jones, R
   Nelson, M
   Low, E
   Atkins, M
   Asboe, D
   Brown, D
   Bhagani, S
   Dusheiko, G
   Danta, M
   Pybus, O
AF Jones, Rachael
   Nelson, Mark
   Low, Emma
   Atkins, Mark
   Asboe, David
   Brown, David
   Bhagani, Sanjay
   Dusheiko, Geoff
   Danta, Mark
   Pybus, Oliver
TI Re-emergent Hepatitis C Viremia After Apparent Clearance in HIV-Positive
   Men Who Have Sex With Men: Reinfection or Late Recurrence?
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Letter
ID VIRUS REINFECTION; DRUG-USERS
C1 [Jones, Rachael; Nelson, Mark; Low, Emma; Atkins, Mark; Asboe, David] Chelsea & Westminster NHS Fdn Trust, London, England.
   [Brown, David; Bhagani, Sanjay; Dusheiko, Geoff] Royal Free & Univ Coll Med Sch, London WC1E 6BT, England.
   [Danta, Mark] Univ New S Wales, Sydney, NSW, Australia.
   [Pybus, Oliver] Univ Oxford, Oxford, England.
RP Jones, R (corresponding author), Chelsea & Westminster NHS Fdn Trust, London, England.
RI Dusheiko, Geoffrey M/C-7677-2010; Pybus, Oliver G/B-2640-2012
OI Pybus, Oliver G/0000-0002-8797-2667
CR Bukh J, 2008, J VIROL, V82, P8183, DOI 10.1128/JVI.00142-08
   Danta M, 2007, AIDS, V21, P983, DOI 10.1097/QAD.0b013e3281053a0c
   den Hollander G, 2005, AIDS, V19, P639
   FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801
   Ghosn J, 2008, AIDS, V22, P658, DOI 10.1097/QAD.0b013e3282f4e86f
   Giraudon I, 2008, SEX TRANSM INFECT, V84, P111, DOI 10.1136/sti.2007.027334
   Grebely J, 2006, HEPATOLOGY, V44, P1139, DOI 10.1002/hep.21376
   LAI ME, 1994, LANCET, V343, P388, DOI 10.1016/S0140-6736(94)91224-6
   Micallef JM, 2007, J VIRAL HEPATITIS, V14, P413, DOI 10.1111/j.1365-2893.2006.00812.x
   Proust B, 2000, J CLIN MICROBIOL, V38, P3125, DOI 10.1128/JCM.38.8.3125-3127.2000
   Vargas V, 1994, Transpl Int, V7 Suppl 1, pS216
   Zwickl D. J., 2006, THESIS U TEXAS AUSTI
NR 12
TC 7
Z9 7
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR 1
PY 2010
VL 53
IS 4
BP 547
EP 550
DI 10.1097/QAI.0b013e3181ba41e2
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 567YW
UT WOS:000275486600019
PM 20220378
DA 2020-12-08
ER

PT J
AU Warrener, L
   Slibinskas, R
   Brown, D
   Sasnauskas, K
   Samuel, D
AF Warrener, Lenesha
   Slibinskas, Rimas
   Brown, David
   Sasnauskas, Kestutis
   Samuel, Dhanraj
TI Development and Evaluation of a Rapid Immunochromatographic Test for
   Mumps-Specific IgM in Oral Fluid Specimens and Use as a Matrix for
   Preserving Viral Nucleic Acid for RT-PCR
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE near patient test; point-of-care test; recombinant nucleoprotein; enzyme
   immunoassay
ID REAL-TIME PCR; IMMUNOGLOBULIN-M; UNITED-KINGDOM; HIGH-LEVEL; VIRUS;
   MEASLES; ANTIBODIES; ASSAY; DIAGNOSIS; RUBELLA
AB The use of oral fluid specimens for diagnosis of mumps by detection of virus-specific IgM or nucleic acid is now well established. The utility of oral fluids would be improved further if testing could be performed closer to the patient. A near patient test (NPT) for the detection of mumps-specific IgM in oral fluid specimens was developed and evaluated using 196 oral fluid specimens from suspected cases of mumps and measles. Compared to enzyme immunoassay (EIA), the sensitivity, specificity, positive and negative predictive value of the mumps IgM NPT were 79.5%, 100%, 100%, and 72.6%, respectively. On oral fluid specimens with a test to negative control optical density ratio (T/N) >= 10 in the EIA, sensitivity of the NPT increased to 95.2%. To determine whether viral nucleic acid from oral fluid was preserved on the NPT strips used for IgM detection, reverse transcription-polymerase chain reaction (RT-PCR) was performed on 58 oral fluids before and after testing on NPT strips. In RT-PCR-positive oral fluids, mumps virus was detected in 19/21 (90.5%) specimens extracted from NPT strips. Mumps virus RNA was not detected in 37/37 (100%) NPT strips from mumps RT-PCR-negative oral fluid specimens. Mumps IgM NPT is rapid and simple to perform, with an acceptable level of performance for confirmation of a clinical diagnosis outside of the laboratory. The NPT strip is also a suitable matrix for preserving nucleic acid, enabling virus-specific RT-PCR to be performed. J. Med. Virol. 82:485-493, 2010. (C) 2010 Wiley-Liss, Inc.
C1 [Warrener, Lenesha; Brown, David; Samuel, Dhanraj] Hlth Protect Agcy, Ctr Infect, Virus Reference Dept, London NW9 5EQ, England.
   [Slibinskas, Rimas; Sasnauskas, Kestutis] Inst Biotechnol, Vilnius, Lithuania.
   [Samuel, Dhanraj] Microimmune Ltd, Hounslow, Middx, England.
RP Warrener, L (corresponding author), Hlth Protect Agcy, Ctr Infect, Virus Reference Dept, 61 Colindale Ave, London NW9 5EQ, England.
EM lenesha.warrener@hpa.org.uk
CR Bitsko RH, 2008, J CLIN MICROBIOL, V46, P1101, DOI 10.1128/JCM.01803-07
   Blacksell SD, 2006, CLIN INFECT DIS, V42, P1127, DOI 10.1086/501358
   Blacksell SD, 2006, CLIN VACCINE IMMUNOL, V13, P1166, DOI 10.1128/CVI.00219-06
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990
   BROWN DWG, 1994, BRIT MED J, V308, P1015, DOI 10.1136/bmj.308.6935.1015
   Cao M, 2007, AM J TROP MED HYG, V76, P553, DOI 10.4269/ajtmh.2007.76.553
   Carbone KM, 2001, FIELDS VIROLOGY, V4, P1381
   Cohen BJ, 2006, J VIROL METHODS, V131, P209, DOI 10.1016/j.jviromet.2005.08.001
   Delaney KP, 2006, AIDS, V20, P1655, DOI 10.1097/01.aids.0000238412.75324.82
   Gasem MH, 2002, J MED MICROBIOL, V51, P173, DOI 10.1099/0022-1317-51-2-173
   *HPA, 2003, COMMUN DIS REP CDR W, V13
   Jin L, 1999, J INFECT DIS, V180, P829, DOI 10.1086/314957
   Jin L, 2005, ARCH VIROL, V150, P1903, DOI 10.1007/s00705-005-0563-4
   Jin L, 2004, J INFECT DIS, V189, P1001, DOI 10.1086/382134
   Jin L, 2002, B WORLD HEALTH ORGAN, V80, P76
   Krause CH, 2007, J CLIN VIROL, V38, P153, DOI 10.1016/j.jcv.2006.10.010
   Krause CH, 2006, J CLIN VIROL, V37, P184, DOI 10.1016/j.jcv.2006.07.009
   MEURMAN O, 1982, J VIROL METHODS, V4, P249
   Myint KSA, 2005, AM J TROP MED HYG, V73, P942, DOI 10.4269/ajtmh.2005.73.942
   Navarrete M, 2007, J MED VIROL, V79, P41, DOI 10.1002/jmv.20759
   Nokes DJ, 1998, TROP MED INT HEALTH, V3, P258, DOI 10.1046/j.1365-3156.1998.00227.x
   O'Brien M, 2004, J CLIN MICROBIOL, V42, P2239, DOI 10.1128/JCM.42.5.2239-2240.2004
   PERRY KR, 1993, J MED VIROL, V40, P235, DOI 10.1002/jmv.1890400312
   Reid F, 2008, J CLIN VIROL, V41, P134, DOI 10.1016/j.jcv.2007.10.009
   Samuel D, 2003, J CLIN VIROL, V28, P121, DOI 10.1016/S1386-6532(02)00273-1
   Samuel D, 2002, J MED VIROL, V66, P123, DOI 10.1002/jmv.2120
   Savage E., 2006, Morbidity and Mortality Weekly Report, V55, P173
   Shaikh NA, 2007, CLIN CHEM, V53, P2031, DOI 10.1373/clinchem.2007.091140
   Slibinskas R, 2003, J BIOTECHNOL, V103, P43, DOI 10.1016/S0168-1656(03)00068-3
   Smits HL, 2003, CLIN DIAGN LAB IMMUN, V10, P1141, DOI 10.1128/CDLI.10.6.1141-1146.2003
   Stockton J, 1998, J CLIN MICROBIOL, V36, P2990, DOI 10.1128/JCM.36.10.2990-2995.1998
   Thomas B, 2007, J MED VIROL, V79, P1587, DOI 10.1002/jmv.20997
   UKKONEN P, 1981, J MED VIROL, V8, P131, DOI 10.1002/jmv.1890080307
   Vyse AJ, 2002, EPIDEMIOL REV, V24, P125, DOI 10.1093/epirev/mxf002
   Vyse AJ, 1997, J VIROL METHODS, V63, P93, DOI 10.1016/S0166-0934(96)02118-0
   Warrener L, 2006, J CLIN VIROL, V35, P130, DOI 10.1016/j.jcv.2005.10.008
   Yoshida N, 2008, J MED VIROL, V80, P517, DOI 10.1002/jmv.21106
NR 37
TC 8
Z9 8
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD MAR
PY 2010
VL 82
IS 3
BP 485
EP 493
DI 10.1002/jmv.21693
PG 9
WC Virology
SC Virology
GA 548IP
UT WOS:000273955000018
PM 20087926
DA 2020-12-08
ER

PT J
AU Ippolito, G
   Nisii, C
   Di Caro, A
   Brown, D
   Gopal, R
   Hewson, R
   Lloyd, G
   Gunther, S
   Eickmann, M
   Mirazimi, A
   Koivula, T
   Courbot, MCG
   Raoul, H
   Capobianchi, MR
AF Ippolito, Giuseppe
   Nisii, Carla
   Di Caro, Antonino
   Brown, David
   Gopal, Robin
   Hewson, Roger
   Lloyd, Graham
   Gunther, Stephan
   Eickmann, Markus
   Mirazimi, Ali
   Koivula, Tuija
   Courbot, Marie-Claude Georges
   Raoul, Herve
   Capobianchi, Maria R.
TI European Perspective of 2-Person Rule for Biosafety Level 4 Laboratories
SO EMERGING INFECTIOUS DISEASES
LA English
DT Letter
C1 [Ippolito, Giuseppe; Nisii, Carla; Di Caro, Antonino; Capobianchi, Maria R.] Natl Inst Infect Dis, I-00149 Rome, Italy.
   [Brown, David; Gopal, Robin] Hlth Protect Agcy, London, England.
   [Hewson, Roger; Lloyd, Graham] Hlth Protect Agcy, Salisbury, Wilts, England.
   [Gunther, Stephan] Bernhard Nocht Inst Trop Med, Hamburg, Germany.
   [Eickmann, Markus] Univ Marburg, Inst Virol, D-3550 Marburg, Germany.
   [Mirazimi, Ali; Koivula, Tuija] Swedish Inst Infect Dis Control, Solna, Sweden.
   [Courbot, Marie-Claude Georges; Raoul, Herve] French Natl Inst Hlth & Med Res, Lyon, France.
RP Ippolito, G (corresponding author), Natl Inst Infect Dis, 292 Via Portuense, I-00149 Rome, Italy.
EM ippolito@inmi.it
RI Ippolito, Giuseppe/J-7207-2017; Di Caro, Antonino/K-6854-2016; nisii,
   carla/B-8871-2017; raoul, herve/G-3403-2013
OI Di Caro, Antonino/0000-0001-6027-3009; nisii, carla/0000-0001-5369-0437;
   Gunther, Stephan/0000-0002-6562-0230; Capobianchi, Maria
   Rosaria/0000-0003-3465-0071; Ippolito, Giuseppe/0000-0002-1076-2979
CR *EUR COMM, 2008, EUR NETW P4 LAB 2005
   Ippolito G, 2008, NAT REV MICROBIOL, V6, DOI 10.1038/nrmicro1896-c1
   NISII C, 2009, CLIN MICROBIOL 0528
NR 3
TC 4
Z9 4
U1 0
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD NOV
PY 2009
VL 15
IS 11
BP 1858
EP 1858
DI 10.3201/eid1511.091134
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 518ML
UT WOS:000271696600034
PM 19891889
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Elliot, AJ
   Powers, C
   Thornton, A
   Obi, C
   Hill, C
   Simms, I
   Waight, P
   Maguire, H
   Foord, D
   Povey, E
   Wreghitt, T
   Goddard, N
   Ellis, J
   Bermingham, A
   Sebastianpillai, P
   Lackenby, A
   Zambon, M
   Brown, D
   Smith, GE
   Gill, ON
AF Elliot, Alex J.
   Powers, Cassandra
   Thornton, Alicia
   Obi, Chinelo
   Hill, Caterina
   Simms, Ian
   Waight, Pauline
   Maguire, Helen
   Foord, David
   Povey, Enid
   Wreghitt, Tim
   Goddard, Nichola
   Ellis, Joanna
   Bermingham, Alison
   Sebastianpillai, Praveen
   Lackenby, Angie
   Zambon, Maria
   Brown, David
   Smith, Gillian E.
   Gill, O. Noel
TI Monitoring the emergence of community transmission of influenza A/H1N1
   2009 in England: a cross sectional opportunistic survey of self sampled
   telephone callers to NHS Direct
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID NEISSERIA-GONORRHOEAE; CHLAMYDIA-TRACHOMATIS; SURVEILLANCE; SWABS
AB Objective To evaluate ascertainment of the onset of community transmission of influenza A/H1N1 2009 (swine flu) in England during the earliest phase of the epidemic by comparing data from two surveillance systems.
   Design Cross sectional opportunistic survey.
   Study samples Results from self samples by consenting patients who had called the NHS Direct telephone health line with cold or flu symptoms, or both, and results from Health Protection Agency (HPA) regional microbiology laboratories on patients tested according to the clinical algorithm for the management of suspected cases of swine flu.
   Setting Six regions of England between 24 May and 30 June 2009.
   Main outcome measure Proportion of specimens with laboratory evidence of influenza A/H1N1 2009.
   Results Influenza A/H1N1 2009 infections were detected in 91 (7%) of the 1385 self sampled specimens tested. In addition, eight instances of influenza A/H3 infection and two cases of influenza B infection were detected. The weekly rate of change in the proportions of infected individuals according to self obtained samples closely matched the rate of increase in the proportions of infected people reported by HPA regional laboratories. Comparing the data from both systems showed that local community transmission was occurring in London and the West Midlands once HPA regional laboratories began detecting 100 or more influenza A/H1N1 2009 infections, or a proportion positive of over 20% of those tested, each week.
   Conclusions Trends in the proportion of patients with influenza A/H1N1 2009 across regions detected through clinical management were mirrored by the proportion of NHS Direct callers with laboratory confirmed infection. The initial concern that information from HPA regional laboratory reports would be too limited because it was based on testing patients with either travel associated risk or who were contacts of other influenza cases was unfounded. Reports from HPA regional laboratories could be used to recognise the extent to which local community transmission was occurring.
C1 [Elliot, Alex J.; Smith, Gillian E.] Hlth Protect Agcy, Realtime Syndr Surveillance Team, Birmingham B3 2PW, W Midlands, England.
   [Brown, David] Hlth Protect Agcy, Ctr Infect, Virus Reference Dept, London NW9 5EQ, England.
   [Gill, O. Noel] Hlth Protect Agcy, Ctr Infect, STI & HIV Dept, London NW9 5EQ, England.
   [Maguire, Helen] Hlth Protect Agcy, Local & Reg Serv, London WC1V 7PP, England.
   [Foord, David; Povey, Enid] NHS Direct, Milton Keynes MK14 6DY, Bucks, England.
   [Wreghitt, Tim] Hlth Protect Agcy, Reg Microbiol Network, Cambridge CB2 0QW, England.
RP Elliot, AJ (corresponding author), Hlth Protect Agcy, Realtime Syndr Surveillance Team, Birmingham B3 2PW, W Midlands, England.
EM alex.elliot@hpa.org.uk
RI Simms, Ian/P-1454-2019; Simms, Ian/AAA-8740-2019
OI Simms, Ian/0000-0003-4519-5684; Elliot, Alex/0000-0002-6414-3065
FU Health Protection Agency
FX This enhanced surveillance was undertaken as part of the national
   surveillance function of the Health Protection Agency.
CR Alexander S, 2008, SEX TRANSM INFECT, V84, P488, DOI 10.1136/sti.2008.031443
   Armitage P, 1987, STAT METHODS MED RES
   Cooper DL, 2008, EPIDEMIOL INFECT, V136, P222, DOI 10.1017/S0950268807008412
   Cooper DL, 2009, J PUBLIC HEALTH-UK, V31, P17, DOI 10.1093/pubmed/fdm068
   *DEP HLTH, WHO WHO HAS ANN MOV
   *DEP HLTH, DEAR COLL LETT H1N1
   *DEP HLTH, SWIN FLU INF LEAFL 4
   Department of Health, 2007, PAND FLU NAT FRAM RE
   DONALDSON L, 2009, SWINE FLU ALERT 0501
   Fang JY, 2008, J PEDIATR ADOL GYNEC, V21, P355, DOI 10.1016/j.jpag.2008.03.010
   Fleming DM, 2008, EPIDEMIOL INFECT, V136, P866, DOI 10.1017/S0950268807009910
   Health Protection Agency, HPA WEEKL NAT INFL R
   HIPPISLEYCOX J, 2006, EURO SURVEILL, V11
   Joseph C A, 1995, Commun Dis Rep CDR Rev, V5, pR141
   Longatto A, 2008, EUR J GYNAECOL ONCOL, V29, P327
   MACKENZIE D, 2009, NEW SCI         0520
   Masek BJ, 2009, J CLIN MICROBIOL, V47, P1663, DOI 10.1128/JCM.02387-08
   *NOTT U DIV PRIM C, 2009, PRIM CAR SECT HLTH P
   Smith B, 2006, PERFORM RES, V11, P4
   *STAT CORP, 2009, INT STAT VERS 10 1 P
   Stewart DE, 2007, J OBSTET GYNAECOL CA, V29, P817, DOI 10.1016/S1701-2163(16)32636-6
   Zambon MC, 2001, LANCET, V358, P1410, DOI 10.1016/S0140-6736(01)06528-X
NR 22
TC 31
Z9 32
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-8146
J9 BRIT MED J
JI Br. Med. J.
PD AUG 27
PY 2009
VL 339
AR b3403
DI 10.1136/bmj.b3403
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 489AY
UT WOS:000269393100007
PM 19713236
OA Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU Phillips, G
   Lopman, B
   Tam, CC
   Iturriza-Gomara, M
   Brown, D
   Gray, J
AF Phillips, Gemma
   Lopman, Ben
   Tam, Clarence C.
   Iturriza-Gomara, Miren
   Brown, David
   Gray, Jim
TI Diagnosing norovirus-associated infectious intestinal disease using
   viral load
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID REVERSE TRANSCRIPTION-PCR; POLYMERASE-CHAIN-REACTION; TIME RT-PCR;
   NONBACTERIAL GASTROENTERITIS; MOLECULAR EPIDEMIOLOGY; HUMAN
   CALICIVIRUSES; CLINICAL VIROLOGY; FECAL SAMPLES; NUCLEIC-ACID; VIRUS
AB Background: Reverse transcription-polymerase chain reaction (RT-PCR) is the main method for laboratory diagnosis of norovirus-associated infectious intestinal disease (IID). However, up to 16% of healthy individuals in the community, with no recent history of IID, may be RT-PCR positive; so it is unclear whether norovirus is actually the cause of illness in an IID case when they are RT-PCR positive. It is important to identify the pathogen causing illness in sporadic IID cases, for clinical management and for community based incidence studies. The aim of this study was to investigate how faecal viral load can be used to determine when norovirus is the most likely cause of illness in an IID case.
   Methods: Real-time RT-PCR was used to determine the viral load in faecal specimens collected from 589 IID cases and 159 healthy controls, who were infected with genogroup II noroviruses. Cycle threshold (Ct) values from the real-time RT-PCR were used as a proxy measure of viral load. Receiver-operating characteristic (ROC) analysis was used to identify a cut-off in viral load for attributing illness to norovirus in IID cases.
   Results: One hundred and sixty-nine IID cases and 159 controls met the inclusion criteria for the ROC analysis. The optimal Ct value cut-off for attributing IID to norovirus was 31. The same cutoff was selected when using healthy controls, or IID cases who were positive by culture for bacterial pathogens, as the reference negative group. This alternative reference negative group can be identified amongst specimens routinely received in clinical virology laboratories.
   Conclusion: We demonstrated that ROC analysis can be used to select a cut-off for a norovirus real time RT-PCR assay, to aid clinical interpretation and diagnose when norovirus is the cause of IID. Specimens routinely received for diagnosis in clinical virology laboratories can be used to select an appropriate cut-off. Individual laboratories can use this method to define in-house cut-offs for their assays, to provide the best possible diagnostic service to clinicians and public health workers. Other clinical and epidemiological information should also be considered for patients with Ct values close to the cut-off, for the most accurate diagnosis of IID aetiology.
C1 [Phillips, Gemma; Lopman, Ben] Hlth Protect Agcy Ctr Infect, Dept Gastrointestinal Emerging & Zoonot Infect, London, England.
   [Phillips, Gemma; Lopman, Ben; Tam, Clarence C.] London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England.
   [Iturriza-Gomara, Miren; Brown, David; Gray, Jim] Hlth Protect Agcy Ctr Infect, Virus Reference Dept, London, England.
RP Phillips, G (corresponding author), Hlth Protect Agcy Ctr Infect, Dept Gastrointestinal Emerging & Zoonot Infect, 61 Colindale Ave, London, England.
EM gemma.phillips@hpa.org.uk; ben.lopman@hpa.org.uk;
   clarence.tam@lshtm.ac.uk; miren.iturriza@hpa.org.uk;
   david.brown@hpa.org.uk; jim.gray@hpa.org.uk
RI Gomara, Miren Iturriza/B-4351-2013
OI Gomara, Miren Iturriza/0000-0001-5816-6423; Tam,
   Clarence/0000-0003-1697-286X
FU Food Standards Agency
FX This study was funded by the Food Standards Agency. We would like to
   thank Corrine Amar, Lisa Griffiths, Fenella Halstead, Dalia Choudhury
   and Mihaela Cirdei who completed the laboratory testing.
CR Adaui V, 2006, J NEUROVIROL, V12, P456, DOI 10.1080/13550280601039634
   AGUS SG, 1973, ANN INTERN MED, V79, P18, DOI 10.7326/0003-4819-79-1-18
   Allen U, 2001, CLIN INFECT DIS, V33, P145, DOI 10.1086/321806
   Amar CFL, 2007, EUR J CLIN MICROBIOL, V26, P311, DOI 10.1007/s10096-007-0290-8
   Amar CFL, 2005, DIAGN MOL PATHOL, V14, P90, DOI 10.1097/01.pas.0000162752.61155.d1
   Atmar RL, 2008, EMERG INFECT DIS, V14, P1553, DOI 10.3201/eid1410.080117
   Bewick V, 2004, CRIT CARE, V8, P508, DOI 10.1186/cc3000
   Bon F, 2005, J CLIN MICROBIOL, V43, P4659, DOI 10.1128/JCM.43.9.4659-4664.2005
   Carman WF, 2007, SAMJ S AFR MED J, V97, P1169
   de Wit MAS, 2001, AM J EPIDEMIOL, V154, P666, DOI 10.1093/aje/154.7.666
   Ewald B, 2006, J CLIN EPIDEMIOL, V59, P798, DOI 10.1016/j.jclinepi.2005.11.025
   Fluss R, 2005, BIOMETRICAL J, V47, P458, DOI 10.1002/bimj.200410135
   Food Standards Agency, 2000, REP STUD INF INT DIS
   Fryer JF, 2008, J CLIN VIROL, V43, P367, DOI 10.1016/j.jcv.2008.08.011
   Gallimore CI, 2004, J CLIN MICROBIOL, V42, P2271, DOI 10.1128/JCM.42.5.2271-2274.2004
   Ghisetti V, 2004, J MED VIROL, V73, P223, DOI 10.1002/jmv.20079
   Gomara MI, 2008, EPIDEMIOL INFECT, V136, P23, DOI 10.1017/S0950268807008059
   GROVE DS, 2007, J BIOMOLECULAR TECHN, V10, P11
   Gunson R N, 2003, Commun Dis Public Health, V6, P63
   Gunson RN, 2008, J CLIN VIROL, V43, P372, DOI 10.1016/j.jcv.2008.08.020
   HARUKI K, 1991, MICROBIOL IMMUNOL, V35, P83, DOI 10.1111/j.1348-0421.1991.tb01536.x
   *HLTH PROT AG, 2007, 2 VSOP HLTH PROT AG
   *HLTH PROT AG, 2007, 30 BSOP HLTH PROT AG
   Houde A, 2006, J VIROL METHODS, V135, P163, DOI 10.1016/j.jviromet.2006.03.001
   Jiang X, 2000, J INFECT DIS, V181, pS349, DOI 10.1086/315577
   Kageyama T, 2003, J CLIN MICROBIOL, V41, P1548, DOI 10.1128/JCM.41.4.1548-1557.2003
   Kirkwood CD, 2005, J MED VIROL, V77, P96, DOI 10.1002/jmv.20419
   Lee SC, 2000, J CLIN MICROBIOL, V38, P4171, DOI 10.1128/JCM.38.11.4171-4179.2000
   Leeflang MMG, 2008, CLIN CHEM, V54, P729, DOI 10.1373/clinchem.2007.096032
   Medici MC, 2006, J MED VIROL, V78, P1486, DOI 10.1002/jmv.20723
   Medici MC, 2005, J CLIN MICROBIOL, V43, P3772, DOI 10.1128/JCM.43.8.3772-3778.2005
   O'Neill HJ, 2002, J CLIN VIROL, V25, P335, DOI 10.1016/S1386-6532(02)00124-5
   Phillips G, 2009, J CLIN VIROL, V44, P242, DOI 10.1016/j.jcv.2008.12.001
   Roman E, 2003, J MED MICROBIOL, V52, P435, DOI 10.1099/jmm.0.05079-0
   RUBENSTEIN AS, 1982, J CLIN MICROBIOL, V15, P938, DOI 10.1128/JCM.15.5.938-944.1982
   SCHREIBER DS, 1973, NEW ENGL J MED, V288, P1318, DOI 10.1056/NEJM197306212882503
   Sethi D, 1999, Commun Dis Public Health, V2, P101
   *STATACORP LP, 2007, STAT STAT SOFW REL 1
   THORNHILL TS, 1975, J INFECT DIS, V132, P28, DOI 10.1093/infdis/132.1.28
   Tompkins D S, 1999, Commun Dis Public Health, V2, P108
   TROEGER H, 2008, GUT IN PRESS
   Wittek M, 2007, EXPERT REV MOL DIAGN, V7, P237, DOI 10.1586/14737159.7.3.237
   YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
NR 43
TC 119
Z9 120
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD MAY 14
PY 2009
VL 9
AR 63
DI 10.1186/1471-2334-9-63
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 467OI
UT WOS:000267747800001
PM 19442278
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-08
ER

PT J
AU van de Laar, T
   Pybus, O
   Bruisten, S
   Brown, D
   Nelson, M
   Bhagani, S
   Vogel, M
   Baumgarten, A
   Chaix, ML
   Fisher, M
   Gotz, H
   Matthews, GV
   Neifer, S
   White, P
   Rawlinson, W
   Pol, S
   Rockstroh, J
   Coutinho, R
   Dore, GJ
   Dusheiko, GM
   Danta, M
AF van de Laar, Thijis
   Pybus, Oliver
   Bruisten, Sylvia
   Brown, David
   Nelson, Mark
   Bhagani, Sanjay
   Vogel, Martin
   Baumgarten, Alex
   Chaix, Marie-Laure
   Fisher, Martin
   Gotz, Hannelore
   Matthews, Gail V.
   Neifer, Stefan
   White, Peter
   Rawlinson, William
   Pol, Stanislav
   Rockstroh, Jurgen
   Coutinho, Roel
   Dore, Greg J.
   Dusheiko, Geoffrey M.
   Danta, M.
TI Evidence of a Large, International Network of HCV Transmission in
   HIV-Positive Men Who Have Sex With Men
SO GASTROENTEROLOGY
LA English
DT Article
ID HEPATITIS-C-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; DRUG-USERS; MOLECULAR
   EPIDEMIOLOGY; INFECTED PATIENTS; HOMOSEXUAL-MEN; AMSTERDAM; OUTBREAK;
   INCREASE; RISK
AB Background & Aims: Since 2000, there has been a marked rise in acute hepatitis C virus (HCV) in human immunodeficiency virus (HM-positive men who have sex with men (MSM). We conducted an international phylogenetic study to investigate the existence of an HCV transmission network among MSM. Methods: HIV-positive MSM diagnosed with recent HCV (n = 226) in England (107), The Netherlands (58), France (12), Germany (25), and Australia (24) between 2000 and 2006 were enrolled into a molecular phylogenetic study. Using real-time polymerase chain reaction (PCR), the NS5B region of the HCV genome (436 base pair) was amplified, sequenced, and compared with unrelated NS5B sequences. Results: NS5B sequences were obtained from 200 (89%) cases. Circulating HCV genotypes were la (59%), 4d (23%), 3a (11%), 1b (5%), and 2b/c (3%). Phylogenetic analysis revealed 156 (78%) sequences that formed 11 clusters (bootstrap value > 70%) containing between 4 and 37 individual sequences. Country mixing was associated with larger cluster size (17 vs 4.5 sequences; P = .03). "Molecular clock" analysis indicated that the majority (85%) of transmissions occurred since 1996. Conclusions: Phylogenetic analysis revealed a large international network of HCV transmission among HIV-positive MSM. The rapid spread of HCV among neighboring countries is supported by the large proportion (74%) of European MSM infected with an HCV strain co-circulating in multiple European countries, the low evolutionary distances among HCV isolates from different countries, and the trend toward increased country mixing with increasing cluster size. Temporally, this epidemic coincides with the introduction of highly active antiretroviral therapy and associated increases in sexual risk behaviors. International collaborative public health efforts are needed to mitigate HCV transmission among this population.
C1 [Danta, M.] Univ New S Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia.
   [van de Laar, Thijis; Bruisten, Sylvia; Coutinho, Roel] Hlth Serv, Cluster Infect Dis, Amsterdam, Netherlands.
   [Pybus, Oliver] Univ Oxford, Dept Zool, Oxford OX1 3PS, England.
   [Brown, David; Dusheiko, Geoffrey M.; Danta, M.] Royal Free Hosp, UCL Ctr Hepatol, London NW3 2QG, England.
   [Nelson, Mark] Chelsea & Westminster Hosp, Dept HIV Med, London, England.
   [Bhagani, Sanjay] Royal Free & Univ Coll, Dept HIV Med, London, England.
   [Vogel, Martin; Rockstroh, Jurgen] Univ Bonn, Med Klin & Poliklin 1, D-5300 Bonn, Germany.
   [Baumgarten, Alex; Neifer, Stefan] Practice Dupke Carganico Baumgarten, Berlin, Germany.
   [Chaix, Marie-Laure] Univ Paris 05, Virol CHU Necker, AP HP, EA3620, Paris, France.
   [Fisher, Martin] Brighton & Sussex Univ Hosp Trust, Dept HIV Med, Brighton, E Sussex, England.
   [Gotz, Hannelore] Hlth Serv, Dept Infect Dis, Rotterdam, Netherlands.
   [Matthews, Gail V.; Dore, Greg J.] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia.
   [White, Peter; Rawlinson, William] Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia.
   [Pol, Stanislav] Univ Paris 05, Cochin Hosp, Hepatol Unit, Paris, France.
   [Coutinho, Roel] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands.
   [Coutinho, Roel] Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands.
RP Danta, M (corresponding author), Univ New S Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia.
EM m.danta@unsw.edu.au
RI Pybus, Oliver G/B-2640-2012; White, Peter A/C-6573-2012
OI Pybus, Oliver G/0000-0002-8797-2667; White, Peter A/0000-0002-6046-9631;
   Gotz, Hannelore Martha/0000-0002-1236-6224; Rawlinson,
   William/0000-0003-0988-7827
FU Special Trustees of Royal Free & University College Medical School
   Fellowship; Peter Samuel Fellowship; UNSW Faculty Research; Health
   Service Amsterdam; Netherlands Organization for Health Research and
   DevelopmentNetherlands Organization for Health Research and Development
   [912-03-005]; National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 DA
   15999]; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA) [R01DA015999, R01DA015999,
   R01DA015999, R01DA015999, R01DA015999, R01DA015999, R01DA015999,
   R01DA015999, R01DA015999, R01DA015999] Funding Source: NIH RePORTER
FX Supported by Special Trustees of Royal Free & University College Medical
   School Fellowship (to M.D.), Peter Samuel Fellowship (to M.D.), UNSW
   Faculty Research Grant 2008 (to M.D.), and Health Service Amsterdam;
   Netherlands Organization for Health Research and Development Grant
   912-03-005 (T.vdL.); and the National Institutes of Health Grant R01 DA
   15999 (to G.D. and G.M.).
CR Alter MJ, 2002, HEPATOLOGY, V36, pS93, DOI 10.1053/jhep.2002.36389
   BATEMAN K, 2007, 14 INT S HEP C VIR R
   Browne R, 2004, SEX TRANSM INFECT, V80, P326, DOI 10.1136/sti.2003.008532
   Clift SM, 1999, AIDS CARE, V11, P281, DOI 10.1080/09540129947929
   Cochrane A, 2002, J INFECT DIS, V186, P1212, DOI 10.1086/344314
   Crepaz N, 2008, HEALTH PSYCHOL, V27, P4, DOI 10.1037/0278-6133.27.1.4
   Danta M, 2008, J INFECT DIS, V197, P1558, DOI 10.1086/587843
   Danta M, 2007, AIDS, V21, P983, DOI 10.1097/QAD.0b013e3281053a0c
   de Oliveira T, 2006, NATURE, V444, P836, DOI 10.1038/444836a
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Fierer DS, 2008, J INFECT DIS, V198, P683, DOI 10.1086/590430
   Fox J, 2008, AIDS, V22, P666, DOI 10.1097/QAD.0b013e3282f5f4cf
   Gerlach JT, 2003, GASTROENTEROLOGY, V125, P80, DOI 10.1016/S0016-5085(03)00668-1
   Ghosn J, 2008, AIDS, V22, P658, DOI 10.1097/QAD.0b013e3282f4e86f
   Giraudon I, 2008, SEX TRANSM INFECT, V84, P111, DOI 10.1136/sti.2007.027334
   Gotz HM, 2005, AIDS, V19, P969, DOI 10.1097/01.aids.0000171412.61360.f8
   Graham CS, 2001, CLIN INFECT DIS, V33, P562, DOI 10.1086/321909
   Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3
   JONES R, 2008, 15 C RETR OPP INF CR
   Luetkemeyer A, 2006, JAIDS-J ACQ IMM DEF, V41, P31, DOI 10.1097/01.qai.0000191281.77954.27
   Macdonald N, 2004, SEX TRANSM INFECT, V80, P492, DOI 10.1136/sti.2004.011197
   Marcus U, 2006, Euro Surveill, V11, P157
   Marcus U, 2004, INT J STD AIDS, V15, P533, DOI 10.1258/0956462041558221
   Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501
   Matthews GV, 2007, AIDS, V21, P2112, DOI 10.1097/QAD.0b013e3282ef3873
   Matthews-Greer JM, 2001, CLIN DIAGN LAB IMMUN, V8, P690, DOI 10.1128/CDLI.8.4.690-694.2001
   Mercer CH, 2007, SEX TRANSM INFECT, V83, P517, DOI 10.1136/sti.2007.026377
   Morice Y, 2006, J MED VIROL, V78, P1296, DOI 10.1002/jmv.20692
   Parsons JT, 2005, AIDS, V19, pS13, DOI 10.1097/01.aids.0000167348.15750.9a
   Pybus OG, 2001, SCIENCE, V292, P2323, DOI 10.1126/science.1058321
   Richardson D, 2008, J INFECT DIS, V197, P1213, DOI 10.1086/533454
   Rockstroh JK, 2008, HIV MED, V9, P82, DOI 10.1111/j.1468-1293.2007.00535.x
   Serpaggi J, 2006, AIDS, V20, P233, DOI 10.1097/01.aids.0000200541.40633.56
   Soriano V, 2008, AIDS, V22, P1, DOI 10.1097/QAD.0b013e3282f0e2fd
   Stene-Johansen K, 2007, J MED VIROL, V79, P356, DOI 10.1002/jmv.20781
   Swofford DL, 2001, SYST BIOL, V50, P525, DOI 10.1080/106351501750435086
   Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P15584, DOI 10.1073/pnas.242608099
   Thomas DL, 2000, JAMA-J AM MED ASSOC, V284, P450, DOI 10.1001/jama.284.4.450
   URBANUS AT, 2008, INT AIDS C 3 8 AUG M
   van de Laar TJW, 2007, J INFECT DIS, V196, P230, DOI 10.1086/518796
   van de Laar TJW, 2005, J MED VIROL, V77, P509, DOI 10.1002/jmv.20486
   Van der Bij AK, 2006, CLIN INFECT DIS, V42, P186, DOI 10.1086/498904
   van Houdt R, 2007, VACCINE, V25, P2698, DOI 10.1016/j.vaccine.2006.06.058
   Vogel M, 2005, J VIRAL HEPATITIS, V12, P207, DOI 10.1111/j.1365-2893.2005.00580.x
NR 44
TC 210
Z9 212
U1 0
U2 9
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAY
PY 2009
VL 136
IS 5
BP 1609
EP 1617
DI 10.1053/j.gastro.2009.02.006
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 440WQ
UT WOS:000265730800024
PM 19422083
OA Green Accepted
DA 2020-12-08
ER

PT J
AU Ijaz, S
   Vyse, AJ
   Morgan, D
   Pebody, RG
   Tedder, RS
   Brown, D
AF Ijaz, Samreen
   Vyse, Andrew J.
   Morgan, Dilys
   Pebody, Richard G.
   Tedder, Richard S.
   Brown, David
TI Indigenous hepatitis E virus infection in England: More common than it
   seems
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Seroprevalence; Indigenous; Incidence; Gender distribution; Age-specific
   acquisition
ID WILD BOAR; PREVALENCE; ANTIBODIES; SEQUENCE; WALES; PIGS
AB Background: Indigenous hepatitis E virus (HEV) is increasingly diagnosed in England due to abetter awareness and understanding of the virus. However, the true burden of infection and therefore its implication to public health remains undefined.
   Objectives: To estimate the HEV seroprevalence in the general population and to investigate how the risk of HEV infection had fluctuated over time.
   Study design: Two sample collections stratified by age ranging from 1 to 80 years, were screened for HEV IgG antibody. The two collections were separated by 13 years enabling the average incidence between 1991 and 2004 to be estimated. Additional force of infection calculations were also undertaken.
   Results: An overall HEV antibody prevalence of 13% was determined, increasing with age and peaking at 25% in those aged over 50 years. Analysis of the two sample collections demonstrated a temporal shift in seroprevalence indicating that the risk of acquiring HEV infection was not solely age dependant. Data showed that the force of infection had been particularly high in the middle of the 20th century but had subsequently decreased. Current HEV incidence estimates revealed that the incidence did not vary in different age groups.
   Conclusions: This study indicated a high anti-HEV seroprevalence in England and that there was a period of increased risk of acquiring HEV infection which has now decreased. Incidence estimates show that shared risk factors still exist for acquiring HEV infection across all age groups in England. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Ijaz, Samreen; Tedder, Richard S.; Brown, David] Hlth Protect Agcy, Ctr Infect, Virus Reference Dept, London NW9 5HT, England.
   [Vyse, Andrew J.; Pebody, Richard G.] Hlth Protect Agcy, Ctr Infect, Immunisat Dept, London NW9 5HT, England.
RP Ijaz, S (corresponding author), Hlth Protect Agcy, Ctr Infect, Virus Reference Dept, 61 Colindale Ave, London NW9 5HT, England.
EM samreen.ijaz@hpa.org.uk
OI Ijaz, Samreen/0000-0001-6658-3542; Tedder, Richard/0000-0002-9672-5721;
   Pebody, Richard/0000-0002-9069-2885
CR Arankalle VA, 2001, J VIRAL HEPATITIS, V8, P223, DOI 10.1046/j.1365-2893.2001.00290.x
   Banks M, 2004, VET REC, V154, P223, DOI 10.1136/vr.154.8.223
   Boutrouille A, 2007, J CLIN MICROBIOL, V45, P2009, DOI 10.1128/JCM.00235-07
   Buti M, 2006, CLIN VACCINE IMMUNOL, V13, P1328, DOI 10.1128/CVI.00255-06
   Dalton HR, 2007, J VIRAL HEPATITIS, V14, P304, DOI 10.1111/j.1365-2893.2006.00800.x
   Gay N J, 1994, Commun Dis Rep CDR Rev, V4, pR104
   Herremans M, 2007, CLIN VACCINE IMMUNOL, V14, P562, DOI 10.1128/CVI.00231-06
   Hirano M, 2003, HEPATOL RES, V27, P1, DOI 10.1016/S1386-6346(03)00192-X
   HUMPHREYS J, 2001, GREAT FOOD GAMBLE
   Ijaz S, 2005, J INFECT DIS, V192, P1166, DOI 10.1086/444396
   Lewis HC, 2008, EMERG INFECT DIS, V14, P165, DOI 10.3201/eid1401.070307
   Mansuy JM, 2004, J MED VIROL, V74, P419, DOI 10.1002/jmv.20206
   Meng XJ, 1999, J MED VIROL, V59, P297, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;297::AID-JMV6&gt;3.0.CO;2-3
   Olsen BR, 2006, SCAND J INFECT DIS, V38, P55, DOI 10.1080/00365540500321470
   Osborne K, 2000, INT J EPIDEMIOL, V29, P362, DOI 10.1093/ije/29.2.362
   Pina S, 2000, J HEPATOL, V33, P826, DOI 10.1016/S0168-8278(00)80316-5
   Sainokami S, 2004, J GASTROENTEROL, V39, P640, DOI 10.1007/s00535-003-1359-5
   Schlauder GG, 1998, J GEN VIROL, V79, P447, DOI 10.1099/0022-1317-79-3-447
   Takahashi K, 2004, VIROLOGY, V330, P501, DOI 10.1016/j.virol.2004.10.006
   Tamada Y, 2004, J HEPATOL, V40, P869, DOI 10.1016/j.jhep.2003.12.026
   Tei S, 2003, LANCET, V362, P371, DOI 10.1016/S0140-6736(03)14025-1
   VYSE AJ, 2008, EPIDEMIOL INFECT, V15, P1
   Wang YC, 2002, J MED VIROL, V67, P516, DOI 10.1002/jmv.10131
   Widdowson MA, 2003, CLIN INFECT DIS, V36, P29, DOI 10.1086/345439
NR 24
TC 100
Z9 104
U1 1
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD APR
PY 2009
VL 44
IS 4
BP 272
EP 276
DI 10.1016/j.jcv.2009.01.005
PG 5
WC Virology
SC Virology
GA 436WL
UT WOS:000265446700004
PM 19217345
DA 2020-12-08
ER

PT J
AU Maple, PAC
   Gray, J
   Brown, K
   Brown, D
AF Maple, P. A. Chris
   Gray, Jim
   Brown, Kevin
   Brown, David
TI Performance characteristics of a quantitative, standardised varicella
   zoster IgG time resolved fluorescence immunoassay (VZV TRFIA) for
   measuring antibody following natural infection
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE VZV time resolved fluorescence immunoassay; Merck glycoprotein EIA;
   Standardised cut-offs for susceptibility and protection
ID INDIRECT IMMUNOFLUORESCENCE; MEMBRANE ANTIGEN; VIRUS; IMMUNITY; VACCINE;
   DIPHTHERIA; MEASLES; ASSAYS
AB Infection by Varicella Zoster virus (VZV) during pregnancy has been associated with adverse foetal development and more severe disease in the mother. Accurate determination of VZV immunity in pregnant women exposed to VZV, with no history of chickenpox, guides therapeutic interventions. The accepted gold standard assay for the determination of immunity/protection against Varicella Zoster virus was for many years the fluorescent antibody to membrane antigen (FAMA) assay which is labour intensive and subjective. A validated alternative is the Merck glycoprotein EIA (Merck Sharp & Dohme Research Laboratories, West Point, PA, USA) which reports VZV IgG levels in enzyme units per ml (EU/ml) because an internal, non-international reference serum is used as calibrator. Comparison of different VZV IgG detection assays is hampered by a lack of an agreed cut-off in standardised units. A time resolved fluorescence immunoassay (TRFIA) for VZV IgG using British Standard VZV antibody has been developed and standardised. The limit of detection of VZV IgG by this assay was of the order 39-78 mIU/ml. Following comparison with the Merck glycoprotein EIA and the application of the USA Advisory Committee on Immunization Practices recommended 5.0 EU/ml cut-off the following standardised cut-offs in mIU/ml are proposed. A VZV TRFIA IgG cut-off of less than 100mIU/ml VZV IgG equates with susceptibility and an equivocal range of 100 mIU/ml to less than 150 mIU/ml is proposed. VZV IgG levels of 150 mIU/ml, or greater, are indicative of natural infection at some time and the ability to mount a protective immune response is inferred. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Maple, P. A. Chris; Gray, Jim; Brown, Kevin; Brown, David] Hlth Protect Agcy Ctr Infect, Virus Reference Dept, London NW9 5HT, England.
RP Maple, PAC (corresponding author), Hlth Protect Agcy Ctr Infect, Virus Reference Dept, 61 Colindale Ave, London NW9 5HT, England.
EM chris.maple@hpa.org.uk
OI Maple, Peter/0000-0002-5534-5191
CR Arvin AM, 2001, NEW ENGL J MED, V344, P1007, DOI 10.1056/NEJM200103293441310
   Cohen BJ, 2007, VACCINE, V26, P59, DOI 10.1016/j.vaccine.2007.10.046
   GRANDIEN M, 1976, SCAND J INFECT DIS, V8, P65, DOI 10.3109/inf.1976.8.issue-2.01
   GROSE C, 1979, J INFECT DIS, V139, P432, DOI 10.1093/infdis/139.4.432
   Li S, 2002, PEDIATR INFECT DIS J, V21, P337, DOI 10.1097/00006454-200204000-00014
   MAPLE PA, 1995, LANCET, V345, P963, DOI 10.1016/S0140-6736(95)90705-X
   Maple PAC, 2006, CLIN VACCINE IMMUNOL, V13, P214, DOI 10.1128/CVI.13.2.214-218.2006
   Maple PAC, 2002, VACCINE, V20, P1378, DOI 10.1016/S0264-410X(01)00474-1
   Maple PAC, 2000, VACCINE, V19, P167, DOI 10.1016/S0264-410X(00)00184-5
   Marin Mona, 2007, Morbidity and Mortality Weekly Report, V56, P1
   NDUMBE PM, 1988, J MED VIROL, V25, P171, DOI 10.1002/jmv.1890250207
   PROVOST PJ, 1991, VACCINE, V9, P111, DOI 10.1016/0264-410X(91)90266-9
   Robert Koch-Institut, 2001, EPIDEMIOL B, V8, P58
   Sauerbrei A, 2004, J VIROL METHODS, V119, P25, DOI 10.1016/j.jviromet.2004.02.012
   STEINBERG SP, 1991, J CLIN MICROBIOL, V29, P1527, DOI 10.1128/JCM.29.7.1527-1529.1991
   Tischer A, 2007, EPIDEMIOL INFECT, V135, P787, DOI 10.1017/S0950268807008266
   WASMUTH EH, 1990, J MED VIROL, V32, P189, DOI 10.1002/jmv.1890320310
   WILLIAMS V, 1974, J INFECT DIS, V130, P669, DOI 10.1093/infdis/130.6.669
   ZAIA JA, 1977, J INFECT DIS, V136, P519, DOI 10.1093/infdis/136.4.519
NR 19
TC 15
Z9 15
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
J9 J VIROL METHODS
JI J. Virol. Methods
PD APR
PY 2009
VL 157
IS 1
BP 90
EP 92
DI 10.1016/j.jviromet.2008.12.007
PG 3
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 425VY
UT WOS:000264667000013
PM 19135089
DA 2020-12-08
ER

PT J
AU Phillips, G
   Lopman, B
   Tam, CC
   Iturriza-Gomara, M
   Brown, D
   Gray, J
AF Phillips, Gemma
   Lopman, Ben
   Tam, Clarence C.
   Iturriza-Gomara, Miren
   Brown, David
   Gray, Jim
TI Diagnosing rotavirus A associated IID: Using ELISA to identify a cut-off
   for real time RT-PCR
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Rotavirus A; ELISA; RT-PCR; Viral load; Aetiology; Asymptomatic
ID POLYMERASE-CHAIN-REACTION; DIRECT ELECTRON-MICROSCOPY; FECAL SAMPLES;
   GASTROENTERITIS; NETHERLANDS; ETIOLOGY; CHILDREN
AB Background: The use of RT-PCR for diagnosis of group A rotaviruses is increasing, but up to 14% of healthy individuals may be positive by RT-PCR. If RT-PCR is not well correlated with disease, rotavirus A may not always be the cause of illness in RT-PCR positive patients with infectious intestinal disease (IID).
   Objectives: To describe the differences in faecal viral load between ELISA positive IID cases, RT-PCR positive cases and healthy controls. To develop a cut-off in faecal viral load for attributing illness to rotavirus A in RT-PCR positive IID cases.
   Study design: Faecal viral load was measured, using real time RT-PCR, in 118 community IID cases and 65 healthy controls, previously tested by ELISA. Cycle threshold (Ct) values from the real-time RT-PCR were used as a proxy measure of viral load. A cut-off for attributing illness to rotavirus A was selected, using ROC analysis.
   Results: There was little overlap in viral load between ELISA positive IID cases (median Ct 17) and healthy controls (median Ct 37), but ELISA negative, RT-PCR positive IID cases (median Ct 37) had viral loads similar to healthy controls, indicating that RT-PCR is not detecting extra cases of group A rotavirus associated IID, only sub-clinical infections. The optimal cut-off in the real time RT-PCR was at Ct value 24-27.
   Conclusion: ELISA is the best method for the laboratory diagnosis of rotavirus A associated IID. If RT-PCR is used, it is advisable to use a real time platform and to use a viral load cut-off equivalent to the detection limit of ELISA. (c) 2008 Elsevier B.V. All rights reserved.
C1 [Phillips, Gemma; Lopman, Ben] Hlth Protect Agcy Ctr Infect, Dept Gastrointestinal Emerging & Zoonot Infect, London NW9 5EQ, England.
   [Phillips, Gemma; Lopman, Ben; Tam, Clarence C.] Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1E 7HT, England.
   [Iturriza-Gomara, Miren; Brown, David; Gray, Jim] Hlth Protect Agcy Ctr Infect, Virus Reference Dept, London NW9 5EQ, England.
RP Phillips, G (corresponding author), Hlth Protect Agcy Ctr Infect, Dept Gastrointestinal Emerging & Zoonot Infect, 61 Colindale Ave, London NW9 5EQ, England.
EM gemma.phillips@hpa.org.uk
RI Gomara, Miren Iturriza/B-4351-2013
OI Gomara, Miren Iturriza/0000-0001-5816-6423; Tam,
   Clarence/0000-0003-1697-286X
FU Food Standards Agency
FX This study was funded by the Food Standards Agency. We would like to
   thank Corrine Amar, Fenella Halstead, Dalia Chouclhury and Mihaela
   Cirdei who completed the laboratory testing.
CR Amar CFL, 2007, EUR J CLIN MICROBIOL, V26, P311, DOI 10.1007/s10096-007-0290-8
   Bewick V, 2004, CRIT CARE, V8, P508, DOI 10.1186/cc3000
   CHEUNG EY, 1982, J CLIN MICROBIOL, V16, P562, DOI 10.1128/JCM.16.3.562-563.1982
   de Wit MAS, 2001, CLIN INFECT DIS, V33, P280, DOI 10.1086/321875
   Fluss R, 2005, BIOMETRICAL J, V47, P458, DOI 10.1002/bimj.200410135
   Food Standards Agency, 2000, REP STUD INF INT DIS
   GOMARA MI, 2007, EPIDEMIOL INFECT, P1
   Gunson R N, 2003, Commun Dis Public Health, V6, P63
   GUNSON RN, 2008, J CLIN VIROL
   Kang G, 2004, J MED VIROL, V73, P118, DOI 10.1002/jmv.20053
   KJELDSBERG E, 1982, J VIROL METHODS, V4, P45, DOI 10.1016/0166-0934(82)90053-2
   Nokes DJ, 2008, PLOS MED, V5, P1154, DOI 10.1371/journal.pmed.0050153
   O'Neill HJ, 2002, J CLIN VIROL, V25, P335, DOI 10.1016/S1386-6532(02)00124-5
   Phan TG, 2005, CLIN LAB, V51, P429
   Ramig RF, 2004, J VIROL, V78, P10213, DOI 10.1128/JVI.78.19.10213-10220.2004
   Rohayem J, 2004, J VIROL METHODS, V118, P49, DOI 10.1016/j.jviromet.2004.01.016
   Sethi D, 1999, Commun Dis Public Health, V2, P101
   StataCorp, 2007, STAT STAT SOFTW REL
   Tompkins D S, 1999, Commun Dis Public Health, V2, P108
   WILDE J, 1991, LANCET, V337, P323, DOI 10.1016/0140-6736(91)90945-L
   World Health Organisation, 2002, GEN PROT HOSP BAS SU
   XU L, 1990, J VIROL METHODS, V27, P29, DOI 10.1016/0166-0934(90)90143-4
   YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
   2001, AM J EPIDEMIOL, V154, P666
NR 24
TC 49
Z9 50
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD MAR
PY 2009
VL 44
IS 3
BP 242
EP 245
DI 10.1016/j.jcv.2008.12.001
PG 4
WC Virology
SC Virology
GA 424OC
UT WOS:000264575000014
PM 19179107
OA Green Accepted
DA 2020-12-08
ER

PT J
AU Bungay, A
   Selden, C
   Brown, D
   Malik, R
   Hubank, M
   Hodgson, H
AF Bungay, Anton
   Selden, Clare
   Brown, David
   Malik, Raza
   Hubank, Mike
   Hodgson, Humphrey
TI Microarray analysis of mitogenic effects of T3 on the rat liver
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE cell cycle; Kruppel factor; primary mitogen; proliferation;
   transcriptome
ID GENE-EXPRESSION PATTERNS; IN-VIVO; HEPATOCYTE PROLIFERATION; PEROXISOME
   PROLIFERATORS; RAPID ACTIVATION; DNA-SYNTHESIS; KAPPA-B; REGENERATION;
   TRIIODOTHYRONINE; TRANSCRIPTION
AB A single dose of the thyroid hormone tri-iodothyronine, T3, can enhance both size and function of normal rodent liver, which is potentially of value in the treatment of liver disease. However the mechanism of this has not been fully elucidated, and it cannot be modeled in vitro. We therefore investigated the transcriptome response to T3 in rat liver in vivo.
   After adult rats were administered 5 mu g T3 subcutaneously, a whole rat genome microarray comparing global hepatic gene expression against vehicle-only treated liver after 3 h was performed.
   Informative transcripts which had identifiable gene ontology biological processes were grouped according to function, broadly reflecting general metabolic effects and those linked to cell-proliferation control. We then compared the transcriptome response after 5-mu g T3 initiating hepatocyte DNA synthesis (mitogenic) with that after 0.1 mu g T3, a supraphysiological amount not initiating hepatocyte DNA synthesis.
   We compared the results with published results of the response to other primary mitogens, and identified the Gadd45beta/MyD118 gene as a common early factor upregulated during proliferation.
C1 [Bungay, Anton; Selden, Clare; Brown, David; Malik, Raza; Hodgson, Humphrey] Royal Free & Univ Coll Med Sch, London NW3 2PF, England.
   [Hubank, Mike] Inst Child Hlth, ICH Gene Microarray Ctr, London, England.
RP Hodgson, H (corresponding author), Royal Free & Univ Coll Med Sch, Rowland Hill St, London NW3 2PF, England.
EM h.hodgson@medsch.ucl.ac.uk
RI Hubank, Michael JF/C-1837-2008
OI Hubank, Michael JF/0000-0002-2901-0742; Selden,
   Angela/0000-0003-2648-443X
FU Royal Free Hospital Special Trustees; Dunhill Medical TrustDunhill
   Medical Trust; Liver Group Charity; Wellcome Trust Equipment
   GrantWellcome Trust
FX Royal Free Hospital Special Trustees, Dunhill Medical Trust, Liver Group
   Charity, Wellcome Trust Equipment Grant.
CR Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273
   Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003
   BRENT GA, 1994, NEW ENGL J MED, V331, P847
   Bustin SA, 2005, EXPERT REV MOL DIAGN, V5, P493, DOI 10.1586/14737159.5.4.493
   Chevalier S, 1999, J CELL SCI, V112, P4785
   Columbano A, 2005, HEPATOLOGY, V42, P1118, DOI 10.1002/hep.20883
   Columbano A, 2003, CELL DEATH DIFFER, V10, pS19, DOI 10.1038/sj.cdd.4401113
   COLUMBANO A, 1983, AM J PATHOL, V110, P83
   Columbano A, 2001, HEPATOLOGY, V34, P262, DOI 10.1053/jhep.2001.26172
   Columbano A, 1996, FASEB J, V10, P1118
   Columbano A, 1997, ONCOGENE, V14, P857, DOI 10.1038/sj.onc.1200891
   CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3
   CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429
   De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560
   Fausto N, 2006, HEPATOLOGY, V43, pS45, DOI 10.1002/hep.20969
   Feng X, 2000, MOL ENDOCRINOL, V14, P947, DOI 10.1210/me.14.7.947
   Flores-Morales A, 2002, MOL ENDOCRINOL, V16, P1257, DOI 10.1210/me.16.6.1257
   Forbes SJ, 2000, GENE THER, V7, P784, DOI 10.1038/sj.gt.3301143
   FRANCAVILLA A, 1994, HEPATOLOGY, V20, P1237, DOI 10.1002/hep.1840200521
   Fujii C, 2005, INT J CANCER, V114, P209, DOI 10.1002/ijc.20719
   Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206
   Ledda-Columbano GM, 2000, AM J PATHOL, V156, P91, DOI 10.1016/S0002-9440(10)64709-8
   Ledda-Columbano GM, 1998, ONCOGENE, V17, P1039, DOI 10.1038/sj.onc.1202018
   Lerner LE, 2005, J BIOL CHEM, V280, P20642, DOI 10.1074/jbc.M500957200
   Malik R, 2003, HEPATOLOGY, V37, P79, DOI 10.1053/jhep.2003.50001
   Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60
   Parzefall W, 2001, CARCINOGENESIS, V22, P519, DOI 10.1093/carcin/22.3.519
   PARZEFALL W, 1989, ARCH TOXICOL, V63, P456, DOI 10.1007/BF00316448
   Pibiri M, 2001, FASEB J, V15, P1006, DOI 10.1096/fj.00-0416com
   Rose ML, 1999, CARCINOGENESIS, V20, P27, DOI 10.1093/carcin/20.1.27
   Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314
   Stahlberg Nina, 2005, BMC Physiol, V5, P8, DOI 10.1186/1472-6793-5-8
   Weitzel JM, 2003, J MOL ENDOCRINOL, V31, P291, DOI 10.1677/jme.0.0310291
   Weitzel JM, 2001, NUCLEIC ACIDS RES, V29, P5148, DOI 10.1093/nar/29.24.5148
   Witzgall R, 1998, AM J PHYSIOL-RENAL, V275, pF928
   Yen PM, 2003, EMBO REP, V4, P581, DOI 10.1038/sj.embor.embor862
NR 36
TC 9
Z9 9
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
EI 1440-1746
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD DEC
PY 2008
VL 23
IS 12
BP 1926
EP 1933
DI 10.1111/j.1440-1746.2008.05506.x
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 377LN
UT WOS:000261252800028
PM 18717759
DA 2020-12-08
ER

PT J
AU Bible, JM
   Iturriza-Gomara, M
   Megson, B
   Brown, D
   Pantelidis, P
   Earl, P
   Bendig, J
   Tong, CYW
AF Bible, Jon M.
   Iturriza-Gomara, Miren
   Megson, Brian
   Brown, David
   Pantelidis, Panagiotis
   Earl, Pam
   Bendig, Justin
   Tong, C. Y. William
TI Molecular epidemiology of human enterovirus 71 in the United Kingdom
   from 1998 to 2006
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID POLIOMYELITIS-LIKE DISEASE; MOUTH-DISEASE; 71 INFECTION; TAIWAN; FOOT;
   HAND; OUTBREAK; MALAYSIA; STRAINS; EVOLUTION
AB The last decade witnessed a significant increase in epidemic activity of human enterovirus 71 (EV71) in the Western Pacific Region (WPR). In most European countries, this risk is unrecognized despite occasional cases of severe disease and two severe outbreaks in Eastern Europe 30 years ago. In this study we report the first examination of the molecular epidemiology of EV71 in the United Kingdom from 1998 to 2006. Genomic regions encoding the 1D coat protein (VP1) and 3D polymerase (Pol) from 32 EV71 isolates associated with neurological or cutaneous manifestations were sequenced. Phylogenetic analyses of VP1 and 3D Pol sequences identified genotype C as the dominant strain. Several United Kingdom isolates had genetic linkages with predated C1 or C2 strains from Europe and the WPR. Recombination events were not detected between United Kingdom strains. However, a previously published Taiwanese strain was identified as an intergenotypic recombinant. EV71 genotype C appears to have continuous circulation in the United Kingdom from 1998 to 2006 with repeated introductions of new strains replacing previous strains. It is necessary to continuously monitor the molecular evolution and recombination events of EV71.
C1 [Bible, Jon M.; Tong, C. Y. William] Guys & St Thomas NHS Fdn Trust, Infect & Immunol Delivery Unit, London, England.
   [Iturriza-Gomara, Miren; Megson, Brian; Brown, David] Hlth Protect Agcy, Ctr Infect, Virus Reference Dept, Enter Virus Unit, London, England.
   [Pantelidis, Panagiotis] Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Populat Genet & Gene Therapy, Interstitial Lung Dis Grp,Natl Heart & Lung Inst, London, England.
   [Earl, Pam; Bendig, Justin] Epsom & St Helier Univ Hosp, Dept Med Microbiol, Surrey, England.
   [Tong, C. Y. William] Kings Coll London, Sch Med, Dept Infect Dis, London, England.
RP Tong, CYW (corresponding author), St Thomas Hosp, Guys & St Thomas NHS Fdn Trust, Infect & Immunol Unit, 5th Floor,North Wing, London SE1 7EH, England.
EM william.tong@gstt.nhs.uk
RI Tong, Cheuk Yan William/C-1312-2012; Gomara, Miren Iturriza/B-4351-2013
OI Tong, Cheuk Yan William/0000-0001-8401-6832; Gomara, Miren
   Iturriza/0000-0001-5816-6423
FU Guy's and St Thomas' Charity [R041075]
FX Funding for this study was provided by Guy's and St Thomas' Charity
   grant R041075.
CR Brown BA, 1999, J VIROL, V73, P9969, DOI 10.1128/JVI.73.12.9969-9975.1999
   Cardosa MJ, 2003, EMERG INFECT DIS, V9, P461
   CHONMAITREE T, 1981, PEDIATRICS, V67, P489
   CHUMAKOV M, 1979, ARCH VIROL, V60, P329, DOI 10.1007/BF01317504
   Felsenstein J, 2005, PHYLIP PHYLOGENY INF
   Herrero LJ, 2003, ARCH VIROL, V148, P1369, DOI 10.1007/s00705-003-0100-2
   Ho MT, 1999, NEW ENGL J MED, V341, P929, DOI 10.1056/NEJM199909233411301
   Kehle J, 2003, J NEUROVIROL, V9, P126, DOI 10.1080/13550280390173364
   Liu CC, 2000, J CLIN VIROL, V17, P23, DOI 10.1016/S1386-6532(00)00068-8
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Lukashev AN, 2005, REV MED VIROL, V15, P157, DOI 10.1002/rmv.457
   Lum LCS, 1998, J PEDIATR-US, V133, P795, DOI 10.1016/S0022-3476(98)70155-6
   McMinn P, 2001, J VIROL, V75, P7732, DOI 10.1128/JVI.75.16.7732-7738.2001
   McMinn P, 2001, CLIN INFECT DIS, V32, P236, DOI 10.1086/318454
   Mizuta K, 2005, J CLIN MICROBIOL, V43, P6171, DOI 10.1128/JCM.43.12.6171-6175.2005
   Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357
   PALLANSCH MA, 2001, FIELDS VIROLOGY, P723
   Richter J, 2006, J MED MICROBIOL, V55, P1035, DOI 10.1099/jmm.0.46447-0
   Roth B, 2007, J MED VIROL, V79, P956, DOI 10.1002/jmv.20917
   SCHMIDT NJ, 1974, J INFECT DIS, V129, P304, DOI 10.1093/infdis/129.3.304
   Shih SR, 2000, VIRUS RES, V68, P127, DOI 10.1016/S0168-1702(00)00162-3
   Shimizu H, 2004, PEDIATR INT, V46, P231, DOI 10.1046/j.1442-200x.2004.01868.x
   Shimizu H, 1999, JPN J INFECT DIS, V52, P12
   SHINDAROV LM, 1979, J HYG EPID MICROB IM, V23, P284
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Van Tu P, 2007, EMERG INFECT DIS, V13, P1733, DOI 10.3201/eid1311.070632
   Wang JR, 2002, J CLIN MICROBIOL, V40, P10, DOI 10.1128/JCM.40.1.10-15.2002
   Wang SM, 1999, CLIN INFECT DIS, V29, P184, DOI 10.1086/520149
   *WHO, 1979, WKLY EPIDEMIOL REC, V7, P484
   Witso E, 2007, VIRUS RES, V123, P19, DOI 10.1016/j.virusres.2006.07.015
NR 31
TC 91
Z9 111
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD OCT
PY 2008
VL 46
IS 10
BP 3192
EP 3200
DI 10.1128/JCM.00628-08
PG 9
WC Microbiology
SC Microbiology
GA 356DM
UT WOS:000259758900002
PM 18650362
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Brown, D
   Featherstone, JJ
   Fooks, AR
   Gettner, S
   Lloyd, E
   Schweiger, M
AF Brown, David
   Featherstone, John J.
   Fooks, Anthony R.
   Gettner, Sharmeen
   Lloyd, Elizabeth
   Schweiger, Martin
TI Intradermal pre-exposure rabies vaccine elicits long lasting immunity
SO VACCINE
LA English
DT Article
DE immunisation; immunity; intradermal; rabies
ID NEUTRALIZING ANTIBODY; ECONOMICAL REGIMENS; IMMUNIZATION; RESPONSES
AB A retrospective cohort study of current rabies antibody titres from adults who received pre-exposure immunisation administered intradermally between 1994 and 2005, examining the decay in titre over time relative to the interval since last dose, and the total dose received. Participants receiving at least 0.6 ml total dose intradermally of vaccine over at least two clinic visits and all with three clinic visits, were shown to have an adequate titre with measurable levels of antibody indicating sero-conversion above 0.5 IU/ml, irrespective of the time interval since the last dose. No clear relationship was found between time interval since immunisation and the level of antibody. Using a schedule that administers 0.6 ml of rabies vaccine over three clinic visits the boosting interval could be extended towards ten years; substantially cheaper than the standard licensed intramuscular dosing schedule. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Schweiger, Martin] HPA Lab, W Yorkshire Hlth Protect Unit, Hlth Protect Agcy, Leeds LS15 7TR, W Yorkshire, England.
   [Brown, David] HPA, Ctr Infect, Virus Reference Dept, London, England.
   [Fooks, Anthony R.] Vet Labs Agcy Weybridge, Rabies & Wildlife Zoonoses Grp, Addlestone KT15 3NB, Surrey, England.
   [Lloyd, Elizabeth] Univ Leeds, Leeds LS2 9JT, W Yorkshire, England.
RP Schweiger, M (corresponding author), HPA Lab, W Yorkshire Hlth Protect Unit, Hlth Protect Agcy, Leeds LS15 7TR, W Yorkshire, England.
EM martin.schweiger@hpa.org.uk
RI Fooks, Anthony R/F-5418-2010
CR BERNARD KW, 1982, JAMA-J AM MED ASSOC, V247, P1138, DOI 10.1001/jama.247.8.1138
   BERNARD KW, 1985, AM J TROP MED HYG, V34, P633
   *CDCP, 1983, MMWR-MORBID MORTAL W, V32, P601
   Cliquet F, 1998, J IMMUNOL METHODS, V212, P79, DOI 10.1016/S0022-1759(97)00212-3
   FISHBEIN DB, 1987, J INFECT DIS, V156, P50, DOI 10.1093/infdis/156.1.50
   Lau C, 2002, J TRAVEL MED, V9, P285, DOI 10.2310/7060.2002.30088
   LEMON SM, 1984, LANCET, V1, P1098
   PHANUPHAK P, 1987, ASIAN PAC J ALLERGY, V5, P33
   Plotkin S.A., 2004, VACCINES
   Sabchareon A, 1998, PEDIATR INFECT DIS J, V17, P1001, DOI 10.1097/00006454-199811000-00007
   Strady C, 2000, VACCINE, V18, P2661, DOI 10.1016/S0264-410X(00)00054-2
   TURNER GS, 1976, LANCET, V1, P1379
   WARRELL MJ, 1984, LANCET, V1, P874
   *WHO, 2004, WHO TECHN REP SER, V931
NR 14
TC 22
Z9 23
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JUL 23
PY 2008
VL 26
IS 31
BP 3909
EP 3912
DI 10.1016/j.vaccine.2008.04.081
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 331JR
UT WOS:000258009000018
PM 18547689
DA 2020-12-08
ER

PT J
AU Vianna, RAD
   de Oliveira, SA
   Camacho, LAB
   Knowles, W
   Brown, D
   Pereira, ACD
   Velarde, LGC
   Siqueira, MM
AF de Oliveira Vianna, Renata Artimos
   de Oliveira, Solange Artimos
   Bastos Camacho, Luiz Antonio
   Knowles, Wendy
   Brown, David
   de Medeiros Pereira, Antonio Carlos
   Coca Velarde, Luis Guillermo
   Siqueira, Marilda Mendonca
TI Role of human herpesvirus 6 infection in young Brazilian children with
   rash illnesses
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE human herpesvirus 6; young children; exanthem subitum; population
   surveillance
ID HUMAN HERPESVIRUS-6 INFECTION; RIO-DE-JANEIRO; EXANTHEM-SUBITUM; AND-7
   INFECTIONS; ROSEOLA INFANTUM; MEASLES; ANTIBODIES; DIAGNOSIS; AVIDITY;
   RUBELLA
AB Background: Human herpesvirus type 6 (HHV-6) has been shown to infect almost all children by 4 years of age. Primary infection causes an undifferentiated febrile illness, with approximately 30% of children exhibiting the classic clinical manifestations of exanthem subitum. Even with typical clinical presentation, exanthem subitum is frequently misdiagnosed as measles or rubella. Our aim was to describe the frequency and clinical manifestations of HHV-6 infection in children less than 4 years of age enrolled in a study designed to define the etiology of rash diseases.
   Patients and Methods: The study was conducted between January 1998 and December 2006 at a general hospital and a large primary health care unit from Niteroi, Rio de Janeiro, Brazil. Sera from 223 children, in whom measles, rubella, dengue fever, and parvovirus B19 infections were excluded, were studied for anti-HHV-6 antibodies using an indirect immunofluorescence test. Demographic and clinical data of those patients were described.
   Results: Ninety-seven (43.5%) of the children had evidence of primary HHV-6 infection. The age of onset peaked at 6-11 months and 75% of the HHV-6 infection occurred in children between 6 and 17 months. Only 21% of the HHV-6 cases had a typical roseola-like illness and 73% and 46%, respectively, fulfilled the clinical criteria of measles and rubella suspected case.
   Conclusions: Our study confirms the importance of HHV-6 infection in young children and highlights the difficulties of diagnosing a rash illness on clinical grounds alone.
C1 [de Oliveira Vianna, Renata Artimos; de Oliveira, Solange Artimos; de Medeiros Pereira, Antonio Carlos] Univ Fed Fluminense, Hosp Univ Antonio Pedro, Disciplina Doencas Infecc & Parasitarias, BR-24030210 Niteroi, RJ, Brazil.
   [Bastos Camacho, Luiz Antonio] Escola Nacl Saude Publica, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Knowles, Wendy; Brown, David] Hlth Agengy Protect, London, England.
   [Coca Velarde, Luis Guillermo] Univ Fed Fluminense, Dept Estat, BR-24030210 Niteroi, RJ, Brazil.
   [Siqueira, Marilda Mendonca] Inst Oswaldo Cruz, Fundacao Oswaldo Cruz, BR-20001 Rio De Janeiro, Brazil.
RP de Oliveira, SA (corresponding author), Univ Fed Fluminense, Hosp Univ Antonio Pedro, Disciplina Doencas Infecc & Parasitarias, Rua Marques Parana 303,2 Andar, BR-24030210 Niteroi, RJ, Brazil.
EM artimos@vin.uff.br
CR ASANO Y, 1994, PEDIATRICS, V93, P104
   Black JB, 1996, CLIN INFECT DIS, V23, P1156, DOI 10.1093/clinids/23.5.1156
   Braun DK, 1997, CLIN MICROBIOL REV, V10, P521, DOI 10.1128/CMR.10.3.521
   Clark DA, 1997, ARCH DIS CHILD, V77, P42, DOI 10.1136/adc.77.1.42
   CUBEL RCN, 1994, J CLIN MICROBIOL, V32, P1997, DOI 10.1128/JCM.32.8.1997-1999.1994
   HALL CB, 1994, NEW ENGL J MED, V331, P432, DOI 10.1056/NEJM199408183310703
   HUANG LM, 1991, ARCH DIS CHILD, V66, P1443, DOI 10.1136/adc.66.12.1443
   JURETIC M, 1963, HELVETICA PAEDIATRIC, V1, P80
   KUNO G, 1987, AM J TROP MED HYG, V36, P153, DOI 10.4269/ajtmh.1987.36.153
   *MIN SAUD SECR VIG, 2003, MAN VIG EP DOENC EX, P1
   NOGUEIRA RMR, 1992, RES VIROLOGY, V143, P423, DOI 10.1016/S0923-2516(06)80136-6
   Norton RA, 1999, J CLIN MICROBIOL, V37, P3672, DOI 10.1128/JCM.37.11.3672-3675.1999
   OKADA K, 1993, PEDIATR INFECT DIS J, V12, P204, DOI 10.1097/00006454-199303000-00006
   OKUNO T, 1991, J PEDIATR-US, V119, P759, DOI 10.1016/S0022-3476(05)80294-X
   Oliveira SA, 2003, EPIDEMIOL INFECT, V131, P873, DOI 10.1017/S0950268803008823
   Oliveira SA, 2001, EPIDEMIOL INFECT, V127, P509, DOI 10.1017/S0950268801005908
   PELLET P, 2000, CAN COMMUN DIS REP, P4
   PRUKSANANONDA P, 1992, NEW ENGL J MED, V326, P1445, DOI 10.1056/NEJM199205283262201
   Setubal Sergio, 1998, Revista do Instituto de Medicina Tropical de Sao Paulo, V40, P185, DOI 10.1590/S0036-46651998000300010
   Tait DR, 1996, BRIT MED J, V312, P101
   Ward KN, 2005, J CLIN VIROL, V32, P183, DOI 10.1016/j.jcv.2004.11.008
   WARD KN, 1993, J MED VIROL, V39, P131, DOI 10.1002/jmv.1890390209
   Ward KN, 2002, J VIROL METHODS, V106, P107, DOI 10.1016/S0166-0934(02)00141-6
   Ward KN, 2001, J CLIN MICROBIOL, V39, P959, DOI 10.1128/JCM.39.3.959-963.2001
   YAMANISHI K, 1988, LANCET, V1, P1065
NR 25
TC 8
Z9 9
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JUN
PY 2008
VL 27
IS 6
BP 533
EP 537
DI 10.1097/INF.0b013e3181673c50
PG 5
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 311NI
UT WOS:000256606500009
PM 18449066
DA 2020-12-08
ER

PT J
AU Panning, M
   Laue, T
   Olschlager, S
   Eickmann, M
   Becker, S
   Raith, S
   Courbot, MCG
   Nilsson, M
   Gopal, R
   Lundkvist, A
   di Caro, A
   Brown, D
   Meyer, H
   Lloyd, G
   Kummerer, BM
   Gunther, S
   Drosten, C
AF Panning, Marcus
   Laue, Thomas
   Olschlager, Stephan
   Eickmann, Markus
   Becker, Stephan
   Raith, Sabine
   Courbot, Marie-Claude Georges
   Nilsson, Mikael
   Gopal, Robin
   Lundkvist, Ake
   di Caro, Antonino
   Brown, David
   Meyer, Hermann
   Lloyd, Graham
   Kummerer, Beate M.
   Gunther, Stephan
   Drosten, Christian
TI Diagnostic reverse-transcription polymerase chain reaction kit for
   filoviruses based on the strain collections of all European biosafety
   level 4 laboratories
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT Symposium on Recent Advances and Future Challenges in Filovirus Research
CY SEP, 2006
CL Winnipeg, CANADA
ID EXTERNAL QUALITY-ASSURANCE; EBOLA HEMORRHAGIC-FEVER;
   MOLECULAR-DETECTION; RAPID DETECTION; PCR; VIRUS; QUANTIFICATION;
   PROFICIENCY; OUTBREAK; CONGO
AB A network of European biosafety level 4 laboratories has designed the first industry-standard molecular assay for all filoviruses species, based on the strain collections of all participants. It uses 5 optimized L gene primers and 3 probes, as well as an internal control with a separate detection probe. Detection limits (probit analysis, 95% detection chance) were as follows: Zaire ebolavirus, 487 copies/mL of plasma; Sudan ebolavirus Maleo, 586 copies/mL; Sudan ebolavirus Gulu, 1128 copies/mL; Cote d'Ivoire ebolavirus, 537 copies/mL; Reston ebolavirus, 4546 copies/mL; Lake Victoria marburgvirus Musoke, 860 copies/mL; and Lake Victoria marburgvirus Ravn, 1551 copies/mL. The assay facilitates reliable detection or exclusion screening of filovirus infections.
C1 Bernhard Nocht Inst Trop Med, Clin Virol, D-20359 Hamburg, Germany.
   Bernhard Nocht Inst Trop Med, Hamburg, Germany.
   Qiagen, Hamburg, Germany.
   Univ Marburg, Marburg, Germany.
   Bundeswehr Inst Microbiol, Munich, Germany.
   Inst Pasteur, Unit Biol Infect Virales Emergentes, Lyon, France.
   Swidish Ctr Infect Dis Control, Solna, Sweden.
   Hlth Protect Agcy, London, England.
   Hlth Protect Agcy Porton Down, Salisbury, Wilts, England.
   Natl Inst Infect Dis L Spallanzani, Rome, Italy.
RP Drosten, C (corresponding author), Bernhard Nocht Inst Trop Med, Clin Virol, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.
EM drosten@bni-hamburg.de
RI Becker, Stephan/A-1065-2010; Laue, Tom/AAI-5136-2020; Panning,
   Marcus/I-7889-2016; Di Caro, Antonino/K-6854-2016
OI Becker, Stephan/0000-0002-2794-5659; Di Caro,
   Antonino/0000-0001-6027-3009; Gunther, Stephan/0000-0002-6562-0230
CR Bausch DG, 2006, NEW ENGL J MED, V355, P909, DOI 10.1056/NEJMoa051465
   Drosten C, 2000, TRANSFUSION, V40, P718, DOI 10.1046/j.1537-2995.2000.40060718.x
   Drosten C, 2004, J CLIN MICROBIOL, V42, P2043, DOI 10.1128/JCM.42.5.2043-2047.2004
   Drosten C, 2004, EMERG INFECT DIS, V10, P2200, DOI 10.3201/eid1012.040416
   Drosten C, 2003, ANTIVIR RES, V57, P61, DOI 10.1016/S0166-3542(02)00201-2
   Drosten C, 2002, J CLIN MICROBIOL, V40, P2323, DOI 10.1128/JCM.40.7.2323-2330.2002
   Formenty P, 2006, CLIN INFECT DIS, V42, P1521, DOI 10.1086/503836
   Leroy EM, 2000, LANCET, V355, P2210, DOI 10.1016/S0140-6736(00)02405-3
   Leroy EM, 2000, J MED VIROL, V60, P463, DOI 10.1002/(SICI)1096-9071(200004)60:4&lt;463::AID-JMV15&gt;3.0.CO;2-M
   Niedrig M, 2004, J CLIN MICROBIOL, V42, P1753, DOI 10.1128/JCM.42.4.1753-1755.2004
   Niedrig M, 2006, J CLIN MICROBIOL, V44, P1283, DOI 10.1128/JCM.44.4.1283-1287.2006
   Niedrig M, 2006, CLIN CHEM, V52, P1851, DOI 10.1373/clinchem.2005.064451
   Sanchez A, 1999, J INFECT DIS, V179, pS164, DOI 10.1086/514282
   Towner JS, 2006, J VIROL, V80, P6497, DOI 10.1128/JVI.00069-06
   Towner JS, 2004, J VIROL, V78, P4330, DOI 10.1128/JVI.78.8.4330-4341.2004
NR 15
TC 51
Z9 54
U1 0
U2 12
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 15
PY 2007
VL 196
SU 2
BP S199
EP S204
DI 10.1086/520600
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 233KS
UT WOS:000251090400013
PM 17940950
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Danta, M
   van de Laar, T
   Brown, D
   Pybus, O
   Bhagani, S
   Vogel, M
   Neifer, S
   Baumgarten, A
   Gotz, H
   Rockstoh, J
   Bruisten, S
   Dusheiko, GM
AF Danta, Mark
   van de Laar, Thijs
   Brown, David
   Pybus, Oliver
   Bhagani, Sanjay
   Vogel, Martin
   Neifer, Stefan
   Baumgarten, Axel
   Gotz, Helena
   Rockstoh, Juergen
   Bruisten, Sylvia
   Dusheiko, Geoffrey M.
TI Evidence of international transmission of HCV in pan-European study of
   HIV-positive men who have sex with men (MSM)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 58th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 02-06, 2007
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 St Vincents Clin Sch, Sydney, NSW, Australia.
   Univ Coll & Free Med Sch, Ctr Hepatol, London, England.
   Univ Oxford, Dept Zool, Oxford OX1 2JD, England.
   Royal Free Hosp, Dept HIV Med, London NW3 2QG, England.
   Univ Bonn, D-5300 Bonn, Germany.
   Baumgarten, Carganico, Practice Dupke, Berlin, Germany.
   Hlth Serv, Dept Infect Dis, Rotterdam, Netherlands.
   Hlth Serv, Cluster Infect Dis, Amsterdam, Netherlands.
RI Pybus, Oliver G/B-2640-2012
OI Pybus, Oliver G/0000-0002-8797-2667
NR 0
TC 2
Z9 2
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2007
VL 46
IS 4
SU S
MA 137
BP 297A
EP 298A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 216WT
UT WOS:000249910400143
DA 2020-12-08
ER

PT J
AU Patel, SR
   Cohen, B
   Brown, D
   Heath, PT
AF Patel, Soonie R.
   Cohen, Bernard
   Brown, David
   Heath, Paul T.
TI Reply to arya and agarwal and meisel and dilloo
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
ID PNEUMOCOCCAL CONJUGATE VACCINE; CHILDREN; REVACCINATION; CHEMOTHERAPY;
   POLIOVIRUS; ANTIBODY
C1 Royal Marsden Hosp, Dept Pediat Oncol, Sutton, Surrey, England.
   Univ London, Ctr Infect, Hlth Protect Agcy, Virus Reference Dept, London, England.
   Univ London St Georges Hosp, Child Hlth & Vaccine Inst, London, England.
RP Patel, SR (corresponding author), Mayday Univ Hosp, Dept Paediat, Croydon CR7 7YE, England.
EM soonier@doctors.org.uk
OI Heath, Paul/0000-0002-7540-7433
CR [Anonymous], 2002, IMM IMM CHILD BEST P, P10
   Arya SC, 2007, CLIN INFECT DIS, V45, P397, DOI 10.1086/518980
   Diedrich S, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-2
   Goldblatt D, 2006, PEDIATR INFECT DIS J, V25, P312, DOI 10.1097/01.inf.0000207483.60267.e7
   Meisel R, 2007, BLOOD, V109, P2322, DOI 10.1182/blood-2006-06-032284
   Meisel R, 2007, CLIN INFECT DIS, V45, P397, DOI 10.1086/518981
   Patel SR, 2007, CLIN INFECT DIS, V44, P625, DOI 10.1086/511641
   Patel SR, 2007, CLIN INFECT DIS, V44, P635, DOI 10.1086/511636
   *WHO, 1993, IMM BAS IMM MOD POL, V6
   World Health Organization, 2004, POL LAB MAN
NR 10
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2007
VL 45
IS 3
BP 398
EP 399
DI 10.1086/518982
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 184DK
UT WOS:000247621100022
OA Bronze
DA 2020-12-08
ER

PT J
AU Gumbo, T
   Louie, A
   Liu, WG
   Brown, D
   Ambrose, PG
   Bhavnani, SM
   Drusano, GL
AF Gumbo, Tawanda
   Louie, Arnold
   Liu, Weiguo
   Brown, David
   Ambrose, Paul G.
   Bhavnani, Sujata M.
   Drusano, George L.
TI Isoniazid bactericidal activity and resistance emergence: Integrating
   pharmacodynamics and pharmacogenomics to predict efficacy in different
   ethnic populations
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID MINIMAL INHIBITORY CONCENTRATIONS; MUTANT PREVENTION CONCENTRATION;
   MYCOBACTERIUM-TUBERCULOSIS; ANTITUBERCULOSIS DRUGS; PULMONARY
   TUBERCULOSIS; STAPHYLOCOCCUS-AUREUS; INFECTION MODEL; ETHAMBUTOL;
   SELECTION; GENE
AB Isoniazid, administered as part of combination antituberculosis therapy, is responsible for most of the early bactericidal activity (EBA) of the regimen. However, the emergence of Mycobacterium tuberculosis resistance to isoniazid is a major problem. We examined the relationship between isoniazid exposure and M. tuberculosis microbial kill, as well as the emergence of resistance, in our in vitro pharmacodynamic model of tuberculosis. Since single-nucleotide polymorphisms of the N-acetyltransferase-2 gene lead to two different clearances of isoniazid from serum in patients, we simulated the isoniazid concentration-time profiles encountered in both slow and fast acetylators. Both microbial kill and the emergence of resistance during monotherapy were associated with the ratio of the area under the isoniazid concentration-time curve from 0 to 24 h (AUC(0-24)) to the isoniazid MIC. The time in mutant selection window hypothesis was rejected. Next, we utilized the in vitro relationship between the isoniazid AUC(0-24)/MIC ratio and microbial kill, the distributions of isoniazid clearance in populations with different percentages of slow and fast acetylators, and the distribution of isoniazid MICs for isonazid-susceptible M. tuberculosis clinical isolates in Monte Carlo simulations to calculate the EBA expected for similar to 10,000 patients treated with 300 mg of isoniazid. For those patient populations in which the proportion of fast acetylators and the isoniazid MICs were high, the average EBA of the standard dose was similar to 0.3 log(10) CFU/ml/day and was thus suboptimal. Our approach, which utilizes preclinical pharmacodynamics and the genetically determined multimodal distributions of serum clearances, is a preclinical tool that may be able to predict the EBAs of various doses of new antituberculosis drugs.
C1 Univ Texas, SW Med Ctr, Div Infect Dis, Dallas, TX 75390 USA.
   Inst Clin Pharmacodynam, Emerging Infect & Host Def Sect, Albany, NY 12208 USA.
   Ordway Res Inst, Emerging Infect & Host Def Sect, Albany, NY 12208 USA.
RP Gumbo, T (corresponding author), Univ Texas, SW Med Ctr, Div Infect Dis, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM Tawanda.Gumbo@UTSouthwestern.edu
OI Gumbo, Tawanda/0000-0001-7592-8012
CR Adams CH, 2003, CLIN CHEM LAB MED, V41, P600, DOI 10.1515/CCLM.2003.090
   [Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
   Berecz R, 2003, EUR J CLIN PHARMACOL, V59, P45, DOI 10.1007/s00228-003-0576-4
   Bernard S, 2006, ONCOLOGIST, V11, P126, DOI 10.1634/theoncologist.11-2-126
   *CLIN LAB STAND I, 2003, SUSC TEST MYC NOC AE
   Colangeli R, 2005, MOL MICROBIOL, V55, P1829, DOI 10.1111/j.1365-2958.2005.04510.x
   Dandara C, 2003, PHARMACOGENETICS, V13, P55, DOI 10.1097/00008571-200301000-00008
   DARGENIO DZ, 1997, ADAPT 2 PROGRAM SIMU
   Donald P R, 2003, Expert Rev Anti Infect Ther, V1, P141, DOI 10.1586/14787210.1.1.141
   Donald PR, 2004, CLIN INFECT DIS, V39, P1425, DOI 10.1086/424999
   Donald PR, 1997, AM J RESP CRIT CARE, V156, P895, DOI 10.1164/ajrccm.156.3.9609132
   Dong YZ, 2000, ANTIMICROB AGENTS CH, V44, P2581, DOI 10.1128/AAC.44.9.2581-2584.2000
   Drusano GL, 2006, CLIN INFECT DIS, V42, P525, DOI 10.1086/499046
   EVANS DAP, 1960, BRIT MED J, V2, P485, DOI 10.1136/bmj.2.5197.485
   Fietta A, 2001, J CHEMOTHERAPY, V13, P167, DOI 10.1179/joc.2001.13.2.167
   Firsov AA, 2003, ANTIMICROB AGENTS CH, V47, P1604, DOI 10.1128/AAC.47.5.1604-1613.2003
   *GLOB ALL TB DRUG, 2006, RFP 2006 01 PRECL EV
   Gumbo T, 2005, ANTIMICROB AGENTS CH, V49, P3178, DOI 10.1128/AAC.49.8.3178-3181.2005
   Gumbo T, 2004, J INFECT DIS, V190, P1642, DOI 10.1086/424849
   Gumbo T, 2007, J INFECT DIS, V195, P194, DOI 10.1086/510247
   Haas WH, 1997, ANTIMICROB AGENTS CH, V41, P1601, DOI 10.1128/AAC.41.7.1601
   Jayaram R, 2004, ANTIMICROB AGENTS CH, V48, P2951, DOI 10.1128/AAC.48.8.2951-2957.2004
   JINDANI A, 1980, AM REV RESPIR DIS, V121, P939
   Jindani A, 2003, AM J RESP CRIT CARE, V167, P1348, DOI 10.1164/rccm.200210-1125OC
   Katoh T, 2000, INT J CANCER, V85, P46, DOI 10.1002/(SICI)1097-0215(20000101)85:1<46::AID-IJC8>3.0.CO;2-0
   LEARY R, 2001, ADAPTIVE GRID NONPAR
   LEE CN, 1987, AM REV RESPIR DIS, V136, P349, DOI 10.1164/ajrccm/136.2.349
   Ma QW, 2004, BIOMED ENVIRON SCI, V17, P291
   MITCHISON DA, 1979, CHEST, V76, P771, DOI 10.1378/chest.76.6_Supplement.771
   Ordway D, 2003, ANTIMICROB AGENTS CH, V47, P917, DOI 10.1128/AAC.47.3.917-922.2003
   Parsons LA, 2005, ANTIMICROB AGENTS CH, V49, P2218, DOI 10.1128/AAC.49.6.2218-2225.2005
   Peloquin CA, 1997, ANTIMICROB AGENTS CH, V41, P2670, DOI 10.1128/AAC.41.12.2670
   Rieder HL, 2002, INTERVENTIONS TUBERC
   SARMA G R, 1990, Indian Pediatrics, V27, P134
   Silva MSN, 2003, J CLIN MICROBIOL, V41, P4471, DOI 10.1128/JCM.41.9.4471-4474.2003
   Sindelar G, 2000, ANTIMICROB AGENTS CH, V44, P3337, DOI 10.1128/AAC.44.12.3337-3343.2000
   Sirgel FA, 2000, J ANTIMICROB CHEMOTH, V45, P859, DOI 10.1093/jac/45.6.859
   SUO J, 1988, AM REV RESPIR DIS, V138, P999, DOI 10.1164/ajrccm/138.4.999
   Tam CM, 2002, INT J TUBERC LUNG D, V6, P3
   Tam VH, 2007, ANTIMICROB AGENTS CH, V51, P744, DOI 10.1128/AAC.00334-06
   Varma M, 2002, INDIAN J TUBERC, V490, P217
   Viveiros M, 2002, ANTIMICROB AGENTS CH, V46, P2804, DOI 10.1128/AAC.46.9.2804-2810.2002
   Weiner M, 2005, CLIN INFECT DIS, V40, P1481, DOI 10.1086/429321
   Weiner M, 2003, AM J RESP CRIT CARE, V167, P1341, DOI 10.1164/rccm.200208-951OC
   *WHO, 2004, DTH6 2002 REV
   Yamane N, 1998, Rinsho Byori, V46, P719
   Zhao XL, 2001, CLIN INFECT DIS, V33, pS147, DOI 10.1086/321841
NR 47
TC 111
Z9 113
U1 0
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUL
PY 2007
VL 51
IS 7
BP 2329
EP 2336
DI 10.1128/AAC.00185-07
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 184TS
UT WOS:000247665800006
PM 17438043
OA Bronze, Green Published
DA 2020-12-08
ER

PT J
AU Danta, M
   Brown, D
   Bhagani, S
   Pybus, OG
   Sabin, CA
   Nelson, M
   Fisher, M
   Johnson, AM
   Dusheiko, GM
AF Danta, Mark
   Brown, David
   Bhagani, Sanjay
   Pybus, Oliver G.
   Sabin, Caroline A.
   Nelson, Mark
   Fisher, Martin
   Johnson, Anne M.
   Dusheiko, Geoffrey M.
CA HIV Acute HCV HAAC Grp
TI Recent epidemic of acute hepatitis C virus in HIV-positive men who have
   sex with men linked to high-risk sexual behaviours
SO AIDS
LA English
DT Article
DE HIV; hepatitis C virus; hepatitis C; acute; co-infection; transmission;
   phylogenetic; epidemiology
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HOMOSEXUAL-MEN; LIVER-DISEASE; SUBSTANCE
   USE; T-CELLS; INFECTION; MORTALITY; ENVIRONMENT; INCREASE; GAY
AB Objective: To characterize the mode of hepatitis C virus (HCV) transmission in a recent epidemic of acute HCV in HIV-infected individuals using linked molecular and clinical epidemiological studies.
   Design: Individuals diagnosed with acute HCV between 1999 and 2005 at three urban HIV units in the UK were enrolled into a phylogenetic and case-control study. Phylogenetic trees were constructed from the amplified sequences of the E1/E2 region of the HCV genome and were used to compare cases with unrelated sequences. A questionnaire-based, case-control study using matched controls recruited from each HIV unit identified putative transmission factors.
   Results: One hundred and eleven HIV-positive men who have sex with men with acute HCV (genotype 1: 84%) were enrolled. Phylogenetic analysis of 93 E1/E2 sequences revealed seven monophyletic clusters signifying multiple independent HCV lineages co-circulating in the HIV-positive population. Permucosal rather than percutaneous transmission factors were associated with case/control status. Cases (n = 60) had more sexual partners, increased levels of high-risk sexual behaviour and were more likely to have shared drugs via a nasal or anal route in the preceding year in comparison with controls (n = 130). Sex in a group of more than two people was the strongest predictor of case/control status; odds ratios associated with participation in two or at least three types of high-risk sexual behaviour in a group were 9.16 (95% confidence interval, 3.51-23.90) and 23.50 (95% confidence interval, 9.47-58.33), respectively.
   Conclusion: The identified co-circulating HCV lineages belong to different subtypes and genotypes, implying that rather than viral change, the epidemic is due to permucosal transmission factors that should be the focus of public health interventions. (C) 2007 Lippincott Williams & Wilkins.
C1 UCL, Inst Hepatol, London NW3 2PF, England.
   Royal Free & Univ Coll, Sch Med, Dept HIV Med, London, England.
   Royal Free & Univ Coll, Sch Med, Dept Primary Care & Populat Sci, London, England.
   Chelsea & Westminster Hosp, Dept HIV Med, London, England.
   Brighton & Sussex Univ Hosp, Dept HIV Med, Oxford, England.
   Univ Oxford, Dept Zool, Oxford, England.
RP Danta, M (corresponding author), UCL, Inst Hepatol, Rowland Hill St, London NW3 2PF, England.
EM m.danta@unsw.edu.au
RI Pybus, Oliver G/B-2640-2012; Sabin, Caroline/C-2464-2008
OI Pybus, Oliver G/0000-0002-8797-2667; Sabin, Caroline/0000-0001-5173-2760
CR ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259
   Benhamou Y, 1999, HEPATOLOGY, V30, P1054, DOI 10.1002/hep.510300409
   Bica I, 2001, CLIN INFECT DIS, V32, P492, DOI 10.1086/318501
   Briat A, 2005, AIDS, V19, P1827, DOI 10.1097/01.aids.0000189847.98569.2d
   Browne R, 2004, SEX TRANSM INFECT, V80, P326, DOI 10.1136/sti.2003.008532
   CATANIA J, 1995, ANN REV SEX RES, V6, P77
   *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P1
   Clatts MC, 2005, SEX TRANSM INFECT, V81, P373, DOI 10.1136/sti.2005.014894
   Colfax G, 2004, AM J EPIDEMIOL, V159, P1002, DOI 10.1093/aje/kwh135
   Crepaz N, 2004, JAMA-J AM MED ASSOC, V292, P224, DOI 10.1001/jama.292.2.224
   Dodds JP, 2000, BRIT MED J, V320, P1510, DOI 10.1136/bmj.320.7248.1510
   Dodds JP, 2004, SEX TRANSM INFECT, V80, P236, DOI 10.1136/sti.2003.007286
   DRUMMOND AJ, 2003, BEAST V1 0
   Farci P, 2000, SCIENCE, V288, P339, DOI 10.1126/science.288.5464.339
   Gambotti L, 2005, Euro Surveill, V10, P115
   Gerlach JT, 2003, GASTROENTEROLOGY, V125, P80, DOI 10.1016/S0016-5085(03)00668-1
   Gotz HM, 2005, AIDS, V19, P969, DOI 10.1097/01.aids.0000171412.61360.f8
   Halkitis PN, 2005, AIDS, V19, pS27, DOI 10.1097/01.aids.0000167349.23374.a3
   Harcourt G, 2006, GUT, V55, DOI 10.1136/gut.2005.083758
   Hoofnagle JH, 1997, HEPATOLOGY, V26, pS15, DOI 10.1002/hep.510260703
   Kim AY, 2005, BLOOD, V105, P1170, DOI 10.1182/blood-2004-06-2336
   Luetkemeyer A, 2006, JAIDS-J ACQ IMM DEF, V41, P31, DOI 10.1097/01.qai.0000191281.77954.27
   Macdonald N, 2004, SEX TRANSM INFECT, V80, P492, DOI 10.1136/sti.2004.011197
   McFarlane M, 2000, JAMA-J AM MED ASSOC, V284, P443, DOI 10.1001/jama.284.4.443
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Puoti M, 2000, J ACQ IMMUN DEF SYND, V24, P211
   Purcell DW, 2005, AIDS, V19, pS37, DOI 10.1097/01.aids.0000167350.00503.db
   Serpaggi J, 2006, AIDS, V20, P233, DOI 10.1097/01.aids.0000200541.40633.56
   Simms I, 2005, SEX TRANSM DIS, V32, P220, DOI 10.1097/01.olq.0000149848.03733.c1
   Stall RD, 2000, AIDS, V14, pS101
   Sulkowski MS, 2003, ANN INTERN MED, V138, P197, DOI 10.7326/0003-4819-138-3-200302040-00012
   Swofford DL., 2003, PAUP PHYLOGENETIC AN
   Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P15584, DOI 10.1073/pnas.242608099
   *WHO REG OFF EUR, 2007, HLTH EV NETW HIV HCV
NR 34
TC 308
Z9 315
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD MAY 11
PY 2007
VL 21
IS 8
BP 983
EP 991
DI 10.1097/QAD.0b013e3281053a0c
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 171RW
UT WOS:000246754100011
PM 17457092
DA 2020-12-08
ER

PT J
AU Gumbo, T
   Louie, A
   Liu, WG
   Ambrose, PG
   Bhavnani, SM
   Brown, D
   Drusano, GL
AF Gumbo, Tawanda
   Louie, Arnold
   Liu, Weiguo
   Ambrose, Paul G.
   Bhavnani, Sujata M.
   Brown, David
   Drusano, George L.
TI Isoniazid's bactericidal activity ceases because of the emergence of
   resistance, not depletion of Mycobacterium tuberculosis in the log phase
   of growth
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
CY DEC 16-19, 2005
CL Washington, DC
ID PULMONARY TUBERCULOSIS; ANTITUBERCULOSIS DRUGS; INFECTION MODEL;
   MOXIFLOXACIN; ETHAMBUTOL; GENE; PHARMACOKINETICS; CIPROFLOXACIN;
   AMPLIFICATION; MUTATIONS
AB Background. It is believed that the cessation of isoniazid's early bactericidal activity during the initial phase of antituberculosis therapy is due to the depletion of Mycobacterium tuberculosis in the exponential phase of growth. We examined the veracity of this cornerstone belief.
   Methods. We used an in vitro infection model in which M. tuberculosis was exposed to isoniazid concentration time profiles encountered in human patients. Experiments were performed to examine the time-related changes in the total bacterial population, the isoniazid-susceptible subpopulation, and the isoniazid-resistant subpopulation.
   Results. The cessation of microbial kill occurred between days 3 and 4 of isoniazid therapy, as occurs in patients. There were multiple logs of organisms in the exponential phase of growth remaining at the time when bactericidal activity ceased. The isoniazid-susceptible subpopulation was replaced by an isoniazid-resistant subpopulation after 80 h of therapy. The size of the isoniazid-susceptible subpopulation continued to decrease after the total population had ceased to decrease, whereas the resistant subpopulation remained in the exponential phase of growth. Resistance was due to single point mutations in the catalase-peroxidase gene and to reserpine-inhibitable efflux pumps.
   Conclusions. The age-old hypothesis that isoniazid's microbial killing of M. tuberculosis during log-phase growth ceases because of the depletion of this bacillary population needs to be modified.
C1 Ordway Res Inst, Emerging Infect & Host Def Sect, Albany, NY USA.
RP Gumbo, T (corresponding author), Univ Texas, SW Med Ctr, Div Infect Dis, 5323 Harry Hines Blvd, Dallas, TX USA.
EM Tawanda.Gumbo@UTSouthwestern.edu
OI Gumbo, Tawanda/0000-0001-7592-8012
CR Alland D, 1998, P NATL ACAD SCI USA, V95, P13227, DOI 10.1073/pnas.95.22.13227
   [Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
   CANETTI G, 1965, AM REV RESPIR DIS, V92, P687
   Colangeli R, 2005, MOL MICROBIOL, V55, P1829, DOI 10.1111/j.1365-2958.2005.04510.x
   DARGENIO DZ, 1997, ADAPT, V2
   DICKINSON JM, 1976, TUBERCLE, V57, P251, DOI 10.1016/S0041-3879(76)80002-5
   Donald P R, 2003, Expert Rev Anti Infect Ther, V1, P141, DOI 10.1586/14787210.1.1.141
   Donald PR, 2001, J ANTIMICROB CHEMOTH, V48, P877, DOI 10.1093/jac/48.6.877
   Donald PR, 1997, AM J RESP CRIT CARE, V156, P895, DOI 10.1164/ajrccm.156.3.9609132
   Drusano GL, 2006, CLIN INFECT DIS, V42, P525, DOI 10.1086/499046
   Gillespie SH, 2002, AM J RESP CRIT CARE, V166, P31, DOI 10.1164/rccm.2112077
   Ginsburg AS, 2003, NEW ENGL J MED, V349, P1977, DOI 10.1056/NEJM200311133492023
   Gumbo T, 2005, ANTIMICROB AGENTS CH, V49, P3178, DOI 10.1128/AAC.49.8.3178-3181.2005
   Gumbo T, 2004, J INFECT DIS, V190, P1642, DOI 10.1086/424849
   Haas WH, 1997, ANTIMICROB AGENTS CH, V41, P1601, DOI 10.1128/AAC.41.7.1601
   HOBBY GL, 1952, AM REV TUBERC PULM, V65, P771
   Jayaram R, 2004, ANTIMICROB AGENTS CH, V48, P2951, DOI 10.1128/AAC.48.8.2951-2957.2004
   JINDANI A, 1980, AM REV RESPIR DIS, V121, P939
   Jindani A, 2003, AM J RESP CRIT CARE, V167, P1348, DOI 10.1164/rccm.200210-1125OC
   Johnson JL, 2006, INT J TUBERC LUNG D, V10, P605
   Lee ASG, 1999, ANTIMICROB AGENTS CH, V43, P2087, DOI 10.1128/AAC.43.8.2087
   MITCHISON DA, 1979, CHEST, V76, P771, DOI 10.1378/chest.76.6_Supplement.771
   *NCCLS, 2003, SUSC TEST MYC NOC OT
   PANSY F, 1952, AM REV TUBERC PULM, V65, P761
   Parsons LA, 2005, ANTIMICROB AGENTS CH, V49, P2218, DOI 10.1128/AAC.49.6.2218-2225.2005
   Peloquin CA, 1997, ANTIMICROB AGENTS CH, V41, P2670, DOI 10.1128/AAC.41.12.2670
   Pletz MWR, 2004, ANTIMICROB AGENTS CH, V48, P780, DOI 10.1128/AAC.48.3.780-782.2004
   Rieder HL, 2002, INTERVENTIONS TUBERC
   Rinder H, 2001, INT J TUBERC LUNG D, V5, P339
   SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P404, DOI 10.1128/AAC.27.3.404
   SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P408, DOI 10.1128/AAC.27.3.408
   Silva MSN, 2003, J CLIN MICROBIOL, V41, P4471, DOI 10.1128/JCM.41.9.4471-4474.2003
   SIRGEL FA, 1993, J ANTIMICROB CHEMOTH, V32, P867, DOI 10.1093/jac/32.6.867
   Sirgel FA, 1997, AM J RESP CRIT CARE, V156, P901, DOI 10.1164/ajrccm.156.3.9611066
   Viveiros M, 2002, ANTIMICROB AGENTS CH, V46, P2804, DOI 10.1128/AAC.46.9.2804-2810.2002
   Weiner M, 2005, CLIN INFECT DIS, V40, P1481, DOI 10.1086/429321
   Weiner M, 2003, AM J RESP CRIT CARE, V167, P1341, DOI 10.1164/rccm.200208-951OC
NR 37
TC 71
Z9 73
U1 0
U2 9
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN 15
PY 2007
VL 195
IS 2
BP 194
EP 201
DI 10.1086/510247
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 122OW
UT WOS:000243237300007
PM 17191164
OA Bronze
DA 2020-12-08
ER

PT J
AU Cohen, C
   White, JM
   Savage, EJ
   Glynn, JR
   Choi, Y
   Andrews, N
   Brown, D
   Ramsay, ME
AF Cohen, Cheryl
   White, Joanne M.
   Savage, Emma J.
   Glynn, Judith R.
   Choi, Yoon
   Andrews, Nick
   Brown, David
   Ramsay, Mary E.
TI Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID EFFICACY; POPULATION; ANTIBODIES; RUBELLA; MEASLES; FIELD; IMMUNIZATION;
   AGE
AB The United Kingdom and United States have recently experienced large outbreaks of mumps, which raises concerns about vaccine effectiveness. The effectiveness of the mumps component of the measles, mumps, rubella (MMR) vaccine was estimated using the screening method. In England from January 2004 through March 2005, 312 cases of mumps were reported in children eligible to have received 2 doses of MMR vaccine. Of these children, 52 (16.7%) had received 1 dose of MMR vaccine, and 97 (31.1%) had received 2 doses. Vaccine effectiveness was 88% (95% confidence interval [CI] 83%-91%) for 1 dose and 95% (95% CI 93%-96%) for 2 doses. The effectiveness of 1 dose declined from 96% (95% CI 81%-99%) in 2-year-olds to 66% (95% CI 30%-83%) in 11- to 12-year-olds, and the effectiveness of 2 doses declined from 99% (95% CI 97%-99.5%) in 5- to 6-year-olds to 86% (95% CI 74%-93%) in 11- to 12-year-olds (p < 0.001 for 1 or 2 doses). Waning immunity may contribute to mumps outbreaks in older vaccinated populations.
C1 London Sch Hyg & Trop Med, London WC1, England.
   Hlth Protect Agcy, Ctr Infect, London, England.
RP Cohen, C (corresponding author), Natl Inst Communicable Dis, Private Bag X4, ZA-2131 Johannesburg, South Africa.
EM cherylc@nicd.ac.za
RI English, Peter Mark Bandele/E-1341-2014; Choi, Yoon Hong/AAY-1740-2020;
   ramsay, mary elizabeth/S-8281-2016
OI English, Peter Mark Bandele/0000-0001-6914-9127; Choi, Yoon
   Hong/0000-0001-5561-4366; White, Joanne/0000-0001-7786-4462; Cohen,
   Cheryl/0000-0003-0376-2302; ramsay, mary elizabeth/0000-0002-7156-7640
CR ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A
   BRISS PA, 1994, J INFECT DIS, V169, P77, DOI 10.1093/infdis/169.1.77
   Broliden K, 1998, VACCINE, V16, P323, DOI 10.1016/S0264-410X(97)88332-6
   Chamot E, 1998, REV EPIDEMIOL SANTE, V46, P100
   CHEEK JE, 1995, ARCH PEDIAT ADOL MED, V149, P774, DOI 10.1001/archpedi.1995.02170200064010
   Davidkin I, 1998, VACCINE, V16, P2052, DOI 10.1016/S0264-410X(98)00081-4
   *DEP HLTH, 2001, STAT B NHS IMM STAT
   FARRINGTON CP, 1993, INT J EPIDEMIOL, V22, P742, DOI 10.1093/ije/22.4.742
   FARRINGTON CP, 1992, INT J EPIDEMIOL, V21, P1014, DOI 10.1093/ije/21.5.1014
   FINE PEM, 1994, AM J EPIDEMIOL, V139, P77, DOI 10.1093/oxfordjournals.aje.a116937
   GAY N, 1997, COMMUNICAB DIS REP, V7, P21
   Gershman K., 2006, Morbidity and Mortality Weekly Report, V55, P559
   Ghebrehewet S, 2003, Commun Dis Public Health, V6, P144
   Harling R, 2005, VACCINE, V23, P4070, DOI 10.1016/j.vaccine.2004.10.020
   HERSH BS, 1991, J PEDIATR-US, V119, P187, DOI 10.1016/S0022-3476(05)80726-7
   HILLEMAN MR, 1967, NEW ENGL J MED, V276, P252, DOI 10.1056/NEJM196702022760502
   *HLTH PROT AG, 2006, MUMPS NOT AG GROUP 1
   *HLTH PROT AG, 2006, MUMPS NOT CONF CAS E
   *HLTH PROT AG, 2002, COMMUN DIS REP CDR W, V12, P7
   *HLTH PROT AG, 2003, CDR WEEKLY, V13, P11
   *INT MIGR, 2005, MIGR ENT LEAV UK ENG
   Jones A G, 1991, CDR (Lond Engl Rev), V1, pR93
   KASSIANOS GC, 2001, IMMUNIZATION CHILDHO
   KIMFARLEY R, 1985, AM J EPIDEMIOL, V121, P593, DOI 10.1093/oxfordjournals.aje.a114037
   MILLER E, 1995, VACCINE, V13, P799, DOI 10.1016/0264-410X(94)00086-3
   ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023
   Ramsay M, 2002, BRIT MED J, V324, P1394, DOI 10.1136/bmj.324.7350.1394
   Savage E, 2005, BRIT MED J, V330, P1119, DOI 10.1136/bmj.330.7500.1119
   Savage E., 2006, Morbidity and Mortality Weekly Report, V55, P173
   Schlegel M, 1999, BRIT MED J, V319, P352, DOI 10.1136/bmj.319.7206.352
   SUGG WC, 1968, J PEDIATR-US, V72, P461, DOI 10.1016/S0022-3476(68)80334-8
   SULLIVAN KM, 1985, AM J DIS CHILD, V139, P909, DOI 10.1001/archpedi.1985.02140110063030
   Vandermeulen C, 2004, VACCINE, V22, P2713, DOI 10.1016/j.vaccine.2004.02.001
   Warrener L, 2006, J CLIN VIROL, V35, P130, DOI 10.1016/j.jcv.2005.10.008
   WEIBEL RE, 1980, P SOC EXP BIOL MED, V165, P260, DOI 10.3181/00379727-165-40967
   WHARTON M, 1988, J INFECT DIS, V158, P1253, DOI 10.1093/infdis/158.6.1253
   1998, COMMUN DIS REP CDR W, V8, P345
NR 37
TC 160
Z9 165
U1 0
U2 11
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JAN
PY 2007
VL 13
IS 1
BP 12
EP 17
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 128XH
UT WOS:000243692500003
PM 17370510
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Danta, M
   Semmo, N
   Brown, D
   Sabin, CA
   Fabris, P
   Bhagani, S
   Klenerman, P
   Dusheiko, GM
AF Danta, Mark
   Semmo, Nasser
   Brown, David
   Sabin, Caroline A.
   Fabris, Paolo
   Bhagani, Sanjay
   Klenerman, Paul
   Dusheiko, Geoffrey M.
TI HIV has a significant impact on the early HCV host-viral responses
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY OCT 27-31, 2006
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 UCL, UCL Inst Hepatol, London, England.
   Royal Free Hosp, HIV Med, London, England.
   UCL, Dept Primary Care & Populat Sci, London, England.
   Univ Oxford, Nuffield Dept Clin Med, Oxford, England.
   Bortolo Hosp, Dept Infect Dis & Trop Med, Vicenza, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2006
VL 44
IS 4
SU 1
MA 163
BP 250A
EP 250A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 096FF
UT WOS:000241362300164
DA 2020-12-08
ER

PT J
AU Chu, K
   Jiamton, S
   Pepin, J
   Cowan, F
   Mahakkanukrauh, B
   Suttent, R
   Robinson, NJ
   Deslandes, S
   Frost, E
   Chaisilwattana, P
   Suthipinittharm, P
   Grosskurth, H
   Brown, D
   Jaffar, S
AF Chu, Kathryn
   Jiamton, Sukhurn
   Pepin, Jacques
   Cowan, Frances
   Mahakkanukrauh, Bussakorn
   Suttent, Ruengpung
   Robinson, Noah J.
   Deslandes, Sylvie
   Frost, Eric
   Chaisilwattana, Pongsakdi
   Suthipinittharm, Puan
   Grosskurth, Heiner
   Brown, David
   Jaffar, Shabbar
TI Association between HSV-2 and HIV-1 viral load in semen, cervico-vaginal
   secretions and genital ulcers of Thai men and women
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE HSV-2; HIV-1; viral load; Thailand
ID HERPES-SIMPLEX-VIRUS; NORTHERN THAILAND; TYPE-2 INFECTION;
   HAEMOPHILUS-DUCREYI; YOUNG MEN; TRANSMISSION; ACQUISITION;
   OPPORTUNITIES; DISEASE; UGANDA
AB We studied the association between herpes simplex virus type-2 (HSV-2) and HIV-1 viralload in plasma, semen, cervico-vaginal secretions and genital ulcers. Forty-seven (68%) men and 57 (80%) women were HSV-2 antibody positive, of whom 12 (26%, 95% confidence interval [CI] 20, 32) and five (8%, 95% Cl 4, 12), respectively, had HSV-2 genital shedding detected by polymerase chain reaction. The mean HIV-1 seminal and cervico-vaginal viral loads did not differ significantly according to the presence of HSV-2 shedding. Eleven men and 15 women presented with genital ulcers; all ulcers were due to HSV-2. Ten men and nine women were followed up over six days: the mean (95% CI) HIV-1 log viral load copies/mL in the genital ulcers at baseline and final visits were 2.5 (2.3, 2.7) and 3.1 (2.0, 4.2) for men and 3.0 (2.6, 3.4) and 2.7 (2.3, 3.1) for women. These findings do not support the hypothesis that HSV-2 increases the HIV-1 viral load in genital secretions.
C1 Univ London London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Mahidol Univ, Dept Dermatol, Sexually Transmitted Infect Clin, Bangkok 10700, Thailand.
   Univ Sherbrooke, Ctr Int Hlth, Sherbrooke, PQ J1K 2R1, Canada.
   UCL, Ctr Sexual Hlth & HIV Res, London, England.
   Mahidol Univ, Dept Microbiol, Bangkok 10400, Thailand.
   GlaxoSmithKline, Worldwide Epidemiol, Greenford, Middx, England.
   Mahidol Univ, Dept Obstet & Gynaecol, Bangkok 10700, Thailand.
   Med Res Council Programme AIDS Uganda, Entebbe, Uganda.
RP Jaffar, S (corresponding author), Univ London London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM shabbar.jaffar@lshtm.ac.uk
RI Jiamton, Sukhum/F-1653-2010
OI Jaffar, Shabbar/0000-0002-9615-1588; Frost, Eric/0000-0001-8958-4388;
   Grosskurth, Heiner/0000-0001-9960-7280; Cowan,
   Frances/0000-0003-3087-4422
FU Medical Research CouncilMedical Research Council UK (MRC) [G0700837]
   Funding Source: Medline
CR Baeten JM, 2003, CURR HIV RES, V1, P69, DOI 10.2174/1570162033352110
   Beyrer C, 1998, J INFECT DIS, V178, P243, DOI 10.1086/515603
   Celum Connie L, 2004, Herpes, V11 Suppl 1, p36A
   Corey L, 2004, JAIDS-J ACQ IMM DEF, V35, P435, DOI 10.1097/00126334-200404150-00001
   Dobbins JG, 1999, SEX TRANSM DIS, V26, P67, DOI 10.1097/00007435-199902000-00001
   Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2
   Jiamto S, 2004, JAIDS-J ACQ IMM DEF, V37, P1216, DOI 10.1097/01.qai.0000136092.79153.ac
   Jiamton S, 2003, AIDS, V17, P2461, DOI 10.1097/00002030-200311210-00008
   Johnson G, 2000, J CLIN MICROBIOL, V38, P3274, DOI 10.1128/JCM.38.9.3274-3279.2000
   Limpakarnjanarat K, 1999, SEX TRANSM INFECT, V75, P30, DOI 10.1136/sti.75.1.30
   Malkin Jean-Elie, 2004, Herpes, V11 Suppl 1, p2A
   Mbopi-Keou FX, 2000, J INFECT DIS, V182, P1090, DOI 10.1086/315836
   McClelland RS, 2002, AIDS, V16, P2425, DOI 10.1097/00002030-200212060-00007
   Morency P, 2001, SEX TRANSM INFECT, V77, P125, DOI 10.1136/sti.77.2.125
   Nelson KE, 1997, J ACQ IMMUN DEF SYND, V16, P293, DOI 10.1097/00042560-199712010-00011
   Orle KA, 1996, J CLIN MICROBIOL, V34, P49, DOI 10.1128/JCM.34.1.49-54.1996
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   Reynolds SJ, 2003, J INFECT DIS, V187, P1513, DOI 10.1086/368357
   Rodriguez MDM, 2002, AIDS, V16, P451
   Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507
   Schacker T, 1998, JAMA-J AM MED ASSOC, V280, P61, DOI 10.1001/jama.280.1.61
   Serwadda D, 2003, J INFECT DIS, V188, P1492, DOI 10.1086/379333
   Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231
NR 23
TC 7
Z9 7
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD OCT
PY 2006
VL 17
IS 10
BP 681
EP 686
DI 10.1258/095646206780071108
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 100JL
UT WOS:000241664200006
PM 17059638
DA 2020-12-08
ER

EF